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 Preface 
 
Nanotechnology is a relatively new interdisciplinary field to which much 
attention has been paid for the last years. It involves researchers from very different 
areas: Chemistry, Physics, Biology, Biochemistry, Chemical Engineering, 
Materials Science or Medicine. In the interface of all these disciplines lay the 
possibility to tackle new challenges, unthinkable a few years ago [Klabunde2001]. 
Nanoscience has opened many possibilities in most technology areas, 
unreachable so far. It is devoted to the studies of phenomena at the nanoscale, that 
is, the limit “where the smallest man-made devices meet the atoms and molecules 
of the natural world” [Wong1999]. Nanoscience is based on the fabrication and 
characterization of nanostructured, or nanophase systems. These can be three-
dimensional: nanoparticles or nanospheres, two-dimensional: thin films, or one- 
dimensional: quantum dots. The nanoscale regime is a very special point in the 
length scale, at which the classical laws of physics are not suitable for the 
explanation of many phenomena, so quantum approaches are needed. Significant 
changes in the chemical and physical properties of materials take place at the limit 
at which the interactions correlation length (electrical, magnetic, crystalline…) is 
of the same order of magnitude of the system size. That opens new possibilities for 
the development of smart new functional materials, like improved catalysts, 
polymers, ceramics, tissues, solid state medicines or drug carriers. 
Nanoparticles are the most promising nanostructured systems for the 
application in nanotechnology. Among their main applications are: 
• Environment: small particles are used in decontamination of water, by 
oxidation and reduction of pollutants. The high reactivity of some iron or zinc fine 
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powders towards chlorocarbon compounds is also used for the purification of 
water. And the high surface area of some nanoparticulate metal oxides serves to 
strongly chemisorb acidic gases or organic molecules for air purification. 
• Information Storage: Nanoparticles are already used in audio and 
videotapes, which depend on magnetic and optical properties of fine particles. The 
control of magnetic coercivity and optical absorption will allow much denser 
storage media. 
• Development of new sensors: When semiconductor nanoparticles are 
compressed to yield porous composites, they maintain their high surface areas. 
When these materials undergo a process of gas adsorption, the electrical 
conductivity changes are much stronger since the quantity of gas to be detected is 
much higher. Thus the sensitivity of sensors based on nanophase systems increases 
considerably. 
• Smart magnetic fluids: ferrofluids are stable colloidal solutions of magnetic 
nanoparticles stabilized with surfactants, that can be used as vacuum or 
decontamination seals, and that have a great potential as cooling fluids or 
magnetically controlled heat conductors. 
Perhaps one of the most promising areas on which Nanoscience is focused is 
Biomedicine, and the application of nanoparticles in health issues. Nanoparticles 
present very different and interesting mechanical, magnetic, structural and optical 
properties compared to those of the bulk material. Melting points, specific heats, 
coercive forces or surface areas are all size-dependent. The latter is especially 
remarkable, since the reactivity of a particle will strongly depend on the 
characteristics of its surface, and as size decreases the proportion of atoms on the 
surface per total of atoms rapidly increases. Besides, their small size allows their 
utilisation in in-vivo applications, i. e. inside the organism. Nanoparticles can be 
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tagged with a biomolecule to be directed against the area of choice and there 
perform a specific action, such as the release of a chemotherapy agent, act as a 
contrast agent or selectively heat a specific area by applying an alternate magnetic 
field. 
The research reported in this thesis has been oriented to the production and 
characterisation of novel magnetic particles encapsulated in inorganic coatings, and 
their application in Biomedicine. The work is divided into three major blocks: first, 
the description of the theoretical background, state-of the art and materials used 
throughout this work. In a second block, the synthesis and characterisation of four 
different types of magnetic nanoparticles. And finally, their actual use both in-vitro 
and in-vivo applications. 
 Chapter 1 is a short introduction to the main features concerning the physics 
at the scale of magnetic nanoparticles, and a brief description of some of the 
applications of nanoparticles in Biomedicine: both for diagnostics (MRI) and 
treatment of diseases (hyperthermia, drug delivery) or the magnetic separation of 
biomolecules and their use in biosensors. 
In Chapter 2, materials and methods, the experimental procedures are 
described: the synthesis of the magnetic nanoparticles and the techniques used for 
their characterisation, the protocols used for the chemical functionalisation of the 
particles, as well as the material and methods used in the haematology studies and 
the in-vivo surgery animal model. 
The morphological, physical and chemical characterisation of four different 
types of magnetic particles is presented in Chapter 3: iron nanoparticles 
encapsulated in carbon and silica produced by the discharge-arc method; magnetite 
nanoparticles embedded inside zeolite matrixes by mechanical activation,  and 
magnetite crystallites encapsulated in amorphous silica obtained by a combination 
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of the co-precipitation method and the sol-gel technique. 
Chapter 4 deals with the functionalisation of silica and carbon surfaces of 
magnetic nanoparticles. The introduction of chemical groups on these surfaces  is a 
necessary step to tag the particles with molecules which perform a specific action 
in the organism. The grafting of the specific antibody directed against the human 
chorionic gonadotropin (hCG) to the surface of the particles is described. The 
coating with serum proteins and the hydrophilic polymer poly(ethylene glycol) 
(PEG) has also been studied to avoid the action of the immune system inside a 
living organism, and therefore to allow a longer circulating time in the blood 
stream. 
Chapter 5 comprises the results of the experiments performed in-vitro. The 
interaction of Fe@C particles with blood cells and platelets and the main 
haematological and rheological parameters have been studied to check the 
biocompatibility of circulating particles in blood. Besides, the uptake of Fe@C 
particles into dendritic cells (DCs) has been studied by electron microscopy and 
magnetic measurements allow localising and quantifying the amount of 
internalised magnetic particles. Also, the physical adsorption and release of the 
chemotherapy agent doxorubicin have been studied. The kinetics of adsorption and 
desorption of the drug has been assessed by vis-uv spectrophotometry. 
A thorough description of all the experiments performed in-vivo is comprised 
in Chapter 6. A preclinical experimental animal model is described. Small 
permanent magnets were implanted inside deep solid organs of New Zealand 
rabbits. To achieve the targeted delivery of particles to the desired zone three 
different strategies were designed: intravenous injection of the particles through a 
marginal ear vein of the animal, intrarterial injection and direct inoculation of the 
particles suspension under echographic control. Histopathology studies assessed 
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the distribution, behaviour and tolerance of nanoparticles in a living body after the 
insertion of the magnets.  
Finally, a summary of the work and conclusions are comprised in the last 
chapter. References are all compiled in one last section, ordered alphabetically for 
an easier handling of Bibliography. A list of abbreviations is also included at the 
end of the manuscript. 
 
 
 Chapter 1 
Introduction 
 
This first section is a short introduction to the main features concerning the 
physics at the scale of nanoparticles, and the changes in their physical and 
magnetic properties associated with size reduction. The main methods of 
preparation of nanomaterials are also described, as well as the importance of 
obtaining particles provided with a shell or encapsulation, in order to stabilise 
aqueous suspensions of these particles and render them biocompatible for any kind 
of in-vivo application. 
This introduction chapter ends with the description of some of the main 
applications of nanoparticles in Biomedicine: both for diagnostics (MRI) and 
treatment of diseases (hyperthermia, drug delivery) or the magnetic separation of 
biomolecules and their use in biosensors, magnetix detoxification or magnetic cell 
sorting. 
1.1. Magnetism at the nanoscale 
Magnetism has its origin in the existence of intrinsic or induced atomic 
magnetic moments as a result of moving charges. From an atomic point of view, 
there are two electronic contributions: the orbital and the spin degrees of freedom 
of the electron, which are the source of intrinsic magnetic phenomena in materials 
[Sorensen2001]. 
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From a magnetic point of view we can classify any kind of solid depending on 
its interaction with a magnetic field. The magnetism of a solid has its origin on the 
contributions of the electrons that constitute that solid. At macroscopic scale, the 
magnetic interaction between atoms and the crystalline structure of the solid give 
rise to the different magnetic response of materials. Non-magnetic materials have 
weak magnetic interactions, so that the thermal agitation at room temperature can 
make their magnetic moments flip over continuously, so that their average 
magnetic moment is very close to zero, displaying a linear response to an applied 
magnetic field: Paramagnetic materials have a net atomic or molecular magnetic 
moment and are weakly attracted towards a magnetic pole. For these materials 
magnetic susceptibility, κ, is a small and positive scalar: as H increases, M 
increases linearly. Some Iron salts, like chloride (FeCl3) or sulphate (FeSO4), 
Aluminium, Sodium or Oxygen gas and liquid display paramagnetic behaviour. 
Diamagnetic materials have neither net atomic nor molecular magnetic moment 
and are weakly repelled from a magnet. Their magnetic susceptibility is very small 
and negative, thus when we apply a magnetic field, H, the induced moment will be 
small and opposed to the field. The variation of M with H is constant as well: as H 
increases, M decreases linearly. The vast majority of substances are diamagnetic, 
including water, wood, plastics, SiO2, NaCl, CaCO3 and most of organic and 
biological materials. 
Paramagnetic solids are not long range ordered and the thermal energy shakes 
each atom randomly, whereas diamagnetic solids have negligible field induced 
magnetic moments. In a ferromagnetic material, displacement of domain walls 
results in hysteresis cycles. On the contrary, for single domain particles in the 
superparamagnetic state the whole magnetic moment of each particle is shaken 
simultaneously in the same way as for a paramagnetic material (see Fig. 1.1, 
adapted from Goya2007). 
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Figure 1.1 Variation of M vs. H for ferromagnetic, paramagnetic, diamagnetic and 
superparamagnetic materials. 
If the magnetic interaction is of long range order due to the exchange interaction , 
the atoms within the solid can align the atomic magnetic moments parallel, such is 
the case of ferromagnets, or antiparallel, in the case of antiferromagnets. For the 
latter the antiparallel alignment can reduce the total moment to zero. When the 
antiferromagnetic interaction does not compensate exactly the magnetic moments a 
net ferromagnetic moment can be obtained, these kind of materials are called 
ferrimagnets. Ferro and ferrimagnetic materials are strongly attracted towards a 
magnet. In this case the magnetic susceptibility is large and positive. Iron, cobalt, 
nickel and some iron oxides, are archetypical ferromagnet  whereas magnetite 
(Fe3O4) or maghemite (γ-Fe2O3) are some classical examples of ferrimagnets. Some 
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magnetic phenomena associated with ferromagnetism are magnetic hysteresis, 
magnetic anisotropy, the existence of a transition temperature to paramagnetism, 
and the formation of magnetic domains. 
1.1.1 Hysteresis 
If we apply an increasing magnetic field on a ferromagnet and then decrease it, 
the magnetisation does not follow the initial magnetisation curve. This 
irreversibility is called hysteresis, and it occurs because the magnetic susceptibility 
of ferromagnetic materials is not a scalar. At high applied fields the magnetisation 
approaches the saturation magnetisation, Ms. If the field is decreased to zero, a 
remnant magnetisation remains, Mr. If we now apply a negative field, the 
magnetisation reaches zero at a field magnitude called the coercivity Hc. A 
symmetric behaviour of this hysteresis curve can be obtained as H is varied from 
positive to negative values (Figure 1.1). Permanent magnets as used in motors, 
generators or loudspeakers have large Mr and Ms. Materials with Hc 100 ≥ Oe are 
called hard magnets, whereas soft magnetic materials are those with Hc 10 < Oe, 
commonly used for transformer cores and electronic circuits. In many biological 
applications, high values of Ms and, specially, low values of Hc are required, as we 
will see for the case of superparamagnetism, where coercivity is zero. 
1.1.2 Curie temperature 
The Curie point is the temperature above which a system undergoes a 
transition from ferromagnetic to paramagnetic. As the temperature is increased 
from below the Curie point, thermal fluctuations increasingly destroy the alignment 
of magnetic moments, until the net magnetisation becomes zero at and above the 
Curie point. Above that temperature, the material is purely paramagnetic. 
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1.1.3 Magnetic anisotropy 
The susceptibility of a material depends on the direction in which it is 
measured. This is called magnetic anisotropy. When this occurs, the total 
magnetisation of a ferromagnet, Ms, will prefer to align in a special direction called 
the easy axis. There are anisotropies due to the intrinsic properties of the material, 
as in the case of magnetocrystalline anisotropy, or they can be induced, for instance 
the case of shape anisotropy. Regarding the latter, it is easier to induce 
magnetisation along a long direction of a non-spherical piece of material than along 
the short direction, since the demagnetizing field is less in the long direction, as the 
induced poles at the surface are further from each other. 
Ferromagnetic materials in absence of applied magnetic field have not net 
magnetisation because of the existence of magnetic domains. Their existence was 
proposed by Weiss in 1906. A macroscopic magnetic material breaks up into 
domains that align themselves to minimise the total free energy of the material. The 
energy of a magnetic field is proportional to the field squared and its volume 
extent. Thus the magnetostatic energy of a single domain of parallel spins can be 
decreased by breaking into smaller and oppositely aligned domains. The benefits of 
this decrease in energy would continue with the formation of smaller and smaller 
domains; however there is a competition between the magnetostatic energy and the 
exchange and anisotropy energy at the boundary (the domain wall) between 
oppositely aligned domains. This limits the process of restructuring to domains of a 
finite size. 
As we have seen, the magnetostatic energy of a ferromagnet can be decreased 
by breaking up into domains. On the other hand, apparition of domains costs 
energy due to the formation of domain walls. Thus, there will be a critical domain 
size below which the cost of energy of domain walls formation exceeds the 
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benefits from decreasing the magnetostatic energy. This critical size, or single 
domain size Ds, is where these two energies are equal. Typical values for Ds range 
from 10 to 100 nm, depending on the material (Table 1.2) 
Table 1.2: Estimated single-domain size for spherical particles 
Material Ds (nm) 
Fe 14 
Co 70 
Ni 55 
Fe3O4 128 
γ-Fe2O3 166 
Ultrafine particles display unusual and very interesting properties compared to 
the bulk material. There is a limit of size below which the particle can not gain a 
favourable energy configuration restructuring into domains. As a consequence, 
they are single domain particles and present a magnetic behaviour known as 
superparamagnetism: this is characterised by a decoupling of the magnetisation of 
the particle from the lattice due to thermal energy which overcomes the anisotropy 
energy, which is proportional to the volume of the particle (KV). 
With decreasing particle size, KV decreases until the thermal energy kT can 
cause fluctuations of the overall magnetic moment that take place within the 
particle. Thermal fluctuations can then affect the orientation of the magnetisation, 
M, if they are large enough to overcome the magnetic anisotropy barrier. This 
change in magnetisation according to a temperature-dependent probability 
distribution resembles the behaviour of a paramagnetic material. The difference is 
that the amount of the individual magnetic moment, μ, is several orders of 
magnitude larger because it is the addition of the moment of hundreds of thousands 
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of atoms. For this phenomenon Néel coined the term superparamagnetism 
[Néel1949]. Two key features describe a superparamagnetic system, in analogy to 
the behaviour of paramagnetic materials: lack of hysteresis, and data of different 
temperatures superimpose onto a universal curve of M vs. H/T. 
Superparamagnetism is a timescale-dependent phenomenon. The anisotropy 
energy KV represents an energy barrier to the total spin reorientation; hence the 
probability for jumping this barrier is proportional to the Boltzmann factor e-KV/kT. 
If we introduce the term τ0, which describes the timescale over which the magnetic 
moment of the particle (μp=MsV) attempts to jump the anisotropy barrier, then the 
timescale for a change of orientation of the magnetic moment is: 
τ=τ0 e-KV/kT (Eq. 1.1) 
The attempt timescale, τ0, is about 10-9 s. A typical experiment with a 
magnetometer takes 10 to 100s, so if total magnetisation Ms reverses at times 
shorter than the experimental timescales, the system will appear 
superparamagnetic. Using τ=100s and τ0=10-9s, for the critical superparamagnetic 
volume Vsp can be obtained: 
Vsp=25kT/K (Eq. 1.2) 
Any particle with volume smaller than Vsp will behave as a superparamagnet 
on the 100s experimental timescale. Typical values of Vsp are 16 nm for Iron and 
7.6 nm for Cobalt. Also, eq. 1.2 can be rearranged: 
k
KVT B 25=  (Eq. 1.3) 
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There is a critical temperature, called Blocking Temperature, TB, below which 
the free movement of the individual magnetic moment is blocked by the anisotropy 
of the particle, and above which the thermal activation looses the moment so that 
the system appears superparamagnetic. The blocking temperature for any material 
can be measured with a magnetometer. The sample is cooled under zero applied 
field (zero-field-cooling, ZFC) to a temperature well below the expected TB. Then 
a small field of ~100 Oe is applied. At this point, and presuming T<TB the 
individual particles’ moments are bound to the particles and point in random 
directions, so the induced magnetisation will be small. The system is slowly 
warmed, and as T approaches TB, the thermal energy kT will start to loosen up the 
moments from the particles and the induced magnetisation will rise. At TB the 
moments are unblocked and free to align with the applied field to yield a large total 
magnetisation (see as an example Fig. 3.22 in page 99). Then a peak is observed 
for the curve M vs. T at the ZFC experiment. Once we have empirically measured 
TB, from equation 1.3 values such as saturation magnetisation, anisotropy or size of 
the particles can be obtained. 
Above the blocking temperature, the contribution from an ensemble of 
superparamagnetic particles to the magnetisation is described by the Langevin 
relation: 
 ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −⎟⎟⎠
⎞
⎜⎜⎝
⎛=⎟⎟⎠
⎞
⎜⎜⎝
⎛=
H
T
T
HN
T
HLNTHM k
kk
B
BB μ
μμμμ coth),(  (Eq. 1.4) 
Fitting this equation to the obtained experimental data the value of diameter of 
the particle can be obtained assuming spherical shape of the particle. 
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1.1.4 Coercivity of small particles 
Since there are no domain walls to move, the reversal magnetisation in single-
domain particles is due to the spin rotation. As a consequence, the single-domain 
particles have a larger coercivity than multi-domain systems because it is harder to 
rotate the magnetisation than to move a domain wall. The largest coercivities occur 
exactly at the single-domain size. Below this, Hc decreases because the thermal 
activation is capable to pass the anisotropy barriers, being zero for 
superparamagnetic particles. (Figure 1.2) This is a very important property for a 
number of applications which demand particles with zero coercivity and zero 
remanence, that is, once the magnetic field is removed, particles do not interact 
with each other, and therefore will not remain aggregated. 
  
Figure 1.2 Particle size versus coercivity. 
1.2. Magnetic nanoparticles 
Inside the vast field of nanoparticulate systems, magnetic nanoparticles attract 
special attention due to their unique properties. These are nanostructures that 
contain a metal like iron, nickel or cobalt, or some of their oxides. Because of their 
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response to an applied magnetic field they can be used as magnetic carriers in a 
number of biomedical applications, both in-vitro or in-vivo: by means of a 
magnetic gradient magnetic particles can be directed to a specific target and there 
release a specific drug or molecule (magnetic drug delivery); they can be used as 
contrast agents to enhance the image contrast in magnetic resonance imaging 
(MRI); they can also be heated selectively by applying an alternate magnetic field 
(magnetic thermal ablation or hyperthermia); or they can be functionalised with a 
molecule that specifically recognises an analyte and thus separate it from solution 
by means of a magnet (magnetic separation).  
There are several requirements for the use of magnetic nanoparticles in 
biomedical applications: their size has to be small enough to avoid the action of 
gravitational forces that would make them precipitate in solution. Moreover, in the 
case of in-vivo applications (i.e. inside a living body) they have to be small enough 
to pass through the smallest capillaries in the body, and at the same time they have 
to be big enough to overcome the strength of blood flow. A balance between the 
two factors is then needed. Any material used in-vivo must be sterile and 
biocompatible as well, therefore the use of toxic metals like nickel, cobalt, 
neodymium or samarium is preferably avoided. Iron and iron oxides, especially 
Magnetite (Fe3O4) and Maghemite (γ-Fe2O3) are by far the most used nanosystems 
as magnetic carriers. Finally they must have high magnetic susceptibilities to 
respond rapidly and in an effective way to the action of a magnet. Bigger particles 
generally have higher saturation magnetisation and magnetic susceptibility than 
smaller ones, so a compromise is again required. The stability of magnetic particles 
suspensions is essential, and is not a trivial issue. It depends enormously on the 
synthesis process, hence an appropriate preparation and isolation of the materials is 
a must. 
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1.2.1 General Methods of Synthesis: Top-Down vs. Bottom-Up Methods. 
For the practical application of nanoparticles, it is not only a small size that 
matters. The conditions of synthesis need to be controlled so that resulting products 
have a uniform distribution in morphology, that is, the most similar size and shape 
as possible. Also an identical chemical composition and crystal structure are 
desirable so that the material presents reproducible reactivity and behaviour in its 
application. Finally, agglomeration of the particles needs to be avoided for any 
application; therefore the final purified products need to be rapidly dispersible in 
solution [Cao2004]. 
Many techniques have been developed, or are under development, so as to 
synthesize magnetic nanoparticles. Top-down approaches include mechanical 
milling, evaporation of bulk materials or lithography [Jewell1991]. All these 
methods are relatively quick, simple to handle and economic. Nanoparticles and 
nanocomposites can be thus obtained, along with a number of impurities and 
defects that need to be eliminated in a further treatment. The size of the obtained 
particles can be very small, but in general these are processes that are difficult to 
control in order to produce a specifically desired particle size and shape. For 
instance, High-energy ball milling (HEBM) can induce chemical reactions in 
powder mixtures, a process usually termed mechanochemistry. On the other hand, 
using lower energy ranges during the ball mill of solid/liquid mixtures results in 
homogeneous dispersion of fine particles without changes of the starting phases 
[Pankhurst2003]. 
On the other hand, bottom-up approaches are more utilised for the synthesis of 
small, monodisperse particles. Nanoparticles can be obtained by heterogeneous 
nucleation on solid substrates, or by homogeneous nucleation from liquid or 
vapour. These are the cases of co-precipitation and sol-gel techniques. In the first 
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one the reaction of metallic salts in the presence of a base leads to the formation of 
nanostructured metal oxides. The latter is a wet chemical route for the synthesis of 
inorganic and hybrid materials, generally metal oxides and oxide-based 
composites.  A sol-gel process consists of hydrolysis and condensation of 
precursors, which are usually metal alkoxides and inorganic or organic salts, 
dissolved in either aqueous or organic solvents. Sol-gel techniques have many 
advantages, including low processing temperature and molecular level 
homogeneity. An alternative to these methods is the confinement of chemical 
reactions, nucleation and growth processes inside small space, such as micelles 
[Fendler1987] or microemulsions [Fried1995], or inside droplets by evaporation of 
the precursors, as in the case of aerosol synthesis [Visca1978] or spray pyrolyis 
[Messing1993]. A good control of the particle size is achieved using these 
methods. 
The process of growth from small molecules to bigger particles always 
involves several steps. First is nucleation, which takes place in a very short period 
of time, and it is achieved after supersaturation of the reagents that form the nuclei. 
The introduction of nanosized seeds is another possibility. Subsequent growth 
needs to be diffusion controlled, something achieved introducing a diffusion 
barrier, such as a polymer monolayer on the growth surface, using a low 
concentration of growth species or slowly generating growth species. In all of the 
cases, anyway, monodispersity is never completely fulfilled, so a further separation 
depending on size has to be done. Size-selective precipitation can be applied to 
separate larger particles from smaller ones. Magnetic separation is another 
possibility: by applying a magnetic field gradient larger aggregates can be removed 
from fine particles. A proper design of the geometry of the applied magnetic field 
is then essential to obtain an effective separation of the final materials. 
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1.2.2 Core-shell particles 
All the particles used during this research are Core-shell magnetic 
nanoparticles. They consist of a magnetic core encapsulated in an inorganic or 
polymeric coating. This coating renders the particles biocompatible, prevents them 
from oxidation in suspension, isolates them from each other, avoids the formation 
of magnetic aggregates, and serves as a support for the chemical bonding or 
physical adsorption of biomolecules on the surface of the particle. 
The coating often plays a key role in the stabilisation of the particles in 
suspension. First of all it avoids leaching of the core, that is, the loss of magnetic 
material. Besides, the apparition of charges on the surface can stabilize liquid 
suspensions with a high saline concentration or slightly acid or alkaline pH. For 
example, the isoelectrical point of silica is pH=2-3, so at physiological pH=7.4 the 
surface of silica will be negatively charged, inducing electrostatic repulsion 
between particles to help avoid aggregation. A low ionic force, i.e. a low 
concentration of salts in solution will also help to keep particles separated from 
each other to yield stable suspensions. 
Depending on their size and their hidrophilicity or hydrophobicity, after 
systemic administration nanoparticles are most likely to be uptaken by the 
Mononuclear Phagocyte System (MPS) and cleared to the liver, spleen, and bone 
marrow. Different proteins (antibodies) of the blood serum (opsonins) bind to the 
surface of a nanoparticle (opsonization) and enhance the uptake of the particle by a 
phagocyte. Biodegradable (i.e., dextrane) and non-biodegradable organic coatings 
have been used to reduce the uptake by the macrophages of the RES, to avoid the 
lixiviation of a toxic core to the media (i.e. cobalt or gadolinium magnetic 
nanoparticles), and to provide a hydrophilic surface able to attach different 
functional groups or adsorb or link a specific drug. 
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Inorganic coatings, like carbon or silica are also good candidates for attaining 
suspensions of particles that are suitable and long-term stable. Both materials are 
biocompatible and non-toxic. Also, amorphous silica is a heat-resisting material, 
with a low specific gravity, high surface area, and good mechanical strength. The 
small pore size of silica can give rise to a very selective interaction with the 
adsorbed molecules depending on their size, shape, and chemical characteristics. 
Carbon and silica have hydroxyl (OH) groups on the surface that can be 
substituted with more reactive chemical chains, that will be capable to bind 
covalently to the amine (NH2) or carboxyl (COOH) terminal groups of a protein, 
for example. The number of hydroxyl groups on the carbon surface is quite low in 
comparison to silica, and much less reactive. This fact makes carbon less attractive 
for chemical functionalisation but, on the other hand, it renders its surface highly 
hydrophobic, that way it easily adsorbs any organic molecule in solution. This is 
very important for the spontaneous adsorption and release of chemotherapy drugs 
in the case of drug delivery, and at the same time it makes carbonous particles a 
perfect target for the Rethiculoendothelial System (RES), since, due to the 
hydrophobic nature of their surface, they are more likely to undergo opsonization 
processes. So the objective is double: on one hand, to introduce on the particles 
some chemical groups that avoid the adsorption of opsonin, and therefore the 
action of the immunological defences of the body; and on the other hand the 
hydrophobic nature of carbon must be preserved so it can still be able to efficiently 
adsorb a drug. 
Our strategy has been to first adsorb an amphyphylic molecule on the surface, 
PMAO, with a long hydrophobic chain on one side and carboxyl, hydrophilic 
groups on the other side, and then to covalently bind a Poly-ethyleneglycol chain 
(PEG) functionalised with amino groups at one of its ends. Once the particles have 
been functionalized with PEG, the presence of the polymer prevents the adsorption 
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of big proteins of the blood and hence delays the recognition of the particle from 
the immune system. PEG is currently the most used molecule to prevent the action 
of the RES. The attachment of PEG to the nanoparticle surfaces provides a 
shielding “stealth” effect, delaying recognition and sequestration by the resident 
macrophages of the reticulo-endothelial system. Unfortunately, this 
‘immunostealthing’ function is concurrent with the annihilation of biomolecular 
targeting capabilities, because the PEG molecules hide, in many cases, localizing 
antibodies conjugated on the nanoparticles surfaces which are used in antibody 
conjugated magnetic nanoparticles in MRI applications. In addition, the branching 
of the PEG could affect the diffusion of the drug in magnetic drug delivery 
applications, as well as the biodegradation of the core for SPIONs.  
The presence of the polymeric coating is not an obstacle for small peptides or 
small molecules to be adsorbed on the surface of the particle. This is the case of 
chemotherapy drugs like doxorubicin which, despite the PEG barrier, is able to 
reach the surface of carbon and remain attached to it. Moreover, the presence of the 
coating serves to delay and control desorption of the drug, since now doxorubicin 
finds more obstacles to be released to the medium. 
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1.3. Biomedical Applications 
Biomedical applications of magnetic nanoparticles can be classified into 
therapeutic and diagnostic applications. Among the first ones the delivery of 
chemotherapy agents, magnetic hyperthermia and magnetic detoxification are the 
most extended applications. In diagnostics they are basically used as contrast 
agents in Magnetic Resonance Imaging (MRI) and magnetic separation by 
molecular recognition. 
1.3.1. Hyperthermia 
Hyperthermia, or thermal ablation, is the treatment of tumours by selective 
heating applying an alternating magnetic field (AC field). When temperature 
increases over a certain value, typically 42ºC, different mechanisms of cell damage 
occur in living tissues, basically death by necrosis or induction of death 
(apoptosis). The objective of hyperthermia is to increase the temperature only at a 
desired region, leaving other cells unaffected. Heating may be controlled by 
adjusting the field amplitude and the duration of field exposure, while the local 
temperature increase is measured online using optical fiber sensors introduced into 
the tumour tissue. 
The control of temperature at that point is, therefore, essential, and is one of 
the major tasks in this research area. For this purpose a magnetic nanoparticles 
suspension is introduced into tumour tissue, achieving that way controlled and 
selective heating of tumoral cells. Energy is adsorbed and transformed into heat by 
the magnetic particles when a high frequency magnetic field is applied by the 
reversal of magnetisation inside a magnetic particle and by the rotation of the 
particle in a fluid suspension. The heating potential is strongly dependent on the 
particle size and shape, thus homogenous, uniform batches of particles are needed 
for a strict control on temperature. This technique is often used in combination with 
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other treatments, like chemotherapy or irradiation. The goal of the scientific 
community is then to produce a magnetic nanoparticle that would, at the same 
time, serve for diagnosis and treatment of diseases, i.e., the particle should be able 
to load and release a drug, serve as an MRI contrast agent and also be heated 
selectively by the application of a magnetic field. 
The concentration of magnetic particles in the target tissue and the increase of 
temperature that is required to damage tumoral cells determine the demand of 
specific heating power of magnetic particles for hyperthermia. This heating power 
is determined by the applied AC field. The general tendency is that as amplitude 
and frequency of the magnetic field increase, more heating power can be generated 
in particles. Because of biocompatibility restrictions, most studies have been 
performed with magnetic iron oxides magnetite and maghemite. The specific loss 
power (SLP) of a particle depends on the morphology and structure of the particle: 
for single-domain particles there is a rapid increase in SLP with increasing 
diameter of the particle, whereas for multidomain particles this trend is reversed. A 
narrow particle size distribution and a high magnetic anisotropy are also desirable 
to achieve a high SLP value.  
The two main current limitations for the use of hyperthermia as a regular 
treatment are then the choice of the adequate particles, and the effective delivery of 
those particles to the desired area, to ensure a sufficiently high concentration of 
particles in the tumour tissue. This will depend on the degree of particles uptake 
inside tumour cells, either by endocytosis or by adsorption on cell membranes. For 
an effective delivery particles can be directly injected into the tumour or into blood 
vessels that supply the tumour; or they can be guided, either by the action of an 
external magnetic field, labelling the particles with antibodies that specifically 
recognise the presence of tumour cells. The targeting efficiency is still far from 
what would be desirable. The achieved concentrations of particles are so low until 
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now that, for a useful heating treatment, considerable enhancement of the specific 
heating power of the magnetic particles would be needed. The problem is basically 
the same as for drug delivery: the functionalisation of the particles with tumour-
specific antibodies is not an easy task, whereas the use of external magnets for 
magnetic guidance enriches the target region of the body but presents important 
geometrical limitations. Moreover, since magnetic attraction is proportional to the 
magnetic moment of the particle, superparamagnetic particles are not sufficiently 
targeted. On the other hand, the use of bigger, multi-domain particles presents the 
risk of aggregation and unintended embolization. Taking advantage of this fact, 
this method has been investigated for arterial embolization hyperthermia 
[Moroz2002]. 
Numerous studies of magnetic thermal ablation in-vitro have been reported, 
especially by the group of Andreas Jordan. Particles are introduced in cell cultures 
to test their biocompatibility and citotoxicity, and to determine the interaction of 
different types of particles with cells in aqueous suspensions. There are differences 
in the cellular uptake of magnetic nanoparticles by different cell types, as well for 
different coating of the particles [Jordan1999]. The toxicity of different coatings, 
including dextran, citrates, polyethyleneglycol or starch, has been studied by Häfeli 
and Pauer [Häfeli1999]. Suzuki et al [Suzuki1995] achieved a highly specific 
cellular uptake by coupling tumor-specific monoclonal antibodies onto the surface 
of magnetite particles coated by polyethyleneglycol.  Significant increase of 
temperature in cell cultures have been reported [Jordan1999, Hiergeist1999], 
however we have to take into account that these systems are very well isolated, 
something that avoids undesired losses of temperature during the treatment and is 
not representative for the real situation inside a living body. 
Hyperthermia has also been studied in-vivo [Shinkai2001, Moroz2002]. Mice, 
rabbits, dogs and pigs have been utilized for this purpose. Histological evaluation 
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of the treated tissue proves that temperature elevation produces degradation of 
tumours. This treatment can be performed in animal experiments under tolerable 
systemic loads. There are some drawbacks, however, that have delayed the use of 
these techniques to the treatment of diseases in humans: first of all the equipment 
has been so far developed for animals so it has been traditionally too small. And, 
more important, there is no evidence of the curative value of magnetic particles 
hyperthermia yet, only a few cases of surviving lots with reduction or no further 
tumour growth after treatment [Jordan1997]. Best results have been reported by 
Yanase et al [Yanase1998] who identified 87.5% of rats with no tumour regrowth 
within three months. In spite of all these inconveniences first human trials have 
already started, and a Hyperthermia system for clinical application has been 
developed by Gneveckow et al [Gneveckow2004]. 
1.3.2. Magnetic separation 
The principle of magnetic separation of biomolecules is based on the labelling 
of magnetic particles with adequate functional groups. These can specifically 
recognise a desired molecule, bind to it, and separate it from a suspension of other 
substances that may interfere in our analysis. Some of the main applications of 
Magnetic Separation techniques are cell sorting, magnetic detoxification and 
biomolecular recognition, on which the development of magnetic biosensors is 
based. 
1.3.2.1 Magnetic cell sorting 
One of the most widespread techniques related to magnetic separation is 
magnetic cell sorting. This has special interest in clinical analysis, since practically 
any type of cell can be isolated from complex cell mixtures: one example are 
commercially available kits of magnetic particles labelled with antibodies anti-CD3 
that specifically recognise lymphocytes B, that way we can separate lymphocytes T 
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from B in a human blood sample. Currently, some of the most used applications of 
cell sorting could be: stem cell enrichment for graft engineering, T cell subsets in 
transplantation, Natural Killer cells for tumour therapy, stem cells in cardiac repair 
or enrichment of antigen-specific T cells for immune therapy [Ugelstad1995]. 
Magnetic Cell Separation, or MACS® technology, utilizes superparamagnetic 
nanoparticles for labelling the analites of interest and a separation column. First of 
all, individual cells of a cell suspension are magnetically labelled with magnetic 
particles, which have been previously conjugated to a monoclonal antibody or a 
specific ligand for a certain cell type. After that, the cell suspension is passed 
through the separation column that contains a ferromagnetic matrix, typically 
nickel wires or steel wool. A high magnetic gradient is applied by means of a 
permanent magnet, thus the particles and their conjugated analites will be retained 
in the wires, whereas non-labelled cells will pass through unnoticed. These cells 
can be easily eluted by rinsing with the appropriate buffer. Both separated fractions 
of cells could now be used for further use in flow cytometry, molecular biology, 
cell culture or clinical cellular therapy [Kantor1997]. MACS columns for research 
can process up to 2x1010cells, depending on the size of the column. This is clear 
advantage in comparison to Fluorescence-activated  cell sorting (FACS), where 
cells are sorted one after the other, limiting the sorting speed to 5000 cells per 
second. 
Before designing an experiment of cell sorting, it has to be taken into account 
that the optimal separation strategy depends on the amount of cells of interest in the 
sample, their phenotype compared with the other cells in the mixture, and 
restrictions of desired purity, yield or activation. There are two basic strategies for 
the separation of target cells with magnetic particles: positive selection and 
depletion. Positive selection is when the desired target cells are magnetically 
labelled and isolated directly as the positive cell fraction. This requires one or more 
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cell surface markers which are specific for the target cells, and is specially 
recommended for the isolation of rare cells, such as hematopoietic stem cells from 
complex cell mixtures [Burt2003]. 
On the other hand, depletion means that the unwanted cells are those 
magnetically labelled and removed from the cell mixture, whereas the non-
magnetic fraction contains the cells of interest. This strategy is the most used since 
it can be applied to almost any kind of cells, as it is less aggressive on the 
functional status of the cell. Some typical examples of magnetic depletion are the 
selective removal of fibroblasts which often overgrow other cells from primary 
tissue cultures; the enrichment of nonhematopoietic tumour cells from blood and 
bone marrow of cancer patients by leukocyte depletion; and the depletion of T cells 
from allogeneic stem cell grafts [Barfield2003]. 
1.3.2.2 Magnetic detoxification 
Magnetic detoxification of the blood can also be included among the 
applications of Magnetic Separation techniques. Removing toxins from the blood is 
still a challenge in medicine since most blood-borne toxins and biohazards cannot 
effectively be treated. Current methods for blood detoxification include 
hemodialysis and hemofiltration, plasmapheresis, extracorporeal 
immunoabsorption and direct injection of chelators or antibodies [Chen2007]. Even 
though these techniques have proved to be effective for the treatment of some 
diseases, there is still a need of improvement for the detection and treatment of 
certain intoxications, as in the case of biohazards or biochemical attacks. 
Magnetism increases significantly the sensitivity and performance of this method. 
Magnetic detoxification systems are based on biocompatible magnetic 
nanospheres, which are functionalised with target-specific antitoxin receptors. 
They are then injected intravenously in the human blood stream. While they are in 
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circulation they attach to toxins via the specific receptors on the surface. Toxin-
nanospheres systems are formed within a very short period of time, and via a 
venous or an arterial access the blood is passed through a high gradient magnetic 
separation device, where magnetically labelled toxins are retained. The detoxified 
blood is then returned into the body by extracorporeal circulation [Chen2007]. 
As in the case of any in-vivo application, the persistence of nanospheres in the 
blood stream over prolonged periods of time is basic for a more efficient removal 
of toxins in the blood. This persistence depends on the size of the particle, and the 
chemical surface of the spheres. Monodisperse particles, of homogenous 
morphologies are preferred to facilitate magnetic trapping and blood clearance. To 
avoid the removal from the blood of bare particles by protein adsorption and 
consequent macrophage capture nanospheres are usually coated with hydrophilic 
polyethylenglycol (PEG), derivatives. The copolymer poly(lactic-co-glycolic acid) 
is also a usual choice to avoid the action of the Immune system [Quellec1998, 
Xie2007]. 
1.3.2.3 Separation and Magnetic Biosensors 
Conventional Immunochromatographic tests are based on the biomolecular 
recognition and capture of a certain colloidal coloured analyte, as it passes through 
a membrane on which the corresponding anti-analyte has been immobilised. These 
are very quick, simple and reliable diagnostic tools for many applications. 
However, along with their clear advantages, they have two main inconveniences: 
they are not able to quantify concentrations of analyte and their sensitivity is 
limited. Therefore, immunochromatographic tests are not adequate for certain 
applications, like the detection of infectious diseases. The use of magnetic 
nanoparticles bound to biorecognitive molecules, in substitution of conventional 
coloured colloids, like gold or dyed polymer spheres, permits to separate and to 
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concentrate the analyte of interest, increasing the sensitivity of the test. Moreover, 
magnetically labelled targets generate a magnetic field than can be detected and 
measured directly with a magnetometer. The concentration of the molecule of 
interest can then be quantified. [Jianrong2004]. The quantification of the analyte 
can be performed either by inductive or magnetoresistive methods. The former 
consists of the detection and integration of the magnetic flux generated by 
magnetically labelled analytes. Quantum Design has a commercial prototype of a 
biosensor based on magnetoinductive detection. As an alternative, 
magnetoresistance-based sensors could lead to much higher sensitivities. The 
active component in a magnetoresistive sensor is a material that modifies its 
electric resistance when a magnetic field is applied. Currently, most used MR 
sensor are based on Giant Magnetoresistance phenomenon, also used in the hard 
drives of computers. 
Magnetic separation has also been used in combination with optical sensing to 
perform magnetic enzyme linked immunosorbent assays (magnetic ELISA) 
[Kala1997]. These assays use fluorescent enzymes to optically determine the 
number of cells labelled by the assay enzymes. In a modification of this procedure 
the magnetic microspheres act as the surface for initial immobilisation of the target 
material and magnetic separation is used to increase the concentration of the 
material. [Pankhurst2003]. The mobility of the magnetic nanoparticles allows a 
shorter reaction time and a greater volume of reagent to be used than in standard 
immunoassays, where the antibody is bound to a plate. In a variation of this 
procedure, magnetic separation has been used to localise labelled cells at known 
locations for cell detection and counting via local scanning. Cells are labelled both 
magnetically and fluorescently and move through a magnetic field gradient towards 
a plate on which lines of ferromagnetic material have been lithographically etched. 
Cells align along these lines and the fluorescent tag is used for their optical 
detection.  
30 Chapter 1. Introduction 
1.3.3. Magnetic Resonance Imaging (MRI) 
Diagnosis of some diseases at their early stages remains one of the major tasks 
in modern medicine, since early diagnosis can be vital for the survival of the 
patient. Magnetic Resonance Imaging (MRI) is a powerful, non-invasive and non-
destructive imaging tool, capable of providing 3D internal images of living 
organisms [Licha2005]. It provides high soft tissue contrast and high spatial 
resolution, and offers the possibility to display blood vessels, map brain functions 
or analyze cellular metabolisms. 
Early diagnosis of small tumour cells can facilitate avoiding metastases and 
permits a more efficient treatment of the disease. However, the lack of sensitivity 
has hampered the application of MRI for a really efficient location of cancer at its 
early stage. The apparition of magnetic contrast agents has allowed clinical 
researchers and analysts to increase enormously the sensitivity levels with which 
tissues in a living body can be observed. The function of contrast agents in MRI is 
to enhance the image contrast between healthy and diseased tissue and indicate the 
status of organ functions or blood flow. Up to date most contrast agents have been 
paramagnetic systems, like Gadolinium chelates [Weinmann1984, Merbach2001]. 
The use of superparamagnetic iron oxide nanoparticles (SPIONS) is an alternative 
to conventional contrast agents: Combidex®, Endorem® and Resovist® are 
already commercially available contrast agents. They are all core-shell 
nanoparticles composed of a maghemite core and a polymeric coating. These 
particles tend to accumulate in diseased organs due to differences in tissue 
composition and cell uptake processes [Kim2001]. Taking advantage of this fact, 
these particles are used for location and diagnosis of brain and heart infarcts, as 
well as liver lesions or tumours [Tartaj2003]. 
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Despite the very small magnetic moment of a proton, the great number of 
protons that exist in biological tissue yields an effect than can be measured in the 
presence of large magnetic fields, and this effect is the base for MRI. If we have a 
large number of protons in the presence of an external magnetic moment B0, the 
net moment m precesses around B0 in the Larmor Frequency, ω0.  
ω0 = γ B0 (Eq. 1.5) 
Where γ is the gyromagnetic ratio, for a proton γ = 2.67 x 108 rad s-1 T-1.  
A second external field is applied perpendicular to B0, oscillating at ω0. This 
second field is much weaker than B0, but it has the peculiarity of resonantly 
exciting the moment precession into the perpendicular plane. The oscillating field 
is then removed at time zero, and the in-plane and longitudinal moment amplitudes 
relax back to their initial values [Pankhurst2003]. The radio frequency transverse 
field is applied in a pulsed sequence, long enough in time to obtain a coherent 
response of the net magnetic moment of the protons to the MRI scanner. When the 
radio frequency is turned off the relaxation of the coherent response is measured in 
the scanner. 
For B0 parallel to the z axis, relaxation signals are in the form: 
mz =  m (1 – e-t/T1) (Eq. 1.6) 
mx,y = m sin (ω0t + φ) e-t/T2 (Eq. 1.7) 
φ is a phase constant, T1 is the longitudinal, also known as spin-lattice 
relaxation time, and T2 is the transverse, or spin-spin relaxation time. Longitudinal 
relaxation is associated with loss of energy as heat, from the system to the 
surrounding lattice. On the other hand, the loss of phase coherence in the 
precessing protons due to interaction between them and with other fluctuating 
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moments in the media is the cause of the transverse relaxation. Often T2 is replaced 
by the shorter relaxation time T2*, when local inhomogeneities in the applied 
longitudinal field can lead to extra dephasing phenomena:  
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Δ+= γ  (Eq. 1.8) 
Where ΔB0 is the variation in the field caused by heterogeneity of the applied 
field itself, or due to local variations in the magnetic susceptibility of the system.  
In living tissues the addition of contrast agents enhances contrast between 
adjacent anatomic structures. The magnetic moments of the added particles 
increase magnetic interactions during the collisions between molecules in a fluid, 
accelerating the relaxation of excited spins. Besides, dipolar interactions between 
superparamagnetic cores and surrounding protons from the fluid cause an increase 
in both longitudinal and transversal relaxation rates. New generation 
superparamagnetic agents are also known as T2 contrast agents, since they produce 
a significant decrease in the transversal relaxation time, in opposition to 
paramagnetic particles like Gd-DTPA (Gadolinium diethylenetriaminepentaacetic 
acid) also called T1 (longitudinal) agents. As a result, magnetic nanoparticles 
provoke local heterogeneity of the applied magnetic field in the vicinity of the 
targeted tissue and the signal is therefore enhanced [Richardson2005]. Recently, a 
work by Hartung et al described the labeling of macrophages using iron oxide 
particles of bacterial origin (magnetosomes). In an ex-vivo animal study the 
inflammation caused by induced peritonitis was identified by MRI using 
magnetosomes as contrast agents [Hartung2007]. 
Most significant improvements in sensitivity can be achieved when contrast 
agents are delivered to specific organs or tissues. For this purpose there are several 
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solutions under development: the direct injection of contrast agents in the affected 
zone is the easiest and more obvious approach; it is however limited to regions of 
the body where access allows direct intervention. Another strategy is to utilize the 
size-dependent delivery taking into account the intrinsic porosity of the capillary 
vessels [Okuhata1999] and the specific characteristics of tumour vascularization. 
That way Combidex (commercial superparamagnetic iron oxide) nanoparticles 
have been delivered by accumulation in noncancerous lymph tissue [Shelley2006]. 
Promising results have been achieved in the improvement of sensitivity of 
detection and delineation of pathological structures, such as primary and metastatic 
brain tumours, inflammation or ischemia [Roberts2000]. 
One of the most encouraging alternatives for the targeted delivery of these 
agents is to bind monoclonal antibodies to the surface of magnetic nanoparticles 
that specifically recognise certain receptors of the damaged cells at the desired 
organ. After the work by Suzuki et al [Suzuki1996] many research groups have 
focused their interest in the design and development of antibody-conjugated 
magnetic nanoparticles. When cancer spreads, there is an overexpression of certain 
factors at the tumoral cells. In order to reach selectively the target malignant cells 
antibodies anti-VEGF and anti-VCAM antibodies have been linked to magnetic 
polymeric particles. In the same direction, Huh et al synthesised magnetic 
nanocrystals conjugated with herceptin, a cancer-targeting antibody [Huh2005]. 
Alternatively, the use of other biomolecules for specific reception at diseased 
tissues has been reported: Proteins such as transferring [Högemann2000], peptides 
like the membrane translocating tat peptide of the HIV tat peptide protein 
[Josephson1999] and oligonucleotides [Josephson2001] have been attached to iron 
oxide nanoparticles to obtain specifically deliverable MR imaging agents 
[Högemann2002, Tartaj2003]. 
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1.3.4. Drug delivery 
The targeted delivery of drugs is an elegant and non-invasive strategy to treat 
certain diseases. Magnetic drug delivery utilizes magnetic carriers that can be 
loaded with the therapy agent and directed towards a desired zone, like tumour 
cells or blood clots, by means of a magnetic field gradient. The drugs are adsorbed 
on the surface or embedded inside these nanosystems, and ideally released only at 
the target organ. Drug release can take place by simple diffusion or proceed 
through mechanisms that require enzymatic activity, magnetic triggering or 
changes in physiological conditions such as pH, osmolality or temperature 
[Alexiou2000].  
Two aspects have to be taken into account when tackling the problem of local 
drug delivery: the choice of the adequate magnetic carriers, and how to direct the 
particles to the target. 
1.3.4.1. Magnetic Carriers for local drug delivery 
Because of their biocompatibility and magnetic properties iron oxide 
nanoparticles are the preferred material for most biomedical applications. They 
consist of a magnetite (Fe3O4) or maghemite (γ-Fe2O3) core encapsulated in an 
organic [Massart1987, Bautista2005] or inorganic matrix [Fernández-
Pacheco2006]. An alternative is the use of magnetic nanocapsules, where the drugs 
are confined inside a cavity surrounded by an inorganic membrane [Arruebo2006a] 
or a bilipid layer as in the case of magnetic liposomes [Gonzales2005]. 
The use of magnetic micro and nanoparticles for drug delivery has evolved 
since the 1970’s [Arruebo2007a]. First results refer only to the use of micron size 
particles. Zimmerman and Pilwat [Zimmerman1976] used magnetic erythrocytes 
for the delivery of cytotoxic drugs. Widder et al [Widder1978] described the 
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targeting of magnetic albumin microshperes encapsulating a chemotherapy agent 
doxorubicin in animal models. In the 1980s several authors developed this strategy 
to deliver different drugs using magnetic microcapsules and microspheres 
[Kato1984, Widder1981, Gupta1989, Morimoto1980]. In the 1990s Häfeli et al 
prepared biodegradable poly(lactic acid) microspheres that incorporated magnetite 
and the β-emitter 90Y for targeted radiotherapy, and successfully applied them to 
subcutaneous tumors [Häfeli1995]. 
Magnetic nanoparticles were used for the first time in animal models by Lübbe 
et al [Lübbe1996a]. The first phase I clinical trial was carried out by the same 
group in patients with advanced and unsuccessfully pretreated cancers using 
magnetic nanoparticles loaded with epirubicin [Lübbe1996b]. That first trial faced 
the main problem that researchers try to overcome to achieve an efficient delivery 
of magnetic carriers: most of the particles ended up in the liver, trapped by 
macrophages. 
The case of the company FeRx Inc. is also significant of the difficulty to 
succeed in this field. Founded in 1997, they produced Iron particles encapsulated in 
activated carbon by mechanical milling, and loaded them with doxorubicin. A 
phase II clinical study in patients with primary liver cancer was conducted, but the 
trial was unsuccessful, and the company finally closed down. Chemicell GmbH 
currently commercialises TargetNAG-doxorubicin nanoparticles involving a 
multidomain magnetite core and a cross-linked starch matrix with terminal cations 
that can be reversibly exchanged by the positively charged doxorubicin. These 
particles have a hydrodynamic diameter of 50nm and are coated with 3mg/ml 
doxorubicin [Steinfeld2006]. These nanoparticles loaded with mitoxantrone have 
already been used in animal models with successful results [Wiekhorst2006]. 
Chemicell also commercialises FluidMAG® for drug delivery applications. 
Magnetic nanoparticle hydrogel (MagNaGel®) from Alnis Biosciences Inc. is a 
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material comprising chemotherapeutic agents, Fe oxide colloids, and targeting 
ligands [Sunderland2006]. 
1.3.4.2 Toxicity 
Before the use of any magnetic carriers for any in-vivo application it is 
necessary to analyze its toxicity (acute, subacute and chronic toxicity, teratogenity 
and mutagenicity) in cellular and animal models, haematocompatibility, 
biodegradation (if possible), immunogenicity and pharmacokinetics: body 
distribution, metabolism, bioavailability, elimination, and organ specific toxicity 
before starting with the preclinical testing. Toxicity depends predominantly on the 
size, composition and the coating [Macaroff2006]. Tailoring the magnetic 
nanoparticles surface will be the main point to minimize any toxicological effect 
[Park2006]. In general it is accepted that larger magnetic particles show higher 
cytotoxicity than smaller ones [Yin2005]. It is well documented that the large 
surface area to volume ratio of all nanosized particles can potentially lead to 
unfavourable biological responses if they are inhaled and subsequently absorbed 
via the lung or swallowed and then absorbed across the gastrointestinal tract 
[Duncan2005b]. And not only acute toxicity but also the toxicity of degradation 
products, stimulation of cells with subsequent release of inflammatory mediators, 
and toxic effects through the particulate system have to be seriously considered 
[Neuberger2005]. 
1.3.4.3 Administration and delivery 
There are three parameters that determine the behaviour of magnetic 
nanoparticles inside the organism: the surface chemistry, size, including magnetic 
core, hydrodynamic volume, and size distribution, and the magnetic properties of 
the nanoparticles, especially their magnetic moment, remanence, and coercivity. 
The surface chemistry is very important to hinder the action of the 
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reticuloendothelial system (RES) and avoiding a fast removal. The nanoparticles 
usually need to be coated with a neutral and hydrophilic compound (i.e., 
polyethylene-glycol, polysaccharides, dysopsonins) increasing the circulatory 
clearance half-time from minutes to hours or days. Another possibility is to reduce 
the particle size; however, despite all efforts complete evasion of the RES has not 
yet been possible and additional migration to unwanted areas in the body may 
cause toxicological problems. 
The fate and toxicity of the magnetic nanoparticles mainly depends on the size, 
dose and via of administration into the body. The latter can be divided into oral or 
parenteral, including intravenous delivery, pulmonary delivery, transdermal 
delivery, ocular delivery, and even as coatings in scaffolds. Three most common 
ways of administration are intravenous, oral and direct injection in the tumour. 
 
Pa
rt
ic
le
 s
iz
e
Blood residence time
Ferromagnetic
particles
[F.Pacheco2006]
Large Superparamagnetic Iron
Oxide Nanoparticles (LSPIONS) 
>40 nm [Mornet2004]
Non biodegradable 
micrometric Inorganic
and Polymeric Spheres
[Vonarbourg2006]
Opsonization, 
removal by Liver, 
spleen and lungs
macrophages
Plasma half life = 2h
Accumulation in Lymph nodes
Excreted by urine, heces
Removed by liver
(80%) and spleen
(15%)
Ultrasmall
Superparamagnetic Iron
Oxide Nanoparticles 
(USPIONS) = 5-20 nm
[Gould2006]
Monocrystalline Iron Oxide 
Nanoparticles (MIONS)
<10nm
[Weissleder1990, 
Bonnermain1998, Lu2006]Pa
rt
ic
le
 s
iz
e
 
Figure 1.3 Evolution of blood residence time with particle size [Arruebo2007a]. 
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1.3.4.4 Intravenous administration 
For parenteral application it is essential that the carrier is non-toxic and non-
immunogenic, and it needs to be small enough to avoid embolization in the 
capillary vessels when intravenous application is used. Once a nanoparticle enters 
the bloodstream, the opsonization process activates the response of the reticule-
endothelial system (RES). The circulating mononuclear phagocytes (monocytes) 
clear the nanoparticle to the liver, spleen, and bone marrow principally where 
resident cells (i.e, Kupffer cells in the liver) from the same system capture the 
nanoparticles for their degradation if this is possible. Some of the nanoparticles 
present in the lysosomal vesicles of Kupffer cells (depending on the 
biodegradability and size) are incorporated in the bile and through the digestive to 
the faeces. Some of them after the action of the liver will be filtered by the kidneys 
and incorporated in the urine. In general, the smaller nanoparticles are subjected to 
rapid renal elimination whilst the larger ones show liver, spleen, and bone marrow 
uptake. Large particles will be only removed by cells capable of phagocytosis (i.e, 
by macrophages, dendritic cells), small particles will be removed by cells capable 
of endocytosis (i.e., by lymphocytes T), and if the magnetic nanoparticles are 
biodegradable the decomposition products can be up-taken by all the cells by 
means of pinocytosis. 
According to Neuberger et al. [Neuberger2005] magnetic particles smaller 
than 4 μm are taken up through cells of the reticuloendothelial system, mainly in 
the liver (60–90%) and spleen (3–10%). While it is more likely that small particles 
up to 100 nm will be phagocytosed through liver cells (openings in the 
endothelium of liver sinusoids are between 100 and 150 nm), there is a tendency 
for particles larger than 200 nm to be filtered by the venous sinuses of the spleen. If 
particles between 30 and 100 nm are intravenously applied, the macrophages of the 
liver (Kupffer cells) eliminate the larger particles faster from the bloodstream 
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compared to the smaller sizes. Thus, the larger the particles are, the shorter is their 
plasma half-life-period. This clearance of particles by the kupffer cells can be, on 
the other hand, useful for the treatment of diseases produced in the liver, such as 
liver cancer or leishmania [Chellata2005]. 
1.3.4.5 Oral administration 
The use of magnetic nanoparticles coated with an organic shell for using them 
as oral drug delivery vectors has been described [Cheng2006b], but most of the 
literature is referred to magnetic nanoparticles used as contrast agents for the 
gastrointestinal tract in MRI. The main problem that should be addressed is that 
oral delivery of peptides and proteins is hampered by various factors including 
their gastrointestinal degradation, low absorption, and first-pass metabolism by the 
liver. In addition, drugs delivered orally produce a significant initial increase in 
drug concentration followed by a peak above the therapeutic range. In 2003 the 
work of Feng et al. [Feng2003] describes the fate of chemotherapyl nanoparticles 
for oral delivery. Hence particles smaller than 5000 nm can be taken up via the 
lymphatics, particles smaller than 500 nm can cross the membrane of epithelial 
cells through endocytosis, and particles below 50 nm can achieve paracellular 
passage between intestinal epithelial cells. 
1.3.4.6 Subcutaneous or direct injection into the tumour 
Unlike water-soluble molecules, which are rapidly absorbed through the blood 
capillary wall and pass into circulation, small particles injected locally infiltrate 
into the interstitial space around the injection site and are gradually absorbed by the 
lymphatic capillaries into the lymphatic system [Brigger2002]. For that reason, 
subcutaneously or locally injected (in the peritumoral region) nanoparticles can be 
used for lymphatic targeting, i.e. as a tool for chemotherapy against lymphatic 
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tumours or metastases. This route is rarely used in clinical practice, as it is not 
useful for targeting metastatic tumours. 
1.3.4.7 External magnets and magnetic implants 
The second issue that has to be dealt with is the effective delivery of magnetic 
carriers to the target. The classical approach has been the use of an external source 
of magnetism, like an electromagnet, applied on the desired area to generate a 
magnetic field gradient and thus localise and concentrate magnetic particles. 
However, the use of external magnets presents serious limitations. The 
homogeneity of the magnetic field on the target zone generates very weak field 
gradients, unable to concentrate the carriers in an effective way. Because of the 
weakness of magnetic forces, which have to overcome hydrodynamic forces in the 
blood stream, the administration method is limited to an artery close to the tumour, 
it can only be applied to the treatment of superficial organs and, moreover, well 
defined magnetic field geometries are a must, depending on the tumour allocation, 
to perform an efficient magnetic drug delivery [Shinkai2002, Lübbe2001, 
Alexiou2005].  
To avoid these inconveniences, the insertion of small magnetic implants 
directly into the affected zone, or the combination of both external and internal 
sources of magnetism, appear as a promising alternative. A small stent or a 
magnetic wire is inserted near the diseased area, and an external source of 
magnetism is applied, magnetizing the implant. An internal local magnetic field is 
thus created, rather more effective than those produced by external magnets.  
Several strategies have been described to achieve an effective targeted 
accumulation of the drug carriers. Yellen et al. suggested the use of two 
independent magnetic sources. A small size magnetic mesh, consisting of a 3x3 
array of magnetic wires, in combination with long range externally applied fields 
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were used to magnetize and localize the carriers in an in-vitro experiment 
[Yellen2005]. 
Avilés and coworkers designed a coiled ferromagnetic wire stent in order to 
simulate an intravascular stent in-vitro. They used magnetite nanoparticles 
embedded in poly(styrene/divinylbenzene) matrixes as carriers, and an external 
permanent magnet to magnetize the wire stent.  Changes at the capture efficiency 
by varying the applied magnetic field, the particle concentration and the fluid 
velocity were studied [Avilés2007]. 
The research presented in chapter 6 of this work: the implantation of small 
permanent magnets by minimally invasive surgery is an alternative to these 
procedures. First in-vivo experiments of localisation of magnetic nanoparticles with 
implanted permanent magnets have already been performed in rabbits [Fernández-
Pacheco2007]. 
1.3.4.8. Non-magnetic delivery systems 
As an alternative to magnetic carriers, different organic materials such as 
polymeric nanoparticles, liposomes, and micelles have been investigated as drug-
delivery nanovectors which target a specific area in the body by means of passive 
targeting or with a recognition moiety (i.e., antibody). However, search for 
different alternatives continues in view of a variety of still unsolved problems of 
these systems, such as their limited chemical and mechanic stability, swelling, 
susceptibility to microbiological attack and the inadequate control over the drug-
release rate [Arruebo2006a]. 
One of the main disadvantages of functional polymers for biomedical 
applications is their high polydispersity. Their synthesis produces either very small 
or very large molecules (irregular branching) which could exhibit non-uniform 
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pharmacological properties. That disadvantage was solved by the use of 
dendrimers which show monodisperse character and globular architecture. This 
monodispersity results from the stepwise synthesis used in their preparation and the 
ability to purify dendrons and dendrimers at each step of growth [Fréchet2005a]. 
Dendrimers, as other nanoparticles used for biomedical applications, need to be 
biocompatible, with high plasma-residence time, and water soluble [Fréchet2005b].  
It is still a challenge to prepare dendritic polymers that circulate in the blood 
long enough to accumulate at target sites, but that can be also eliminated from the 
body at a reasonable rate to avoid long-term build-up. In addition, the tissue 
localization of dendritic polymers is still difficult to predict in advance and more 
studies are required to determine the effect of peripheral dendritic groups on these 
properties. To visualise the dendrimers it is necessary to tag them with a specific 
moiety (i.e, fluorophore, metal). 
Passive targeting using drug conjugated dendrimers and dendritic polymers is 
the most extensively studied targeted delivery using the increased permeability of 
tumour vasculature to molecules and its limited lymphatic drainage. Therapies 
based on active targeting such as antibody conjugated dendrimers have been 
developed for boron neutron capture therapy; however a full biological evaluation 
of these systems has not been reported. Antibody conjugated drug-loaded 
dendrimers show promising alternatives, although antibodies have exquisite 
potential for selective targeting but, even as humanized proteins, they can be 
immunogenic [Duncan2005a]. 
 Chapter 2 
Materials and Methods 
 
This chapter is a description of the experimental procedures that have been 
utilised throughout this work: the synthesis of the magnetic nanoparticles and the 
techniques used for their characterization, the protocols used for the chemical 
functionalisation of the particles, as well as the material and methods used in the 
haematology studies and the in-vivo surgery animal model. 
2.1 Characterization techniques 
In order to choose the most adequate particles for each application, we need to 
know the morphology, physical properties, chemical reactivity and biological 
behaviour of the produced materials. The properties of nanoparticles rely especially 
on their size, shape, chemical nature of the core and reactivity of the functional 
groups on the surface. Several spectroscopy techniques have been used to study the 
chemical composition of the obtained compounds. X-Ray and Selected Area 
Diffractions allow us to determine the crystalline structure of the metallic cores of 
the particles. Electron Microscopy gives us information on the morphology and 
heterogeneity of the samples. Finally, magnetic measurements are required to 
determine the magnetic properties of the materials at different temperatures. 
2.1.1 Magnetometry 
The magnetic properties of the compounds were studied with a 
superconducting quantum interference device (SQUID MPMS-5S, Quantum 
44 Chapter 2. Materials and Methods 
Design). DC Measurements were performed up to 50 KOe (5 Tesla). The 
temperature range was 5K to 300K. A SQUID is a superconducting ring immersed 
in liquid helium with two identical Josephson junctions. Samples can be measured 
either as solids or in aqueous suspensions. The latter have to be frozen for 
measurement, since above the melting point of water particles can rotate inside the 
liquid, leading to experimental errors. 
Measurements of magnetisation Vs applied field at a given temperature 
provide us information about the response of our particles to a generated magnetic 
gradient. Superparamagnetism, or zero value for coercivity and remanence, may be 
preferred for certain applications that require the particles to remain not aggregated 
after removal of the applied magnetic field. Measurement of magnetisation with 
increasing temperature allows us to estimate the size of the magnetic core of the 
particle and the size polydispersity of a sample, as well as calculate the blocking 
temperature of our sample, i. e. the temperature above which a material behaves as 
superparamagnetic. 
2.1.2 Scanning Electron Microscopy (SEM) 
The morphology of the particles can be studied at a first approach by scanning 
electron microscopy. SEM yields images of the particles with a resolution from a 
few milimeters to less than 50nm. In a SEM microscope, the surface of the sample 
is irradiated with high energy electrons. A set of magnetic lenses moves the 
focused beam back and forth across the specimen. As the electron beam hits each 
spot on the sample, both electrons and photons are emitted by the specimen 
surface, and their intensity is used to form the SEM image when all the spots are 
convoluted. The signals most commonly used are the Secondary Electrons, the 
Backscattered Electrons and X-rays. An electron detector is used to convert the 
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radiation of interest into an electrical signal for manipulation and display by signal 
processing electronics. 
Using the secondary electron detector a clear and focused topographical image 
of the sample is obtained. The backscatter electron detector produces an image that 
is useful when determining the make-up of the sample. Each element in the sample 
appears as a different shade, from almost white to black. Secondary electrons are 
specimen electrons that obtain energy by inelastic collisions with beam electrons. 
They are defined as electrons emitted from the specimen with energy less than 
50eV. On the other hand, backscattered electrons are the primary incoming beam 
electrons that experience an elastic backscattering with sample electrons. The 
number of backscattered electrons will produce a contrast depending on the mean 
atomic number of the illuminated spot. That way, 2D phase analysis can be 
performed comparing the different contrasts. 
Finally, X-rays are emitted when deep levels electrons are pulled out from the 
sample atoms. The energy of the emitted photon will be characteristic of the 
electronic configuration of each atom. The analysis of the X-ray fluorescence 
spectra gives the chemical composition with the spatial resolution of the beam spot. 
This technique is known as Energy Dispersive X-ray microanalysis (EDAX). 
2.1.3 Transmission Electron Microscopy (TEM) 
The detailed structural and morphological characterization of our samples was 
carried out by means of transmission electron microscopy (TEM) and the power 
spectra obtained by using Fast Fourier Transform (FFT) algorithms on the high-
resolution TEM (HRTEM) micrographs. In order to obtain the high-resolution 
TEM (HRTEM) results we used a field emission gun microscope Jeol 2010F, at the 
Serveis Cientificotècnics of the Universitat de Barcelona, which works at 200 kV 
and has a point-to-point resolution of 0.19 nm. Electron energy loss (EELS) spectra 
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were obtained in a Gatan Image Filter (GIF 2000) coupled to the Jeol 2010F 
microscope. Spectra were obtained with an energy resolution of 1.2 eV. 
In a TEM microscope a beam of electrons is transmitted through a specimen, 
and then an image is formed, magnified and directed to appear on a layer of 
photographic film, or detected by a sensor such as a CCD camera. The difference is 
the energy of the incident electrons, which is higher than in the case of TEM in an 
order of magnitude (20-30kV for SEM compared to 200-300kV of the TEM). 
These electrons can now penetrate in the sample and give us information of the 
morphology, size or crystalline structure. Electrons are emitted from a field 
emission gun and focused by means of magnetic lenses, whose magnetic fields 
deviate the trajectories. A final lens sets the sample either on the image or on the 
focal plane. In the first case a magnified image of the sample is obtained at the 
CCD camera. On the contrary, when the sample is focused on the focal plane an 
image of the reciprocal space is taken, then electron diffraction can be performed. 
A diaphragm placed at the image plane can select a certain 300kV of the TEM). 
These electrons can now penetrate in the sample and give us information of the 
morphology, size or crystalline structure. Electrons are emitted from a field 
emission gun and focused by means of magnetic lenses, whose magnetic fields 
deviate the trajectories. A final lens sets the sample either on the image area of the 
sample for diffraction, a technique known as Selected Area Diffraction Pattern 
(SADP), a tool that allows to characterise crystalline structures at a selected point 
of the sample [Williams1996]. 
In Electron Filtered Transmission Electron Microscopy (EFTEM) only 
electrons of particular kinetic energies are used to form the image or diffraction 
pattern. The technique can be used to aid chemical analysis of the sample to 
complement electron crystallography. To obtain these “coloured maps” of elements 
we must first perform Electron Energy Loss Spectroscopy (EELS) analysis.  In 
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EELS the material is exposed to a beam of electrons with a known, narrow range of 
kinetic energies, then some of the electrons undergo inelastic scattering, which 
means that they lose energy and have their paths slightly and randomly deflected. 
The amount of energy loss can be measured via an electron spectrometer and 
interpreted in terms of what caused the energy loss. Inelastic interactions include 
phonon excitations, inter and intra band transitions, plasmon excitations, inner shell 
ionisations, and Cherenkov radiation. The inner shell ionizations are particularly 
useful for detecting the elemental components of a material [Brydson2006]. 
2.1.4 Fourier Transformed Infrared Spectroscopy (FTIR) 
FTIR data were obtained using a Mattson Research Series spectrometer in air 
at room temperature. The solids were homogeneously dispersed in KBr (2%wt. 
approximately) and pressed into discs. The spectra were recorded with a resolution 
of 4 cm-1 with 80 scans per spectrum. 
Chemical bonds have specific frequencies at which they vibrate corresponding 
to energy levels. The resonant frequencies or vibrational frequencies are 
determined by the shape of the molecular potential energy surfaces, the masses of 
the atoms and, eventually by the associated vibronic coupling. Resonant 
frequencies can be in a first approach related to the strength of the bond, and the 
mass of the atoms at either end of it. Thus, the frequency of the vibrations can be 
associated with a particular bond type. In order to measure a sample, a beam of 
infrared light is passed through the sample, and the amount of energy absorbed at 
each wavelength is recorded. This may be done by scanning through the spectrum 
with a monochromatic beam, which changes in wavelength over time, or by using a 
Fourier transform instrument to measure all wavelengths at once. From this, a 
transmittance or absorbance spectrum may be plotted, which shows at which 
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wavelengths the sample absorbs the IR, and allows an interpretation of which 
bonds are present [Lau1999]. 
In our case IR spectroscopy allows us to identify the effective coating of the 
particles, through the study of the interaction between the metallic core and the 
inorganic matrix that encapsulates the particles. By means of IR we can also track 
the introduction of functional groups covalently bond to the surface of the particles: 
Carboxyl and amine groups have characteristic transmittance peaks so they can be 
easily identified in the final products by comparison with the initial reactants. 
2.1.5 Ultra Violet -Visible Spectroscopy (UV-VIS) 
UV-VIS spectroscopy is routinely used in the quantitative determination of 
solutions of transition metal ions and highly conjugated organic compounds. The 
Beer-Lambert law states that the absorbance of a solution is directly proportional to 
the solution's concentration. Thus UV/VIS spectroscopy can be used to determine 
the concentration of a solution. It is necessary to know how quickly the absorbance 
changes with concentration. This can be taken from references (tables of molar 
extinction coefficients), or more accurately, determined from a calibration curve. 
A UV-VIS spectrophotometer measures the intensity of light passing through a 
sample (I), and compares it to the intensity of light before it passes through the 
sample (Io). The ratio I / Io is called the transmittance, and is usually expressed as a 
percentage (%T). The absorbance, A, is based on the transmittance: 
A = − log(%T) 
The basic parts of a spectrophotometer are a light source (often an 
incandescent bulb for the visible wavelengths, or a deuterium arc lamp in the 
ultraviolet), a holder for the sample, a diffraction grating or monochromator to 
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separate the different wavelengths of light, and a detector. In our 
spectrophotometer the detector is a photodiode. Photodiodes are used with 
monochromators, which filter the light so that only light of a single wavelength 
reaches the detector. 
The adsorption and release of proteins or drugs from the surface of the 
particles can be studied by UV-VIS Spectroscopy with an indirect approach: the 
particles are sedimented with a magnet or centrifuged and the supernatant is 
measured. The difference between the starting concentration of the organic 
molecule that binds to the particle and the remaining concentration in solution is 
the actual concentration of the molecule adsorbed on the particle. 
2.1.6 X-Ray diffraction (XRD) 
Powder X-ray diffraction (XRD) was performed on a Rigaku/Max 
diffractometer using filtered Cu Kα radiation at the Servicio Nacional de EXAFS 
at the ICMA. XRD allows the identification and characterisation of crystalline 
solids. In the case of magnetic oxides, each of which produces a distinctive 
diffraction pattern. Both the positions, corresponding to lattice spacings, and the 
relative intensity of the lines are indicative of a particular phase and material, 
providing a "fingerprint" for comparison. Powder XRD can also be used to 
determine the partial crystallinity or amorphous structure of the particles by 
comparing the integrated intensity of the background pattern to that of the sharp 
peaks. 
Another useful application is the estimation of the size of the metallic core. As 
the size of the particle decreases, the peaks of the pattern will broaden. From the 
broadening it is possible to determine an average crystallite size, in Å, by Debye-
Scherrer formula: 
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Dhkl = k λ/β cosθ 
Where k = 0.8 -- 1.39 (usually close to unity e.g. 0.9) 
λ-wavelength of the radiation λCu = 1.54056 Å, 
β is the  full width at half maximum, or half-width in radians 
θ is the position of the maximum of diffraction. 
β
θ
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Figure 2.1 Full width at half maximum of Intensity 
2.1.7 X-Ray Photoelectron Spectroscopy (XPS) 
The X-ray photoelectron analysis (XPS) was performed with an Axis Ultra 
DLD (Kratos Tech.). The spectra were excited by the monochromatized AlKα 
source (1486.6 e.V) run at 15 kV and 2 mA. For the individual peak regions, a pass 
energy of 20 eV was used. Survey spectrum was measured at 120 eV pass energy. 
Analyses of the peaks were performed with the software provided by the 
manufacturer, using a weighted sum of Lorentzian and Gaussian components 
curves after background subtraction. 
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XPS, also called Electron Spectroscopy for Chemical Analysis, ESCA, is an 
electron spectroscopic method that uses X-rays to eject electrons from inner-shell 
orbitals. The kinetic energy, Ek, of these photoelectrons is determined by the 
energy of the x-ray radiation, hν, and the electron binding energy, Eb, as given by: 
Ek = hν- Eb 
The experimentally measured energies of the photoelectrons are given by: 
Ek = hν - Eb - Ew 
where Ew is the work function of the spectrometer. XPS instruments consist of 
an X-ray source, an energy analyzer for the photoelectrons, and an electron 
detector. The analysis and detection of photoelectrons requires that the sample be 
placed in a high-vacuum chamber. Since the photoelectron energy depends on X-
ray energy, the excitation source must be monochromatic. The energy of the 
photoelectrons is analysed by an electrostatic analyser, and the photoelectrons are 
detected by an electron multiplier tube or a multichannel detector, such as a 
microchannel plate. The energy of the photoelectrons leaving the sample gives a 
spectrum with a series of photoelectron peaks, being the binding energy of the 
peaks characteristic of each element. The peak areas can be used, with appropriate 
sensitivity factors, to determine the composition of the materials surface. And since 
the shape of each peak and the binding energy can be slightly altered by the 
chemical state of the emitting atom, XPS can provide chemical bonding 
information as well. XPS is not sensitive to hydrogen or helium, but can detect all 
other elements. 
In situ low energy Ar etching can be performed in order to probe the desired 
material, in the case of a core-shell nanoparticle this is specially useful to compare 
the chemical nature of the core and the external surface of the nanoparticles. The 
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etching of the sample is obtained sputtering the surface with an Ar+ ion source (4 
keV energy). In this etching process a depth profiling of around 5 nm is estimated.  
2.1.8 Dynamic Light Scattering (DLS) 
The particle-size distribution of the composite material was obtained by 
photon correlation spectroscopy (PCS) measurements (Malvern Zetasizer 3000 HS 
and Beckman Coulter N5). Particle size analysers determine particle size by 
measuring the rate of diffusion of particles through a fluid. The rate of diffusion 
depends on three factors: temperature of the fluid, viscosity of the fluid, and 
particle size. If the temperature and viscosity are known, the particle size can be 
determined. Estimation of size by Dynamic Light Scattering is based on two 
principles: the concept of Brownian Motion and Photon Correlation Spectroscopy. 
The motion caused by thermal agitation, that is, the random collision of 
particles in solution with solvent molecules, is called Brownian motion. These 
collisions result in random movement that causes suspended particles to diffuse 
through the solution. For a solution of given viscosity, at a constant temperature, 
the rate of diffusion or diffusion coefficient (D) is inversely related to the particle 
size according to the Stokes-Einstein equation: 
D=kT/3πηdΗ 
Where k is the Boltzmann constant, T is the absolute temperature, is the 
solvent viscosity and dH is the hydrodynamic size, that is, the size of a particle 
solvated by liquid molecules in a fluid. The hydrodynamic size or molecular 
weight of particles in solution is then obtained by measuring the diffusion 
coefficients of such particles.   
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The other principle is Photon Correlation Spectroscopy (PCS). The particles 
undergoing Brownian motion are detected and analyzed by illuminating the 
particles with a laser and measuring the scattered light with a photomultiplier tube 
(PMT). The light scattered by the particles at any given instant adds together to 
form an interference pattern. The intensity of light detected at the PMT depends on 
this interference pattern, which in turn depends on the pattern of particles in the 
laser beam. As the particles move randomly through the solution, their positions 
relative to one another change, causing a constantly changing interference pattern 
and varying light intensity at the detector. The intensity changes or fluctuations 
caused by the Brownian particles, though random in nature, occur on a time scale 
of microseconds to milliseconds. Large, relatively slowly moving particles, change 
positions slowly and cause slow intensity fluctuations at the detector; conversely, 
small, quickly moving particles cause rapid intensity fluctuations. 
PCS is based on measuring these scattered-light fluctuations, or fluctuations in 
the numbers of scattered-light photons. PCS sizes particles by characterizing the 
exact time scale of the random intensity fluctuations caused by the changing 
patterns of the diffusing Brownian particles.   In order to calculate the diffusion 
coefficient, and therefore the particle size from the changing light intensity signal, 
the signal must be mathematically transformed. The result of this transformation is 
called the autocorrelation function (ACF), which is performed by the size analyser 
correlator.  The time scale of the intensity fluctuations in the light scattered by the 
diffusing Brownian particles is found by computing the ACF of the scattered-light 
intensity. 
In order to calculate the hydrodynamic size of the particles, two modes of 
measurement can be utilised: unimodal and size distribution processor (SDP) 
analysis. Unimodal analysis is a faster method, but it only determines the mean-
scattering-intensity-weighted particle size and standard deviation of the size 
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distribution. Although unimodal results are more accurate for size distributions that 
are not extremely polydisperse, the mean size provided is still a reliable measure of 
the sample's mean size even if the true distribution is complex. The standard 
deviation also provides a good qualitative indication of the polydispersity of the 
sample, though it too, may not be strictly accurate for complex distributions. On 
the other hand, SDP analysis determines the particle size distribution. To perform 
an accurate SDP analysis requires a more accurate ACF than that for unimodal 
analysis, however, because the decay times of the light fluctuations from all the 
different sizes of particles must be mathematically separated from a single 
composite ACF. The accuracy of the correlation function is a function of the length 
of time over which it is accumulated. If you wish to perform an SDP analysis, a 
longer run time should therefore be used.   
2.1.9 BET surface area 
For the adequate adsorption and release of a drug or a defined molecule a high 
surface to volume ratio is required. Gas sorption (both adsorption and desorption) 
at the clean surface of dry solid powders is the most popular method for 
determining the surface area of these powders as well as the pore size distribution 
of porous materials. BET surface areas, N2 adsorption/desorption isotherms, and 
pore-size distributions of the samples reported in this work were obtained by means 
of a Micromeritics ASAP 2020 V1 device at 77 K. In a gas sorption experiment, 
the material is heated and degassed by vacuum force or inert gas purging to remove 
adsorbed foreign molecules. Controlled doses of an inert gas, such as nitrogen, 
krypton, or argon, are introduced and the gas is adsorbed, or alternatively, 
withdrawn and desorbed. The sample material is placed in a vacuum chamber at a 
constant and very low temperature, usually at the temperature of liquid nitrogen (-
195.6 °C), and subjected to a wide range of pressures, to generate adsorption and 
desorption isotherms. The amounts of gas molecules adsorbed or desorbed are 
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determined by the pressure variations due to the adsorption or desorption of the gas 
molecules by the material (the adsorbent). Various amounts of gas molecules will 
be adsorbed or desorbed at different doses of the gas (the adsorbate). Knowing the 
area occupied by one adsorbate molecule, σ (for example, σ= 16.2 Å2 for nitrogen), 
and using an adsorption model, the total surface area of the material can be 
determined. The most well known and widely used is the Brunauer- Emmett- 
Teller (BET) equation for multilayer adsorption [Brunauer1938]:  
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P, PO, c, n, nm are the adsorption pressure, the saturation vapor pressure, a 
constant, the amount adsorbed (moles per gram of adsorbent) at the relative 
pressure P/PO, and the monolayer capacity (moles of molecules needed to make a 
monolayer coverage on the surface of one gram of adsorbent), respectively. 
Through the slope and intercept of a plot of P/[n(PO-P)] against (P/PO), nm can be 
resolved. The specific surface area, S, can then be derived: 
σmAnNS =  
Where NA is Avogadro’s number. The specific surface area that can be 
determined by gas sorption ranges from 0.01 to over 2000 m2/g. Determination of 
pore size and pore size distribution of porous materials can be made from the 
adsorption/desorption isotherm using an assessment model, suitable for the shape 
and structure of the pores. The range of pore sizes that can be measured using gas 
sorption is from a few Ångstroms up to about half a micron. 
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2.2 Synthesis 
Magnetic nanoparticles were produced by physical or chemical methods, in 
order to obtain a range of sizes and properties for different applications. The 
discharge-arc method and ball milling are top-down methods, i. e. from the bulk 
starting material we end up in nanoscaled products. These are fast and relatively 
cheap methods to obtain particles with interesting magnetic properties, like high 
magnetisation saturations. On the contrary, co-precipitation method is a bottom-up 
approach, in which a chemical reaction in an aqueous medium forms nanoparticles, 
that can be further encapsulated in a certain polymer or inorganic coating. Particles 
thus obtained are smaller and present narrower size distributions. Their production 
can be optimised to obtain small superparamagnetic nanoparticles, a quality 
required for a number of applications.  
2.2.1 Discharge-arc 
2.2.1.1 Iron encapsulated in carbon. Fe@C. 
The production of carbon coated iron nanoparticles is accomplished by the 
discharge-arc method designed by Krätschmer-Huffman in 1990. This is a well-
known method for preparing fullerenes and multi-walled carbon nanotubes, and 
has also been used to develop iron and cobalt nanoparticles coated with carbon 
layers. 
The Krätschmer method uses a cylindrical chamber, in which there are two 
graphite electrodes: a stationary anode containing 10 microns starting iron powders 
(ALFA-AESAR), and a moveable graphite cathode (ALDRICH). An arc is 
produced between the graphite electrodes in a helium atmosphere. The graphite 
electrode is sublimed and builds up a deposit on the inner surface of the chamber. 
In the material collected from this deposit we found: carbon nanostructures, 
2.2. Synthesis 57 
amorphous carbon and iron and iron oxide nanoparticles encapsulated in graphitic 
layers. 
Non-coated or partially coated magnetic particles, which are not 
biocompatible, were eliminated by chemical etching. For magnetic purification, 
stable suspensions of the particles are prepared in a surfactant solution: 2.5 g of 
SDS in 500 ml of distilled water. A field gradient produced by 3KOe permanent 
magnet was used for magnetic separation of this suspension. The purified material 
was washed with HCl 3M at 80ºC. The obtained magnetic material was dissolved 
and the coating carbon forms hydroxil and, in some cases, carboxyl groups, which, 
due to their hydrophobic nature, contribute to the stability of ferrofluid 
suspensions. The sample was finally heated at 350ºC in order to evaporate resulting 
amorphous carbon. The resulting powders were then filtered 
Stable suspensions of the particles were obtained resuspending 1g of the 
particles in 50mls of the commercially available Gelafundine®, a succynilated gel 
commonly used as a plasmatic subsitute in blood. 
2.2.1.2 Iron encapsulated in silica. Fe@SiO2 
A modification of the Krätschmer–Huffmann arc-discharge method has been 
used to produce silica-coated ferromagnetic nanoparticles. In our system the 
stationary anode is a 4 mm diameter hollow iron rod containing silica precursor 
fine powders, and the cathode is a moveable tungsten rod. The whole system is 
water cooled, the chamber is evacuated, and filled with helium gas. The gas 
pressure is adjusted to minimise pressure fluctuations during the synthesis. A 
constant current is driven between the electrodes in contact; they are then slowly 
separated until an arc is produced between them, ionizing the helium plasma. The 
system reaches temperatures approximately up to 3000ºC. The iron electrode and 
the silica powders are then sublimed, iron nuclei condense first and a silica shell is 
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formed on the metallic cores, building up a deposit on the inner surface of the 
chamber. After each preparation, three separate samples were collected from the 
bottom, the top and the walls of the cylindrical chamber, and their morphological 
and magnetic properties were studied separately. The magnetic fraction of the 
sample was separated by means of a magnetic gradient. 
Iron rods, purchased form Alfa-Aesar (150 mm, 5 mm diameter, 99.99% 
purity) were drilled to contain the silica powders. As a silica source, commercial Y 
zeolite with a SiO2/Al2O3 ratio of 5.1 and a 900 m2/g surface area purchased from 
Zeolyst International (Valley Forge, PA, USA) was used. Metallic silicon (Sigma-
Aldrich, 99.95 % was also used as a silica source. 6-mm silicon pieces were ball 
milled under atmospheric pressure for 16 h to obtain micrometic oxidized silicon 
powders, which were then placed inside the iron rods and evaporated in the arc-
discharge chamber to obtain the final products. 
2.2.2 Mechanical Milling 
2.2.2.1 Magnetite embedded in a zeolite matrix. Fe3O4@ZY 
Commercial NaY zeolite, purchased from Zeolyst International (Valley Forge, 
PA, USA) with a SiO2/Al2O3 ratio of 5.1, 900 m2/g surface area, and ~ 1 μm crystal 
size (measured by SEM, result not shown) was first calcined at 753 K in order to 
remove any rest of organic template used during the hydrothermal synthesis, and 
then milled together with commercial magnetite nanopowder (Sigma-Aldrich, 
>98%, 20-30 nm particle size) using a zeolite/magnetite ratio of 3:1. The mixture 
zeolite/magnetite was ground through the combination of impact and friction in a 
Fritsch Mill (model: Anlysette) under a vacuum of 1.10-4 mbar for 16 h at room 
temperature. 
 
2.2. Synthesis 59 
2.2.3 Co-precipitarion and Sol-Gel 
2.2.3.1 Magnetite encapsulated in silica. Fe3O4@SiO2 
FeCl3⋅6H2O, FeCl2⋅4H2O, ethanol, ammonia aqueous (25 % wt.), tetraethyl 
ortosilicate (TEOS), 3-aminopropyltriethoxysilane, toluene anhydrous, 
dimethylformamide, glutaric anhydride, imidazole, MES buffer, ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC), and N-hydroxy succinimide (NHS) 
were purchased from Sigma-Aldrich and used as supplied. Ultra pure water was 
used throughout the experiments (MilliQ system, Millipore). 
Magnetite nanoparticles were prepared following the coprecipitation method 
described by Ma et al. [Ma2006]. A basic solution, i.e. ammonia, was slowly added 
from an addition funnel to a mixture of FeCl2.4H20 0.33M and FeCl3-6H20. The 
particles thus obtained were washed three times with distilled water, separated with 
a magnet, centrifuged and dried in an oven at 60ºC. The size of the particles 
depends on a number of factors. The basic solution used restrains the size of the 
nuclei formed, being the smallest particles obtained when NH4OH is used as the 
solution; the size increases as KOH or NaOH are used in the synthesis. A vigorous 
stirring during the process and a very slow addition of the base are the key to 
obtain homogeneous particles. However there is always a dispersity of sizes 
obtained due to the preparation, and further purification and separation are required 
nevertheless.  
The silica shell was synthesized using the sol-gel procedure optimized by 
Deng et al.  [Deng2005] using Tetraorthosilicate (TEOS) as silica source in a basic 
ethanol/water mixture at room temperature. 2g of a 2% suspension of the magnetite 
nanoparticles in distilled water was added to a mixture of 160 ml of EtOH and 
40ml of H2O. Then, 1ml of TEOS was added dropwise to the solution and the 
reaction was kept at room temperature and vigorous stirring for 12h, after which 
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the resulting particles were thoroughly washed and separated magnetically for their 
complete characterization. 
2.3 Functionalisation 
The binding of functional groups on the surface to enhance the reactivity of the 
particles towards certain biomolecules in solution is described in this section.  
2.3.1 Surface functionalisation: Chemical coupling 
The surface of carbon and silica has hydroxyl groups that can be substituted 
with other molecules in order to enhance their reactivity. Amine, carboxyl and 
chloride groups can be introduced by the reaction with the corresponding silane in 
an organic solvent like toluene or THF.  
2.3.1.1 Functionalisation with amine groups 
Surface functionalization of the silica coatings with amine and carboxyl 
groups was carried out following the experimental procedures of Ha et al, and Levy 
et al., respectively. 3-aminopropyl was the covalent linker used to attach amine 
functional groups on the external surface of the silica shells. The amine 
functionalized nanoparticles were prepared by boiling a toluene solution dissolved 
with 3-aminopropyltriethoxysilane (APTES) and refluxed under argon for 3 h to 
tether the 3-aminopropyl groups on the external surface of the silica coated 
nanoparticles.  
2.3.1.2 Functionalisation with carboxyl groups  
The carboxyl-functionalized nanoparticles were prepared by dispersing the 
composite nanoparticles, obtained after the treatment in a reflux of toluene with 
APTES, in a mixture of 3-aminopropyltriethoxysilane and glutaric anhydride 
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dissolved in dimethylformamide (DMF) during 24 h. The particles thus obtained 
were repeatedly washed with acetone first, and mixtures of acetone/water in which 
the ratio of organic/aqueous ratio was consecutively diminished, in order to 
efficiently remove all traces of organic solvent.  
2.3.2 Coupling of antibodies 
In order to develop a contrast agent with potential active targeting properties, 
carbon and silica-coated magnetic nanoparticles have been functionalised with an 
antibody. The antibody anti-hCG was chosen because it is widely studied due to its 
common use in pregnancy testing kits. Antibodies are immune system-related 
proteins, which consist of four polypeptides: two heavy chains and two light 
chains-joined to form a "Y" shaped molecule (see Fig. 4.5, chapter 4). They present 
amine and carboxyl terminal groups that can be used to bind our aminated or 
carboxylated particles through a glutaraldehyde or carbodiimide covalent bond, 
respectively. 
2.3.2.1 Carbodiimide 
The covalent coupling of the antibody (anti-hCG) to the carboxyl-
functionalized nanoparticles was carried out following a standard protocol with 
water soluble carbodiimide (EDC) [Bangs2007]. After covalent coupling the 
nanoparticles were re-suspended in a storage buffer composed of Tris/HCl, 10 mM 
at pH 8.1 and 1% wt. 
2.3.2.2 Glutaraldehyde 
The covalent coupling of the antibody (anti-hCG) to the amino-functionalized 
nanoparticles was carried out with an excess of glutaraldehyde as the amine 
reactive homobifunctional cross-linker in a phosphate-buffered saline (PBS) buffer 
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as the washing/coupling buffer. After immersion in PBS, the initial nanoparticle 
concentration was 10 mg/mL. The obtained pellet was dispersed in 10 mL of a 10 
wt. % glutaraldehyde solution. 0.15 mg of antibody were dissolved in 1 mL of 
coupling buffer. The nanoparticle suspension was combined with the antibody 
solution and reacted for 4 h at room temperature with continuous mixing. The 
obtained product was washed gently and magnetically separated. After covalent 
coupling the nanoparticles were re-suspended in a storage buffer composed of 
Tris/HCl, 10 mM at pH 8.1 and 1 wt. %.  
2.3.2.3 Verification of the antibody coupling 
Both for carbodiimide and glutaraldehyde binding, the suitable attachment of 
the antibody to the magnetic nanoparticles was verified. For this purpose an 
immunochromatographic assay (also termed lateral flow test) was carried out, 
using the attachment of the conjugate particle-antibody to the human chorionic 
gonadotropin hormone and subsequent detection in a nitrocellulose membrane, 
where the complementary anti-antibody was previously immobilized. The specific 
binding streptavidin-biotin is used as the control line in the membrane to assure the 
quality of the test. 
To attain detection of the antibody-conjugated nanoparticles 2 μL of the 1 wt. 
% nanoparticles dispersion were mixed with increasing amounts of the hCG 
hormone in a buffer composed of: phosphate buffer 10mM, NaCl 150mM , BSA 
0.3 wt. %, Tween-20 0.1 wt. %, and sodium azide 0.1 wt. % at pH 7.4. Monoclonal 
anti-Chorionic Gonadotropin (α+β subunits) (hCG) antibody was purchased from 
Medix Biochemica (Finland). One end of the test strip was immersed in this 
suspension and then the elution flow proceeded by capillarity. Capture of the 
antibody-functionalized nanoparticles produced a dark band in the region of the 
test strip where the complementary anti-antibody had been immobilized. The 
2.3. Functionalisation 63 
intensity of colour can be photographically assessed and related to the 
concentration of nanoparticles in the suspension and with the amount of hCG in the 
solution. 
A control assay is also performed using antibody-conjugated nanoparticles 
without adding the hCG hormone to the buffer dispersion. Without the hormone in 
the media no band was detected (optically or magnetically), showing that there is a 
specific interaction between the hormone and the anti-hCG antibodies. 
2.3.3 Pegylated particles 
In order to avoid the action of the immune system and prolonge their stability 
in aqueous suspensions and therefore their residence time in blood, Fe@C particles 
were coated with an hydrophilic PEG layer. The amphiphilic copolymer PMAO-
PEG was obtained following the procedure by Yu et al [Yu2006]. 30 mg of Poly 
(maleic anhydride-alt-1-octadecene) (PMAO, Mw=50000, ALDRICH) and 90 mg 
of primary amino group terminated poly(ethylene glycol)methoxy ether (mPEG-
NH2, Mw=5000, ALDRICH) were mixed in 5 mls of chloroform (CHCl3) and 
stirred at room temperature overnight in a molar ratio of  1-30. After that, a 20 mg 
of Fe-C particles suspension in 5 ml of CHCl3 was sonicated with an ultrasonic 
probe for 5 minutes and the stable suspension was added to the obtained 
copolymer. The mixture was sonicated for 15 min in an ultrasound bath and left to 
react at room temperature for 48h. After this time the magnetic solid was separated 
with a magnet and the liquid decanted. The organic solvent was thoroughly 
removed by washing with ethanol, acetone, and finally distilled water. 
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2.4. In-vitro experiments 
2.4.1 Haematology results 
The study of hemorheological parameters has been recommended for 
biocompatibility testing. Conventional radiological contrast media and those 
involving paramagnetic nanoparticles used in nuclear resonance are usually tested 
for viscosity. We have performed the basic recommended tests adapting them to 
nanoparticles in circulation. 
To prepare the biocompatible suspensions, 100 mg of Fe@C nanoparticles 
produced by the arc-discharge method were suspended in 100 ml of Gelafundine®, 
a commercial succinylated gel commonly used as plasmatic substitute of blood. 
The solution was then sonicated for fifteen minutes. Human blood from 5 healthy 
volunteer donors was tested in vitro, before and after being mixed with the particles 
suspension in different dilutions (1ml of blood and 0.06; 0.12; 0.24 and 0.5 ml of 
particles).  The same procedure was followed for the tests in animals (ex-vivo 
tests): 10 non-injected New Zealand rabbits (as control) and other 10 animals (test 
rabbits) after intravenous injection of 1 ml of the particles suspension in 
Gelafundine®. Blood samples were taken 10´, 30´ and 24 hours after the injection 
of particles.  
Blood viscosity was measured with a Brookfield® DV-3 cone-plate 
viscometer at different shear stress (230 s-1, 23 s-1 y 5.7 s-1), and plasma viscosity 
with a capillary viscometer Fresenius®. We have determined as well erythrocyte 
aggregability in vitro with a Mirenne® aggregometer after 5 and 10 seconds of 
stasis and after 5 and 10 seconds of very low shear stress (3s-1). The shear stress 
applied in this experiment simulates those of circulating blood in different areas of 
circulation: veins, capillaries and arteries. We have done as well a complete blood 
2.4. In-vitro experiments 65 
count, including differential leukocyte count, with a haematology cell counter 
(Coulter LH-750®) and the usual coagulation tests: Prothrombin time, 
thromboplastine time and fibrinogen (ACL-9000® coagulation analyzer and  
Hemosil IL® kit), and D-Dimer immuno-turbidimetry (Turbiquant D-Dimer Dade-
Behring ®). 
2.4.2 Uptake by dendritic cells 
Dendritic Cells (DCs) are the main antigen presenting cells of the immune 
system. The inclusion of Fe@C particles inside DCs has been studied with the aim 
of reaching a tumour site and release a chemotherapy agent or selectively heat and 
kill malignant cells by means of an alternate magnetic field. 
2.4.2.1 Cell culture 
Mononuclear cells obtained from 14 ml of blood were cultivated during seven 
days with AIM-V media with Interleukin 4 (10U5/100ml) and Granulocyte-
macrophage colony stimulation factor (10U5/100ml). On day five 5μg/ml of media 
containing lypopolysacharides were added to induce maturation of DCs. On day 7 
15μl/ml of media of a 5% suspension of Fe-C nanoparticles were added to the 
culture. Finally cells were recollected on day 8, washed twice with PBS and 
resuspended in the same buffer and centrifuged during 25 min at 400 G with Ficoll 
histopaque (1.077 g/ml) DCs were isolated from the PBS/Ficoll interface and 
unincorporated NPs remained in the bottom of the tube. Incorporation of MNP was 
assessed by confocal and electronic microscopy. 
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2.4.2.2 Viability Studies 
DCs were cultured in a 12 wells plate and NPs incorporated as previously 
described and cells were recollected from different plates on days 8, 9, 10, 11 and 
12 and viability of the DCs was assessed with tripan blue. 
2.4.2.3 Electron Microscopy 
Electron Microscopy was done in the Anatomy Service of the University of 
Zaragoza. Cells were fixed with glutataraldehyde and made resistance with lead 
nitrate. 
2.4.3 Kinetics studies of drug adsorption and release 
Doxorubicin hydrochloride injectable solution was purchased from Pharmacia 
Spain. Doxorubicin adsorption was performed by dispersing 10 mg of 
nanoparticles in 4 mL of doxorubicin solution (0.2 mg/mL) until saturation 
following the experimental procedure described by Kuznetsov et al 
[Kuznetsov1999]. At fixed time intervals, the magnetic nanoparticles were 
separated from the supernatant by means of a permanent magnet. 1 mL of 
supernatant was withdrawn from the vial and measured by UV spectrometry at 498 
nm (Varian Cary-100 Bio spectrophotometer). After each measurement each 
sample was reincorporated into the vial. 
After reaching saturation, the drug-loaded magnetic nanoparticles were 
washed three times in distilled water to remove all the non-adsorbed doxorubicin, 
magnetically separated by means of a permanent magnet, and dried. The release 
profile was obtained by dispersing the dried drug-loaded nanoparticles in 4 ml of 
human plasma kept at 37ºC. At fixed time intervals, the magnetic nanoparticles 
were separated from the supernatant by means of a permanent magnet. A small 
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volume of supernatant was withdrawn from the vial and measured by UV 
spectrometry at 498 nm. After each measurement the vial was refilled with plasma 
to keep the volume constant, and the new dilution was recalculated for each 
measurement. 
2.5 In-vivo experiments 
The particles were tested in an in-vivo preclinical animal model. Magnetic 
implants were inserted in the main organs of New Zealand rabbits and the 
capability of the magnet to attract nanoparticles was tested. The design of the 
experimental procedure was previously evaluated by the Ethics Committee for 
Animal Research of the University of Zaragoza, code PI 19/04. To achieve the 
targeted delivery of particles to the implanted organ three different strategies were 
designed: intravenous injection of the particles through a marginal ear vein of the 
animal, intrarterial injection and direct inoculation of the particles suspension 
under echographic control. 
2.5.1 Preclinical experimental model 
Stable suspensions of the carbon coated iron nanoparticles were tested in an 
in-vivo preclinical animal model. Magnetic implants were inserted in the main 
organs of 36 New Zealand rabbits and the capability of the magnet to attract the 
magnetic particles was tested. The experimental procedure was previously 
evaluated by the Ethics Committee for Animal Research of the University of 
Zaragoza, code PI 19/04 
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Figure 2.2 French plastic trocar with a sharpened tip, used to perforate the desred organ and 
insert the small magnetic implant. 
The animals, after 12 hours without being fed, were premedicated with an 
intramuscle Medetomidine (Domtor®) 10mg/Kg + Ketamine (Imalgene® 500) 20 
mg/Kg injection. Only when it was necessary Atropine 0.05 mg was added 
complementarily. A 22 gauge Braunüle Vasocan Catheter was inserted in the 
marginal vein of the ear, and a perfusion of a physiologic saline solution was 
initiated. Next, the peritoneal cavity was insufflated with CO2 through a Veress 
needle and a minilaparoscopic optic was introduced using a 5 mm trocar. Then, 
through an 8 French plastic trocar (Fig. 2.2), and under endoscopic control, the 
lower pole of the left kidney was punctured, inserting a 4x2 mm cylindrical 
permanent magnet (neodymium-iron-boron coated with gold) in it (Fig. 2.3). The 
right kidney was also punctured but no magnet was inserted. The purpose is to 
reproduce the same tissue damage as in the counter lateral kidney, and to have a 
control organ to compare the concentration of the particles attracted to the targeted 
organ. After controlling the absence of bleeding, the trocars were retired and the 
cutaneous insertion orifices were sutured. 
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Figure 2.3 Under laparoscopic control, the kidney is punctured and the magnetic implant is 
inserted. 
2.5.2 Intravenous administration 
2 ml of the particles suspension were injected intravenously in the marginal 
ear vein of the rabbit. Different groups of animals were sacrificed by terminal 
anaesthesia after half an hour, 2, 7, 14, 21 and 28 days, and the main organs (lungs, 
liver, spleen, kidneys and spine) were extracted for histological study. 
2.5.3 Direct injection in the affected organ 
A week after the insertion of the magnet, nanoparticles are directly injected into the 
kidney under ultrasound control. General anaesthesia was induced administering 
0.4 mg of medetomidine (Domtor®) and 60 mg of ketamine (Imalgene 1000®) 
intramuscularly. The left flank was shaved and the zone disinfected with a 50% 
mixture of iodine and ethanol. The guide for biopsy needles was set in the probe of 
the ultrasound scanner Sonosite Titan® with a 20G adaptor. The probe was aimed 
towards the kidney in which a magnet had been inserted. 
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The magnet, a solid and metallic object inside the kidney, produces the apparition 
of an artifact called “comet tail”. The ultrasound beam contacts a narrow and 
echogenic interface and as a consequence a series of linear echoes appear. 
Once the magnet has been identified, the route of penetration of the needle appears 
on the screen so that the position of the magnet can be centred. Once the route of 
injection is made to coincide with the magnet’s position, a 20G calibre and 70mm 
long needle is inserted and the load of nanoparticles is inoculated, after which the 
needle is removed. 
 Chapter 3 
Characterisation 
 
Four novel preparations of core-shell magnetic nanoparticles are presented in 
this work. First, iron nanoparticles encapsulated in carbon and silica have been 
produced by the discharge-arc method [F.-Pacheco2006, F.-Pacheco2007]. The 
mechanical milling of magnetite and zeolite yields a composite material containing 
magnetite nanoparticles embedded inside zeolite matrixes [Arruebo2006b]. And by 
a combination of the co-precipitation method and the sol-gel technique small 
magnetite crystallites have been encapsulated in amorphous silica [Arruebo2007b]. 
The morphological, physical and chemical properties can make each particle more 
suitable for a certain application, either in-vitro or in-vivo, depending on their size, 
magnetic properties, surface area and functional groups on the surface. In order to 
organise data in a more suitable way the characterisation of the materials is 
presented separately for each type of particle. 
3.1 Iron coated by carbon. Fe@C 
With a slight modification of the Krätschmer-Huffman discharge-arc chamber, 
iron nanoparticles coated by graphitic layers have been obtained. The relatively 
low price of the initial reagents and the availability of the arc furnace make it 
possible to produce big quantities of raw materials. After magnetic purification and 
successive filtration fine black powders are obtained. 
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3.1.1 Transmission Electron Microscopy (TEM) and XRD 
 
Figure 3.1 HRTEM images of two different γ-Fe2O3 nanoparticles encapsulated in graphitic 
layers. On both images a perfect encapsulation of the magnetic core by graphitic layers can 
be observed. 
High-resolution TEM (HRTEM) and Energy Filtered TEM (EFTEM) images 
show that the coating of the iron particles is complete, thus rendering them 
biocompatible. Fe appears with a darker contrast whereas C, a lighter element, 
appears with a lighter contrast in Fig. 3.1. 
 
Figure 3.2 EFTEM image composition of a Fe@C nanoparticle. Red corresponds to 
graphitic encapsulation, whereas green represents the presence of the Fe metallic core. 
Moreover HRTEM micrographs showed that the plane spacing observed in 
that specific nanoparticle correspond to the γ-Fe2O3 Maghemite phase, whereas the 
plane observed at the encapsulation layer should be associated with the C graphite 
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phase. For the EFTEM images (Fig.3.2), iron (EELS peak at 708 eV, L3 peak) and 
carbon (EELS peak at 228, K peak) were selected separately. Once both images 
were obtained, an elementary map can be drawn, showing a coloured distribution 
of each of the elements: green for Fe and red for C. 
Furthermore, sample composition could be also analysed by electron 
diffraction (Fig. 3.3). The obtained results were in good agreement with those 
previously obtained by HRTEM. Point symmetry and lattice spacing of iron oxide 
in the core of the nanoparticle was observed (cubic phase of the γ-Fe2O3, 
Maghemite). 
(32-2)
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[011] Fe2O3 Maghemite
 
Fig. 3.3 Electron Diffraction proves that the particle core of the analysed particle 
crystallises in the maghemite phase. 
Figure 3.4 is the image of another particle observed with an Ultra High 
Resolution Transmission Electron Microscope (UHRTEM Titan 80-300). In this 
case the metallic core is crystallised in the α-Fe phase, as it can be observed from 
the distances between atomic planes, much smaller than in the case of iron oxides. 
The presence of iron nanoparticles is predominant for all preparations. 
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Figure 3.4 Ultra High Resolution Transmission Electron Microscopy (UHRTEM Titan 80-
300) image of an iron nanoparticle encapsulated in carbon. Atomic planes of the metallic 
core and the graphitic coating are clearly visible. 
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 Figure 3.5 XR diffractogram of the Fe@C nanoparticles. Experimental diffractogram 
(black) peaks correspond to those of Iron (red), whereas the proportion of iron oxides (blue, 
magnetite) is much smaller.  
This is also checked by X-Ray Difrraction. XR diffractogram proves that most 
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of the material is crystallised in the Fe0 phase, without undergoing oxidation (Fig. 
3.5). The apparition of some very small particles oxidised to maghemite can be due 
to processes of oxidation that take place during the synthesis of the particles at the 
discharge-arc chamber, and that is what can be observed by TEM analysis, 
although those peaks are not significant in the diffractogram of the sample, because 
the fraction of these small particles is really small. 
From TEM images, the size distribution of the particles can be analysed. 
Different images from different regions of a same sample area analysed, and the 
particles’ diameter measured, to obtain a size distribution histogram that can be 
fitted to a log normal distribution (Fig. 3.6). Whereas some particles bigger than 40 
nm could observed, most of the analysed material was distributed between 5 and 23 
nm. Maximum is centred in 10 nm. The sample preparation for TEM analysis is an 
inconvenient for the accurate size measurement, since only smaller particles are 
able to be penetrated by electrons, and therefore bigger particles or aggregates are 
left out.  
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Figure 3.6 Histogram of particles size from TEM images. Slightly broad size dispersion is 
observed, from 5 to 40 nm.  Maximum is centred in 10 nm. 
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3.1.2 Dynamic Light Scattering (DLS). Estimation of size. 
DLS was performed for all the samples, and the obtained average size was 200 
nm (Fig. 3.7). DLS Measurements provide us information about the hydrodynamic 
radius of the particle, i.e. the size of the particle in a liquid suspension, surrounded 
by the solvent molecules. It is expected that DLS yields a particle size different to 
the one obtained by direct TEM analysis: first of all TEM is a local measurement 
and DLS measures the sample as a whole; moreover the behaviour of particulate 
materials in solution or in a liquid suspension is strongly different to their 
behaviour as solids. On the other hand, TEM measures only the fraction of the 
smallest nanoparticles. Particles (or aggregates of particles) bigger than 150 nm are 
opaque to the electron beam, as electrons are not able to penetrate inside such big 
particles. In addition, sample preparation is made by acquiring a drop from a 
suspension of the iron oxide coated powder into n-hexane. Big nanoparticles tend 
to be deposited onto the bottom side of the solution just by gravity, and drop taken 
from the top-middle solution always underestimate the particle size. 
 
 
Fig. 3.7 DLS estimation of the hydrodynamic radius of the Fe@C particles in aqueous 
suspension. A broad distribution is observed, and the maximum is centred on 200 nm. 
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3.1.3 Magnetic Properties 
The magnetisation isotherms can be understood as the superposition of two 
different magnetic behaviours, consistent with the existence of two different 
particle size ranges in our samples (Fig. 3.8). The largest particles give rise to a 
high saturation magnetisation and coercivity is observed, even at room 
temperature. This suggests the existence of ferromagnetic aggregates of particles 
(several hundreds of nanometers, in good agreement with the DLS results). 
Considering this particle size, one can expect in our sample a blocking temperature 
above room temperature. This fact is confirmed by field cooling (FC) and zero-
field cooling (ZFC) magnetisation measurements (Fig. 3.9). On the other hand, the 
high field susceptibility displayed by the hysteresis loop is due to the existence of 
small particles (tens of nanometers, according to the TEM results), showing a 
superparamagnetic behaviour. 
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Fig. 3.8 Hysteresis loop of the Fe@C particles. Ferromagnetic behaviour is observed. 
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Fig. 3.9 Zero Field Cool and Field Cool measurements confirm the presence of blocked 
aggregates of particles for the whole range of temperatures. 
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3.2 Iron coated by silica. Fe@SiO2 
Silica-encapsulated iron nanoparticles were obtained using the arc-discharge 
system. Modifying the Krätschmer–Huffmann method mostly isolated and 
homogeneous particles have been obtained, as proved by TEM and XRD 
measurements. An iron rod was used as the anode, and Y-zeolite or oxidized 
metallic silicon powders were used as the silica source. These particles combine 
the high magnetisation saturation and strong response to magnetic fields of their 
ferromagnetic core with the adsorption properties and chemical versatility of their 
silica coating, presenting a reasonable BET surface area for the adsorption of drugs 
or biomolecules.  
Elementary analysis (ICP-AES) gave an average amount of 12.6±0.5 wt % of 
Silica per total mass of sample, which is in agreement with the initial amount of 
reactants used for the synthesis of iron-silica products. 
3.2.1 Magnetic Properties 
The room temperature magnetisation values obtained is the largest reported for 
magnetic nanoparticles encapsulated in inorganic matrices (see a revision of 
literature results in the Appendix to this chapter). The magnetic moment values are 
given per unit of total mass (emu/g), considering the total weight of both, silica and 
iron in the nanoparticles. Different samples reach values over 160 emu/g, and 
162.9 emu/g is the maximum magnetisation found at 3 Tesla. The closest result, 
140 emu/g, was reported by Tang et al. [Tang2005], for cobalt-silica composites 
produced by the sol-gel method. All the samples showed ferromagnetic behavior, 
attaining saturation at 2 T (Fig. 3.10). Coercivities around 350 Oe were obtained in 
all cases when Zeolite Y was used as the silica source, increasing to 479 Oe when 
metallic silicon was used as precursor. The diamagnetic behavior of SiO2 is 
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responsible for the lower value of magnetisation with respect to that of metallic 
iron, from 217.6 emu/g of pure iron [Crangle1971] to 162.9 emu/g of our material. 
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Fig. 3.10 M Vs H isotherm at 300K for the Fe@SiO2 particles produced by the discharge-
arc method when Y zeolite (squares) or metallic silicon (triangles) is used as the silica 
precursor, respectively. The high coercivity (340 Oe) and magnetic saturation (160.1 
emu/g) values confirm the ferromagnetic behaviour and the strong magnetic response of 
both samples. 
3.2.2 Transmission Electron Microscopy 
When Y zeolite was used as the silica source, TEM images of the obtained 
samples prove the presence of iron nanoparticles well coated by a quasi-amorphous 
silica matrix (Figs. 3.11.A, 3.11.B). The particles are coated with a zeolite-type 
aluminum silicate that decomposes under the electron beam, as zeolites are very 
electrosensitive materials that amorphisise quickly under the electron beam: in 
some areas atomic planes that disappear after some seconds of exposition to the 
electron beam were observed. EELS spectra obtained from the cores show the clear 
presence of iron, while the shell is mainly made of silicon and oxygen, as it can be 
observed by EFTEM (fig. 3.11.D). HRTEM images also show that the atomic 
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interspaces found for the particle cores correspond to those of α-Fe (metallic 
phase). 
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Figure 3.11 Transmission Electron micrographs of the silica-coated iron nanoparticles 
obtained from Y zeolite powder. (C) Electron Energy Loss Spectra (EELS) of the same 
particle. (D) EFTEM shows an iron-rich core and a silica-rich shell. 
On the other hand, when oxidized metallic Silicon was used as the silica 
source, the presence of the silica coating is again observed for all the particles. This 
was identified by examining the low energy EELS plasmon region, where a 
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maximum at 22.4 eV characteristic of SiO2 was observed. Two types of atomic 
planes have been observed, corresponding to Fe2O3 (hematite) and to metallic iron. 
Filtering separately the spots corresponding to each structure on the Fourier space, 
and applying the inverse FFT algorithm to each filter, a very thin (2.3 nm) layer of 
iron oxide (hematite) surrounding the metallic Fe core can be observed (Fig. 3.12). 
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Fig. 3.12 EFTEM and HRTEM patterns for the Fe@SiO2 particles obtained using metallic 
silicon as the silica precursor. Blue: SiO2 plasmon. Red: Fe fcc HRTEM structure. Green: 
Fe2O3 hematite HRTEM structure. After obtaining the electron diffractogram of the sample, 
a Fast Fourier Transform (FFT) is applied the result and the obtained spots can be 
compared to the theoretical values of the distances between atomic planes. That way the 
crystallographic phase is obtained, and metallic iron can be distinguished from its oxides. 
This could not be seen for all the particles, since most of them crystallize in a 
bcc iron phase. EELS spectra clearly proved that the particle cores were very rich 
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in iron, whereas the presence of oxygen was much smaller, due only to the thin 
pasivation layer of iron oxide and the SiO2 coating. 
Especially for the first preparation, (using Y-zeolite as the silica source) the 
particle size distribution is narrow, with the materials produced being rather 
homogenous in size and shape. The presence of silica bridges among some of the 
particles can also be observed (Fig. 3.13). 
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Fig. 3.13 EFTEM and HRTEM patterns for the Fe@SiO2 particles obtained using metallic 
silicon as the silica precursor. The presence of silicon bridges aggregates the particles. 
3.2.3 X-Ray Diffraction 
XRD results revealed the typical diffraction pattern of α-Fe (Fig. 3.14). The 
characteristic diffraction peaks for quartz or Y zeolite at the low angle region did 
not appear, probably due to the fact that only amorphous silica is coating the iron 
cores, something that correlates with TEM results. Using the Scherrer equation and 
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fitting the characteristic peak at 2θ = 44.5 deg to a PseudoVoigt function, the 
average particle size of the iron cores of the bulk sample was 56 nm. However, 
TEM micrographs show smaller particle sizes around 10-30 nm. Elementary 
analysis (ICP-AES) gave an average amount of 12.6 ± 0.5 wt % of Silica per total 
mass of sample. 
 
Fig. 3.14 XRD diffractograms for the Y-zeolite, α-Fe and silica-coated iron nanoparticles 
patterns. The obtained sample presents peaks that correspond to the metallic iron phase. 
The crystalline structure of zeolite is not preserved after preparation. Inset: the low angle 
region magnification shows a slight hump that could correspond to the presence of 
amorphous silicon encapsulating the particles. 
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3.2.4 BET surface area 
The N2 adsorption/desorption isotherms for the silica-coated iron nanoparticles 
are also displayed in Fig. 3.15. Pore size distributions were calculated using the 
adsorption branch of the N2 adsorption/desorption isotherm and the Barret-Joyner-
Halenda (BJH) method. It is important to point out that the BJH method has been 
reported to underestimate the pore size. The micropore volume of the sample was 
almost 0, as calculated from the t-plot method, which is consistent with a particle 
coating consisting of mesoporous silica. The mesopore size was 5.9 nm and the 
obtained BET surface area was 30.61 m2/g. 
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Fig. 3.15 BET adsorption and desorption isotherms for the Fe@SiO2 particles obtained by 
discharge-arc. 
86 Chapter 3. Characterisation 
3.2.5 XPS studies 
XPS analysis provides information about the chemical coposition of the 
surface of our material. The spectra prove the presence of silica insulating the 
particles: a Si 2s peak (153 eV) can be clearly observed; it nearly disappears after 
etching the outer coating (Fig. 3.16), whereas the Fe 2p peaks increase 
significantly. Moreover, more detailed information on the existence and nature of 
the iron oxides present at the particles surfaces can be attained by careful 
inspection of the XPS spectrum shown in Figure 3.17. This spectrum is 
characterized by the existence of two main peaks at 710.3 eV and other at 723.8 eV 
which respectively correspond to Fe+3 2p3/2 (L3) and 2p 1/2 (L2) edges, as previously 
observed [Fuji1999]. It is clearly noticed the existence of a satellite peak at an 
energy binding of 718.8 eV, which is the fingerprint of iron oxide (Fe+3) 
[Mossbauer1990]. It is also perceptible the existence of very small peaks at ~706.9 
eV and 719.8 eV which can be associated with the presence of some very small 
residual metallic iron phases at the surface. 
 
Fig. 3.16: XP spectra of iron encapsulated in silica corresponding to silicon before and after 
Argon etching (5 nm depth). Silicon peak disappears after the effect of the ions etching, 
which remove the silicon encapsulation of the particles. 
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Fig. 3.17 XPS spectra of iron encapsulated in silica, a) before and b) after argon etching 
(approximately 5 nm depth), probing the iron core of the encapsulated nanoparticles. The 
coating of iron oxide is etched, therefore decreasing the Fe+3 2p3/2 edge and increasing the 
Fe0 2p edge of the particle’s core. 
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In-situ low-energy Ar etching was performed. In this etching process a depth 
profiling of around 5 nm is estimated. As a consequence, after the etching process 
the particles core is expected to be probed. The results are shown in Fig 3.17 in 
which a strong enhancement of the L3 and L2 metallic Fe0 edges can be observed. 
These correspond to the typical spectra of full metallic iron. This is an indication 
that the particles cores are iron as shown by HRTEM results. The relevance of 
combining both experimental techniques has to be underlined, as HRTEM probes 
just on a few manometers region, while XPS gives information about the electronic 
states of the elements, scanned on larger areas of the samples. 
3.3 Magnetite encapsulated in silica. Fe3O4@SiO2 
By a combination of the co-precipitation method and the sol-gel technique, 
small magnetite cores have been encapsulated in silica to obtain particles of a size 
in the range of 80 nm. Iron-based magnetic particles less than about 25 nm exhibit 
superparamagnetism at room temperature [Lee1996]. Also, bare superparamagnetic 
iron oxide nanoparticles are considered to be biodegradable. Iron would be reused 
or recycled by cells using normal biochemical pathways for iron metabolism 
[Bulte2004, Saebo2004]. This is supported by the pharmacokinetic data published 
for commercial iron oxide-based contrast agents (e.g., Feridex IV™, from 
Advanced Magnetics, Inc.), showing that at the usual doses a significant fraction of 
the iron in superparamagnetic iron oxide nanoparticles can enter the normal iron 
metabolism cycle, becoming part of the body iron pool, while unabsorbed iron can 
be excreted (mainly via urine). On the other hand, the size of the obtained 
superparamagnetic nanoparticles (∼80 nm) is smaller than the spleen filtration cut-
off (200 nm) [Fahmy2005], meaning that they are not likely to accumulate in the 
spleen; it is therefore reasonable to expect that a significant fraction of these 
nanoparticles will be excreted via urine and bile. In any case, further studies are 
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needed to determine the extent of iron assimilation in silica-coated iron cores, and 
the final fate of the silica coating itself. 
 Even though limited amounts of iron can be assimilated, it is also true that an 
excess of exposed iron would present toxicity problems, and therefore the presence 
of bare (i.e., non-coated) iron must be minimized. This requisite is fulfilled in these 
particles, where the presence of iron at the surface was less than 0.6 atom %, (the 
limit of detection of XPS analysis under the used conditions). 
3.3.1 X-ray diffraction 
XRD analysis carried out on both silica-coated and uncoated magnetic cores 
showed the presence of the characteristic diffraction peaks of magnetite/maghemite 
not only for the iron oxide nanoparticles but also for the silica-coated iron oxide 
nanoparticles (Fig. 3.18). 
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Figure 3.18 X-ray diffractograms of the magnetite pattern, the obtained magnetite 
nanoparticles before sol-gel encapsulation treatment and the silica-coated magnetite 
nanocomposites. The final product preserves the peaks of magnetite, with a slight decrease 
in intensity due to the presence of the silica coating. 
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However, XRD analysis does not allow discrimination between magnetite 
(Fe3O4) and maghemite (γ-Fe2O3) because both have similar crystallographic 
structure and their diffraction patterns overlap. Thus, further characterization 
(HRTEM, EELS and XPS) was carried out, as shown below. The intensity of the 
XRD peaks decreased after coating the particles with silica due to the effect of the 
amorphous silica shell. No other phases (i.e., hematite) were found. Using the 
Scherrer equation (see section 2.1.6) and fitting the characteristic peak at 2θ = 35.9 
deg ([311] diffraction plane) to a PseudoVoigt function, the average particle size of 
the iron-oxide cores of the sample was estimated as 17 nm.  
3.3.2 N2 adsorption/desorption isotherms 
The N2 adsorption/desorption data obtained with the silica-coated 
nanoparticles approached a Type II isotherm, characteristic of macroporous 
materials with surface heterogeneity. However, the isotherm also showed a 
microporous pattern in the region of low relative pressures (< 0.05 P/P0). The 
micropore volume of the sample was 0.005 cm3/g, which is consistent with a small 
contribution of the microporous silica to the macroporosity of the composite. The 
macroporous average pore width was 32.5 nm and the BET surface area was 48.7 
m2/g of which 38.2 m2/g corresponding to the external surface area. The 
macroporosity can be attributed to the spaces between particles, which is in 
agreement with the results obtained using HRTEM, which are discussed next. The 
microporous average pore width was 1.5 nm from the Horvath-Kawazoe analysis 
of the N2 desorption data.  
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3.3.3 Transmission Electron Microscopy 
TEM micrographs showed roughly spherical silica particles with a metallic 
core (Figure 3.19). The mean nanoparticle size was approximately 80 nm for the 
composite material, while the average size for the magnetic cores varied between 6 
and 20 nm. 
 
Fig. 3.19 TEM photographs for the silica coated iron oxide nanoparticles. Some free iron 
oxide (dot-line) can be seen in the bottom right image. The perfect encapsulation of the iron 
oxide cores, the homogeneity of the sample and the narrow size distribution can be 
observed from the images,. 
On the other hand, EFTEM micrographs (Fig. 3.20) clearly showed that the 
iron oxide nanoparticles were almost always coated with an amorphous silica shell, 
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and free magnetite seldom occurred in the samples analyzed. According to the 
results presented so far, it seems appropriate to describe the obtained product as a 
relatively homogeneous collection of nanoparticles with an average size of 80 nm, 
consisting of an iron oxide core encapsulated in a microporous silica shell.  
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Fig. 3.20 a) HRTEM micrograph of the Fe3O4 magnetite nanoparticles encapsulated within 
the silica shell and structural analysis by means of the power spectrum. b) EFTEM colour 
map showing the Iron (red) atomic distribution (in this case forming the Fe3O4 
nanoparticles), and the silicon (green) distribution, as part of the shells. 
Concerning the nature of the iron oxide cores, HRTEM analysis and EELS 
(Fig. 3.21) revealed patterns consistent with the presence of magnetite (Fe3O4). 
Analysing the ELNES spectrum for the iron L2 and L3 peaks it is possible to 
calculate the relative proportions of iron oxidation states in the mixture 
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[Colliex1991, Van Aken1998] and to distinguish between magnetite and 
maghemite. Calculating the ratio of the integrated areas of the peak a ratio 
I(L3)/I(L2) ≈ 2.82 was obtained, indicating a high content of Fe2+ (73.25 %) 
compared to Fe3+ (26.5 %). This again indicates that maghemite is mostly absent 
from the iron oxide phase. 
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Fig. 3.21 EELS Spectra of the Fe3O4@SiO2 particles. From the quantitative relationship 
between iron and oxygen edges the presence of magnetite is confirmed. 
3.3.4 DLS Estimation of Size 
The particle-size distribution for the silica-coated nanoparticles at pH 7.3 
measured by DLS yielded an average value of 98 ± 15 nm in broad agreement with 
the TEM results. These results suggest that, at the pH of the blood, the silica shell 
helps to prevent particle agglomeration, giving a stable suspension. Following 
attachment of the antibody, the particle-size distribution for the antibody-
conjugated nanoparticles was determined again by DLS, yielding an average size 
of 555 ± 14 nm at pH 7.3, indicating some degree of particle agglomeration. This 
agglomeration disappeared by applying a rehydration protocol to the particle 
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suspension, bringing again the average particle sizes to values slightly below 100 
nm. 
3.3.5 Magnetic measurements 
The magnetic measurements carried out at different temperatures for the silica 
coated iron oxide nanoparticles are shown in Figure 3.19. As could be expected 
from the above discussion, the silica-coated iron oxide nanoparticles show a 
behaviour close to superparamagnetism, with a magnetic moment of 10.3 emu/g at 
4 Tesla and a coercivity of 15.7 Oe at 310 K. The low coercive field can be related 
to the remanence of the magnetometer. It must be noted that magnetic moment 
values in this case are given per unit of total mass (emu/g), that is, considering the 
total weight of both silica and iron in the nanoparticles, therefore yielding overall 
magnetic moments lower than those measured for commercial superparamagnetic 
iron oxide preparations (e.g., Feridex IV™, 68 emu/g Fe). [Bomatí2005] When the 
magnetite cores synthesized in this work were measured separately at 3 Tesla, they 
yielded a magnetic moment as high as 68.7 emu/g. This is lower than the magnetic 
moments measured for pure magnetite samples (92 emu/g) due to the increased 
disorder at the particle surfaces as their size is decreased [Huang2004]. If 68.7 
emu/g is considered as the magnetic moment corresponding to the bare 
nanoparticle cores, the magnetite content estimated for the composite would be 
approximately 15 wt. %, which is similar to the values expected from the relative 
amounts of magnetite and silica used in the sol-gel procedure (12.7 wt. % of 
magnetite).  
Above 150 K the coercivity values are comparable to those of the remanent 
field of the coils in the magnetometer, i.e. the coercivity of our samples can be 
assumed to be practically zero. When magnetisation versus field/temperature is 
plotted for each measurement (Figure 3.22 a) above 150 K there is a clear 
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overlapping of the graphs, again characteristic of the superparamagnetic behaviour 
of the sample. 
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Fig. 3.22 a) Magnetisation Vs Field/Temperature for the obtained silica coated iron oxide 
nanoparticles at different temperatures. Above 150K graphs are superimposed, collapsing 
them into one. Inset: zoom in to show the coercivity field; b) ZFC and FC magnetisation 
curves of the silica-coated magnetite nanoparticles. 
The temperature dependence of the magnetisation was also measured. By 
means of the Zero-field-cooling (ZFC) and field cooling (FC) analysis the blocking 
temperature of the sample (maximum of the ZFC curve) can be obtained, above 
which the particles are superparamagnetic (Figure 3.22 b). 
96 Chapter 3. Characterisation 
Below 150 K all the particles are blocked, their magnetic moments remain 
aligned along the direction of the applied magnetic field, displaying ferromagnetic 
behaviour. The presence of blocked particles below 150 K is in strong agreement 
with the magnetisation measurements at different temperatures. These magnetic 
measurements indicate superparamagnetic behaviour of the composite (magnetite-
silica) nanoparticles at room temperature, thus making them suitable for their use 
in potential applications as MRI contrast agents. 
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Figure 3.23 Langevin fit to the experimental isotherm for the Fe3O4@SiO2 particles. The 
high value for R2=0.99732, indicated that experimental data accurately follow Langevin 
law. Form the obtained fit equation the diameter of the particles can be calculated. A value 
of 15 nm of diameter was estimated with this method. 
Particles above 150 K are in the superparamagnetic state; therefore they are 
expected to follow the Langevin law. By fitting the magnetisation isotherm to the 
Langevin function (Fig. 3.23), the mean size of the particles can be estimated. 
Assuming a spherical shape for the particles, a size of 15 nm was obtained, which 
is comparable to the sizes measured by TEM. This size suggests the presence of 
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single-domain magnetite nanoparticles, in agreement with all the previous 
measurements. 
3.4 Magnetite embedded in a zeolite matrix. Fe3O4@ZY 
The mechanical milling of magnetite and Y-zeolite powders in a ball mill 
yielded a composite that exhibits magnetic properties and a high surface area. This 
material was also characterised morphologically and magnetically. 
3.4.1 SEM and TEM 
SEM photographs after milling (Fig. 3.24) showed a bulk material with a 
particle size distribution from 20 nm to 1.2 μm. However, the range of particle 
sizes measured by PCS for this sample (volume average) extended from 20 to 600 
nm, probably because the larger particles settle during DLS measurements. 
Although there are isolated nanosized particles (demonstrated by HRTEM), 
agglomerations up to 1.2 μm were observed. 
 
Figure 3.24 Scanning Electron Micrograph of the bulk composite material. The right side is 
a magnification of the picture on the left. 
Even so, the largest dimension of these measured crystals is still considerable 
smaller than the capillary diameter of the human body (8 μm [Ritter2004]) which 
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makes their size suitable for intravenous injection in drug-delivery applications. In 
addition, the hydrophilic zeolite shell would provide the vector with the required 
biocompatibility needed to minimize the reticuloendothelial system response. 
As expected, the HRTEM micrographs revealed the presence of magnetite in the 
composite material. As an example, Figure 3.25.a shows a region in which several 
iron oxide nanoparticles are visible. The Power Spectrum (Fig. 3.25.c), obtained 
after applying the Fast Fourier Transform (FFT) algorithm to the HRTEM image 
selection (Fig. 3.25.b), allowed the precise identification of the nature of these 
particles by showing the inverse spinel structure characteristic of magnetite. A 
further confirmation of the encapsulation of the magnetite nanoparticles within a 
zeolitic shell was provided by EFTEM (Figure 3.26). In Figure 3.26.b, the red 
pixels correspond to the presence of iron atoms (in this case forming Fe3O4 
magnetite oxide nanoparticles) while green pixels correspond to the presence of 
silicon atoms (in this case as part of Y-zeolite aluminosilicate). There are no visible 
free magnetite nanoparticles and it can be observed that all the magnetite 
nanoparticles are surrounded by a thin (4 nm) zeolite layer. Those results are 
consistent with the observations discussed concerning the XRD patterns of the 
particles attached to the magnetic stirrer, where the presence of zeolite was evident, 
and with the XPS results regarding the Si/Fe ratios of the surface material, that also 
indicated that magnetite particles were coated by a zeolite layer. 
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Fig. 3.25 a) HRTEM micrograph showing magnetite nanoparticles encapsulated within the 
zeolite crystals. b) HRTEM magnified detail extracted from the squared section in a). c) 
Power spectrum obtained after applying the FFT algorithm to the previous selection 
 
Fig. 3.26 a) Bright Field TEM (BFTEM) micrograph showing the magnetite particles 
encapsulated within the zeolite crystals. b) EFTEM colour map showing the iron (red) 
atomic distribution (forming the magnetite particles) and the silicon (green) distribution, as 
part of the zeolite crystals. 
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3.4.2 X-Ray Diffraction 
XRD patterns showed that the only reflections detected correspond to the 
zeolite and the magnetite phases; no other structures or alloys were present (Figure 
3.27). Also, the figure shows that there is not appreciable distortion of the Y 
zeolite/magnetite composite pattern compared to the parent zeolite, indicating the 
absence of changes in the cell dimensions of the zeolite crystals. These results are 
in contrast with the findings of Sorescu et al. [Sorescu2004], who reported a phase 
transformation of magnetite to hematite caused by high-energy ball milling. This 
evolution of phases is caused by the oxygen present during the ball milling in 
conditions of atmospheric pressure or low vacuum (0.1-5 torr). However, in this 
case, used high vacuum (7.5.10-5 torr) was used, hence, although hematite was 
searched specifically, it was not detected in the XRD results, meaning that hematite 
was not formed under the milling conditions employed. 
XRD was also used to assess the stability of the bond between the zeolite and 
magnetite in an aqueous environment. For that purpose, the composite material was 
immersed in distilled water and stirred overnight at room temperature. The 
particles strongly attached to the magnetic stirrer (the place where free magnetite 
would conceivable be preferentially collected) were analyzed using XRD, and the 
diffraction patterns were examined for an enrichment of the peaks corresponding to 
magnetite. The results are shown as the bottom curve in Figure 3.21, and it can be 
seen that they are undistinguishable from the curve obtained after mechanical 
activation. Hence, it can be concluded that, after prolonged exposure to water 
under stirring, magnetite is still firmly attached to the zeolitic matrix, and no 
significant segregation takes place. Those results are in agreement with the results 
obtained with XPS, FTIR, and HRTEM. 
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Fig. 3.27 X-Ray diffractograms of the parent materials (Y zeolite and magnetite) of the 
composite material obtained after milling and of the composite material after aqueous 
dispersion and magnetic separation.  
3.4.3 Magnetic Properties 
The SQUID measurements carried out at room temperature showed a 
saturation magnetisation at 2 Tesla as high as 16 emu/g with a coercitivity of 94.2 
Oe (Fig. 3.28). This is a reliable indication of the existence of blocked magnetic 
particles at room temperature, in good agreement with the observation of 
aggregates of magnetic particles in our samples. Nevertheless it must also be noted 
that the lack of saturation of the magnetisation isotherm reflects a 
superparamagetic behavior resulting form the smallest isolated nanosized magnetic 
particles. An extrapolation of the SQUID measurements to high field values would 
give a value of approximately 17 emu/g. It is important to point out that the 
magnetic moment values are given per unit of total mass (emu/g), that is, 
considering the total weight of both zeolite and magnetite in the composite 
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material. Therefore, after taking into account the zeolite/magnetite ratio of 3:1 for 
the composite material a value of ~ 68 emu/g would be obtained as the magnetite 
contribution, which is very close to the value for commercial magnetite (73.1 
emu/g). 
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Figure 3.28 300K magnetisation isotherm for the composite material after 16h of milling at 
room temperature. The inset details the hysteresis loop, showing a coercive field of 94.2 
Oe. 
The composite sample showed ferromagnetic behavior. The saturation 
magnetisation could be increased by means of optimizing the proportion of 
magnetite/zeolite in the starting material before milling, i.e., increasing the content 
of magnetite while avoiding the presence of free magnetite in the obtained 
composite. Comparing the particles obtained with the composite maghemite/Y 
zeolite prepared by the precipitation procedure by Oliveira et al. [Oliveira2004] 
with the same zeolite/iron oxide weight ratio of 3:1, a very similar saturation 
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magnetisation can be observed (17 and 18 emu/g, respectively), with a 
considerably higher BET surface area for the particles prepared in this work (442.9 
versus 381 m2/g). Thus similar total magnetisation values are obtained, using 
magnetite, in spite of the fact that this material has and intrinsically lower magnetic 
susceptibility than the material used in the work of Oliveira et al. (maghemite). 
3.4.4 BET surface area 
Figure 3.29 shows the characteristic Type I isotherm of microporous materials 
both for the initial zeolite Y and for the magnetite/zeolite composite. A strong 
decrease (from 900 to 486.1 m2/g) of the surface area after calcination was 
observed for the parent zeolite, due to the condensation of surface silanol groups. 
After the inclusion of magnetite during milling the zeolite seems to retain its BET 
area (there is a perceptible decrease, from 486.1 to 442.9 m2 per gram of sample, 
but it must be taken into account that in the composite sample one quarter of the 
weight corresponds to magnetite). Also, a slight reduction in the pore volume (from 
0.17 to 0.16cm3/g) was also observed for the composite material, compared to the 
parent zeolite (Fig 3.30). The fact that both the surface area and the pore volume of 
the zeolite are roughly maintained indicates that most of the pore mouths of the 
zeolitic channels remain open after inclusion of magnetite. This result makes the 
composite material a promising candidate as a drug-delivery vector principally for 
those drugs that can fit within the microporous structure. 
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Fig. 3.29 N2 adsorption isotherm at 77K. pore-size distribution for the parent zeolite and for 
the composite material obtained after milling. 
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Fig. 3.30 Pore-size distribution for the parent zeolite and for the composite material 
obtained after milling. 
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3.4.5 IR Spectroscopy 
A complete Infra-red spectroscopy analysis has been performed for the 
obtained materials. It is of special interest to prove the actual chemical bond 
between the iron oxide particles and the silica matrix in which they are embedded. 
Figure 3.31 shows the IR spectra of the samples in the structural region of zeolites. 
The spectrum of Na-Y zeolite shows the most intense peaks in the range 1300-900 
cm-1, assigned to the asymmetric T-O-T stretching vibration, with the main internal 
component at 1017 cm-1, together with a much less intense band with a maximum 
at about 790 cm-1, assigned to the symmetric stretching vibration [Sobalik1998]. 
Peaks at 460 and 575 cm-1 are assigned to the bending of TO4 tetrahedra and to the 
structurally sensitive double five-membered ring vibration, respectively 
[Dumitriu2003]. The 719 cm-1 band, on the other hand, is associated with the 
surface aluminium species [Mohamed2002].  
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Fig. 3.31 a) FTIR spectra at room temperature for the parent materials (zeolite and 
magnetite) and for the composite materials obtained after milling. b) Detail of the FTIR 
spectra at room temperature. 
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The spectrum of Y zeolite-magnetite showed spectral changes compared to 
that of Y zeolite. The band for the internal asymmetrical TO4 tetrahedra showed a 
shift to a higher wavenumber (1027 cm-1); also, a weak band at 900 cm-1 and there 
is a broadening of the 575 cm-1 band. Even though the increase of frequency with 
decreasing Al content is well known [Halasz2005], the band at 719 cm-1 remains 
unchanged, indicating that dealumination is not the cause of the shift. Besides, 
Duke et al. [Duke1995] observed Al3+ replacement in iron framework-substituted 
LTL zeolites, but in that case, the stretching vibration of the Si-O-T moved to 
lower wavenumbers with iron incorporation. On the other hand, it has been 
reported that the asymmetric stretching of the tetrahedron TO4 is shifted to higher 
wavenumbers as sodium exchange takes place [Falabella1998]. This interpretation 
would be consistent with our results, thus suggesting that a partial ionic exchange 
had taken place in the Y zeolite/magnetite composite. 
Further evidence for Fe-Si interaction is suggested by the observation of the 
band at 900 cm-1. Bands around 950 cm-1 are generally attributed to the stretching 
vibrations of SiO4 tetrahedra perturbed by the presence of a metallic ion 
[Astorino1995]. Witcherlová and co-workers [Sobalik1998] explained the band at 
918 cm-1 as a result of bonding of bare ions to the oxygen in the framework, 
causing deformation of the adjacent T-O-T bonds. This is also in agreement with 
results reported by Kaliaguine and co-workers [Dumitriu2003], who assigned the 
shoulder around 960 cm-1 in the spectra of BiOx clusters occluded in ZSM-5 zeolite 
to an ensemble –(SiO)3Si-O-Bi. The broadening of the double five-membered ring 
absorption for the composite material compared to the parent Y sample could also 
be attributed to the lattice distortion caused by iron oxide clusters in the pores 
[Dimitriu2003]. 
The FTIR spectrum of magnetite is also shown in Figure 3.32 for comparison. 
Undoubtedly, the observation of the 800-400 cm-1 region is not an easy task 
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because of the superimposition of framework bands. The broad band around 600 
cm-1 observed in the iron spectrum has been attributed to the Fe-O stretching 
vibrations [Giri2005]. On the other hand, Huang and Chen [Huang2005] assigned a 
band at 561 cm-1 to Si-O-Fe vibration.. The broadening of the 575 cm-1 band could 
be related to the presence of such vibrations HRTEM images showed that the 
magnetite nanoparticles (with diameters of 20-30 nm) generally maintain their 
individuality (i.e., are not agglomerated) within the zeolite/magnetite composite, 
and that a thin aluminosilicate coating (~ 4 nm thick) envelops the magnetite 
nanoparticles, which appear associated to the larger zeolite particles (200 nm-1.2 
μm long) (Figure 3.32). This is in agreement with the work of Zhou et al. 
[Zhou2002] who showed that the aggregation of the magnetic nanoparticles of 
NiFe2O4 was minimized due to the existence of the amorphous silica matrix. The 
appearance of the TEM micrographs suggests that a homogeneous distribution of 
zeolite-coated magnetite nanoparticles has been achieved, due to repeated impact 
and compression processes during grinding. 
3.4.6 XPS studies 
The XPS spectra of the Y zeolite-magnetite sample evidenced oxygen, silicon, 
aluminum, iron, sodium and carbon peaks. Atomic concentrations were calculated 
from the integrated intensities of the chosen peaks using ionisation cross sections 
provided by the instrument software. The low concentration of Fe atoms on the 
surface of the solid compared to the bulk material (Table 3.1) again suggests that 
most of the magnetite particles are coated with a zeolite layer, in agreement with 
HRTEM observations. The binding energy of the Fe 2p3/2 (710.3 eV) is assigned 
to the stoichiometric Fe3O4 [Banerjee2006]. In addition, no signal of metallic iron 
was observed in the XPS spectrum. Binding energy levels for iron are the same in 
the parent material and in the zeolite/magnetite composite, indicating that there 
were no significant differences in the oxidation state of iron in both materials.  
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Table 3.1: XPS binding energies and relative concentrations of Si and Fe on the surfaced 
and at the overall composite. 
Binding energies (eV)  Solid 
Si 2p3/2 Fe 2p3/2 
Si/Fe 
(bulk)1
Si/Fe 
(surface)2 
ZY-magnetite 102.9 710.3 0.78 21.7 
Magnetite - 710.4 - - 
 
 Appendix: Magnetic saturation and size 
for different nanomaterials 
Core Shell or matrix Size 
(nm) 
Msat 
(emu/g) 
Ref. 
Iron Silica (56) 163 This work 
Mn1-xZnxFe2O4 Polyaniline 100 36.3 [Lee2007] 
Nickel Carbon 30 22.5 [He2008] 
LiNi0.5Fe2O4 Polyaniline 60 9.7 [Jiang2007] 
Iron Iron oxide 12 85 [Bomatí2005a] 
Iron Silica 300 125 [Cheng2006a] 
CoFe2O4 Silica 55 57 [Shang2006] 
PBMA Fe-PGMA 13 1.19 [Bao2006] 
Magnetite Silica 80 1.2 [Wu2004] 
Iron Silica 30 3.5 [Bomatí2005b] 
Iron Silica [a] 3.7 [Grigorieva2005] 
CoFe2O4 Silica (50) 25.3 [García Cerdá2005] 
α-Fe/Fe3C Mesoporous carbon 50 30 [Lee2005] 
Ni Silica (75) 55 [Fu2005] 
Magnetite Silica 9.9 76 [b] [Gao2005] 
Magnetite Silica 40 7.5 [Yong-Hui2005] 
NiZn/Fe2O4 Silica (16) 26 [Wu2004] 
Co Silica (50) 146 [Tang2005] 
Fe1-xREx 
(RE=Nd,Sm,Eu,Tb) 
Alumina and 
maghemite 
(60) 144 [Varanda2004] 
Co Silica 10-15 141 [Vadala2005] 
Magnetite Silica 16 23 [Dormer2005] 
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Core Shell or matrix Size 
(nm) 
Msat 
(emu/g) 
Ref. 
Strontium 
hexaferrite 
Silica - 2.3 [Eliseev2005] 
Co Silica 10-150 130 [Lu2005] 
NiFe2O4 Silica (24.5) 28 [Huang2005] 
Magnetite Silica 360-700 0.4 [Im2005] 
Magnetite  Silica (7.6) 14 [Sun2005] 
Mn0.65Zn0.35Fe2O4 Silica (18) 38 [b] [Yan2004] 
Magnetite Silica (100-
150) 
82 [Bruce2004] 
NiZn/Fe2O4 Silica (2-25) 11 [Huang2004] 
Iron Silica [a] 3.7 [Eliseev2004] 
NiZn/Fe2O4 Silica (14-22) 26 [Wu2004] 
Magnetite Silica 20 61 [Cao2004] 
Magnetite Silica 50-80 19.8 [Liu2004a] 
Maghemite SBA-15 - 0.3 [Jung2004] 
Co/Fe2O4 Silica 92 19.3 [Silva2004] 
Co/Fe2O4 Silica (3-10) 21.8 [García Cerda2004] 
Magnetite Silica 100-200 18.01 [Liu2004b] 
Mn0.65Zn0.35Fe2O4 Silica (3-21) 17.15 [Jan2004] 
Co Silica (9.9) 15.7 [Jabosky2003] 
Maghemite Silica (10-12) 62.6 [Xue2002] 
ZnFe2O4 Silica (5-20) 42 [Zhou2002] 
NiFe2O4 Silica (6-10) 8 [Mohallem2003] 
Magnetite Mullite (13) 3.3 [Morales2000] 
Co/Fe2O4 Silica (40-200) 72 [Mekala2000] 
[a] Nanowires 
[b] Signal of the core 
In parenthesis: size of the core only. Extracted and adapted from Fernández-Pacheco, R., Arruebo, 
M.; Marquina, C. I.; Ibarra, M. R., Arbiol, J.; Santamaría, J. Nanotechnology 17 (2006) 1188.
 Chapter 4 
Functionalisation 
 
This chapter comprises the results and discussion concerning the 
functionalisation of the magnetic particles. Silica and especially carbon are quite 
inert materials with hydroxyl groups on their surface. The introduction of chemical 
groups on these particles makes them more reactive in order to bind certain 
molecules. This process is known as functionalisation, and it allows particles to be 
tagged with a molecule that performs a specific reaction in the organism. This is, 
for instance, the case of an antibody that selectively recognises a tumour cell, 
which is especially interesting for the development of nanoparticles for biomedical 
applications, such as vectors in new drug design, MRI contrast agents or molecular 
recognition for their application in biosensors. 
Also, the coating with serum proteins and the hydrophilic polymer 
poly(ethylene glycol) (PEG) is specially relevant for in-vivo applications. The 
coating of Fe@C nanoparticles has been studied with the objective of avoiding 
opsonisation and therefore the capture by the immune system by steric and 
electrostatic effects. This allows a longer circulating time in the blood stream, and 
a more efficient delivery of the particles to the desired target. 
4.1 Antibody binding 
In the case of drug delivery, MRI or hyperthermia applications, particles have 
to be tagged to recognise a selected zone of the organism. To achieve a selective 
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delivery of the targeted carriers to specific organs and tissues different strategies 
can be used [Arruebo2007]: the most direct one is to use a specific administration 
route (oral, parental, interstitial, nasal, etc.) according to the organ which is 
targeted. Another possibility is size-dependent delivery, by means of the intrinsic 
porosity of the capillary vessels in the body [Okuhata1999, Weinmann2003]. 
Moreover, this strategy takes advantage of the fact that vascularisation changes for 
a tumour cell: enhanced permeability in the capillary, higher tortuosity, and less 
supporting tissue, and at a cellular level: expression of different surface markers 
[Carmeliet2000, Vicent2006]. Based on this mechanism it has been demonstrated 
that commercial SPION Combidex® (Advanced Magnetics Inc.) accumulates in 
non-cancerous lymph node tissue [Shelley2006]. Finally, the use of functional 
agents, like monoclonal antibodies, integrins, peptides, asialoglycoproteins, folates 
or polysaccharides, conjugated with the nanoparticles, produces a specific 
interaction with the cells of the targeted organ or tissue [Morawski2005]. In 1996 
Suzuki et al. [Suzuki1996] described the development of targeted-directed 
magnetic resonance contrast agents using monoclonal antibody-conjugated 
magnetic particles. Since then, several scientific papers concerning targeted iron-
oxide contrasts agents for MRI have been published [Artemov2003, Ahrens2003, 
Pirko2004, Funovics2004]. Huh et al. [Huh2005] have reported magnetic 
nanocrystals conjugated to a cancer-targeting antibody (herceptin), and subsequent 
utilisation of these conjugates as MRI probes. They have successfully 
demonstrated the monitoring of in-vivo selective targeting events of human cancer 
cells implanted in live mice. Moore et al. [Moore2004] reported the synthesis and 
characterization of targeted contrast agents, which show the specific recognition in 
vivo of uMUC-1 antigen in an animal model of human cancer. At this time, 
targeted contrast agents for MRI are already commercialized (i.e., MagNaGel® 
Alnis Biosciences Inc.) 
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In order to develop a contrast agent with potential active targeting properties, 
carbon and silica-coated magnetic nanoparticles have been functionalised with an 
antibody. The antibody anti-hCG was chosen because it is widely studied due to its 
common use in pregnancy testing kits. Ongoing work is aimed at the use of 
antibodies that are able to recognize tumour-associated antigens as well as growth 
factors (anti-VEGF, anti-VCAM). 
4.1.1 Functionalisation with carboxyl and amine groups 
The strong coupling between carboxyl and amine groups via a carbodiimide 
bond is responsible for many interactions between biomolecules. It is the case of 
the peptidic bond between amino-acids to form a protein. In order to make use of 
this coupling, particles can be designed to carry either amino or carboxyl groups on 
the surface to be linked to a desired complementary molecule. The reflux in an 
organic solvent of the particles in the presence of APTES 
(aminopropyltroethoxysilane) leads to the substitution of hydroxyl groups on the 
inorganic surface (silanol, Si-OH in the case of silica coating) by aminosilane 
groups (figure 4.1a). 
 
Figure 4.1 Schematic diagram of the superficial components of the biofunctionalised 
nanoparticles. Carbon or silica coatings initially have hydroxyl groups on their surface, that 
can be substituted to yield: a) Amine functionalised silica coated iron oxide nanoparticles, 
b) carboxyl functionalised silica coated iron oxide nanoparticles. 
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These particles can then react towards carboxyl-modified surfaces or other 
amines, via the glutaraldehyde bond. In the presence of glutaric anhydride the 
amine group of the APTES reacts with the anhydride to yield a carboxyl-modified 
product (figure 4.1.b). Carboxyl-modified particles can then be used for their 
linkage to amino terminal-groups. This functionalisation reaction has proved to be 
rather more effective than alternative procedures, like the reflux in the presence of 
a nitric acid, which has been used for the introduction of carboxyl groups on the 
surface of carbon nanotubes. This method was tested for the carbon-coated 
nanoparticles, but the introduction of carboxyls was scarce. 
Different solvents were tested to obtain more stable functionalised products. 
Many synthesis reactions of nanoparticles involve the use of organic solvents. 
However, any in-vivo application requires the particles to be dispersed in an 
aqueous solution at their final stage. Hence any traces of organic components must 
be eliminated. Dimethylformamide (DMF) is toxic and difficult to remove from the 
reaction, therefore toluene (CH3-C6H5).was finally chosen for a complete 
solubilisation of the initial reagents and a better dispersion within an aqueous 
medium. 
4.1.2 XPS characterisation of functionalised surfaces 
To demonstrate the actual presence of amino and carboxyl groups on the 
particles, the surface was studied by infrared and photoelectron spectroscopy. For 
the amine-functionalised nanoparticles, FTIR analysis could not provide evidence 
of the presence of amino groups in the region of 1650-1500 cm-1 because of the 
interference of adsorbed water on the surface. In contrast, for the carboxyl-
modified nanoparticles this technique clearly showed the presence of absorption 
bands in the range from 1380 to 1550 cm-1 which are associated with the presence 
of COO- groups. 
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Regarding XPS analysis, the main elements detected before functionalisation 
of the iron oxide-silica particles were Si and O, in addition to the usual adventitious 
carbon. Concentrations of Fe and N were less than 0.6 atom %. The peak positions 
detected for Fe 2p3/2 and 2p1/2 at 710.8 and 724.3 eV, respectively are consistent 
with the presence of iron in magnetite [Shah2002]. The particles were again 
analysed by XPS after the chemical functionalisation and before antibody coupling 
showing the presence of amine and carboxyl groups (see Table 4.1).  
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Figure 4.2: XPS spectra of the faminated Fe3O4@SiO2 nanoparticles. The peaks at 397 eV 
and 399 eV correspond to -NH2 and R2-NH bonds [García Fierro2003]. Bare Fe/SiO2 black 
- NH2 functionalised Blue 
The amine-modified particles showed a broad band corresponding to N 1s 
core-level spectrum, which was deconvoluted into two contributions (Fig. 4.2, 
Table 4.1). The peak at 399.3 eV would correspond to –NH2 species while the 
highest Binding Energy component could be attributable to decomposition 
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products of the precursor, i.e. R2-NH, were R is a hydrocarbon chain 
[Arroyo2003]. C 1s (Table 4.1) presents two components, associated to C-C and C-
N bonds; oxygen and Si spectra show peaks consistent with these results. 
Table 4.1: Binding energies and Full width at half maximum (FWHM) of N 1s and C 
1s peaks for the amine and carboxyl functionalised nanoparticles before antibody coupling 
N 1s C 1s  
Binding energy and 
(FWHM) eV 
Peak 
percentage 
Binding energy      
and (FWHM) eV 
Peak 
percentage 
Amine 
functionalised 
nanoparticles 
399.3 (1.5) –NH2 
401.3 (1.7) R2-NH 
74 % 
26 % 
284.9 (1.4) C-C 
286.2 (1.2) C-N 
86 % 
14 % 
Carboxyl 
functionalised 
nanoparticles 
399.8 (1.5) –NH2 
401.6 (1.8) R2-NH 
 
5 % 
95 % 
284.8 (1.4)  C-C 
286.0 (1.5) C-O 
and/or C-N 
288.0 (1.3) ROC=O 
73 % 
13 % 
14 % 
The carboxyl-functionalised nanoparticles showed a broad peak, which can be 
associated with the core level spectra of C 1s were resolved into three peaks (Table 
4.1). The main one, at 284.8 eV was attributed to carbon atoms bonded to carbon 
neighbours [Thomé2006], while the 286.0 eV component can be ascribed to C-N 
bonds [Arroyo2003] and/or to C=O bonds also present the carboxyl-functionalised 
nanoparticles. The last component (288.0 eV) would confirm the presence of 
ROC=O groups. Regarding the N 1s core-level spectrum, the analysis was similar 
to that of the amine-modified particles, with deconvolution into two contributions, 
one at 401.6 eV corresponding to R2-NH bonds, and a second component attributed 
to amine groups not attached to the carboxylic compound [Arroyo2003]. It is 
important to point out that the relative abundance of nitrogen in amine groups is 
4.1. Antibody bindng 117 
very low (5 atom %). The analysis of the rest of the elements present did not 
provide reliable information and are not included in the table. 
4.1.3 Binding to the antibody anti-hCG 
After the grafting of functional groups, the anti-hCG antibody was linked to 
the surface of the particles by two different mechanisms. In the case of carboxyl-
modified particles, the antibody was grafted via the carbodiimide bond (Fig. 4.3). 
An acylisourea unstable intermediate is formed and it rapidly reacts in the presence 
of an amino group to yield a strong covalent bond between the particle and the 
antibody. In the case of the amino-modified particles, the antibody was linked via 
the glutaraldehyde bond (Fig. 4.4). An aldehyde activated sphere is formed on the 
first step that reacts with the amino group of the antibody [Bangs2002]. 
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Figure 4.3: Coupling between a carboxyl-modified particle and an antibody via the 
carbodiimide bond. Even though the antibody is displayed with simplified Y-shape, the 
binding is randomly-oriented. 
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Figure 4.4: Coupling between an amino-modified particle and an antibody via the 
glutaraldehyde bond. The binding is randomly-oriented. 
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To verify that a suitable attachment of the antibody had been achieved for 
either procedures, a standard immunoassay test was carried out.  The human 
chorionic gonadotropin hormone (hCG) is detected in a nitrocellulose membrane 
where the complementary anti-antibody had been previously immobilised. The 
specific binding streptavidin-biotin was used as the control line in the membrane to 
assure the quality of the test. One end of the test strip was immersed in this 
suspension and then the elution flow proceeded by capillarity. Capture of the 
antibody-functionalised nanoparticles produced a dark band in the region of the test 
strip where the complementary anti-antibody had been immobilised (Fig. 4.5). 
Experimental details are fully described in section 2.3.2, Page 64. 
 
Figure 4.5 Schematic diagram showing the method of the detection of the antibody. Visual 
detection of the antibody-conjugated nanoparticles by means of capture in a nitrocellulose 
membrane containing the complementary antibody. The specific binding streptavidin-biotin 
is used as the control line in the membrane to assure the quality of the test. 
The intensity of colour can be photographically assessed and related to the 
concentration of nanoparticles in the suspension and with the amount of hCG in the 
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solution. The interaction between Human chorionic gonadotripin and its 
complementary anti-hCG antibody was chosen as a model because it has been 
widely studied because of its common use in pregnancy test kits. 
In the immunochromatographic assays, also termed lateral flow tests, control 
assays using antibody-conjugated superparamagnetic nanoparticles were also 
performed without adding the hCG hormone to the buffer dispersion. Without the 
hormone in the media no band was detected (optically or magnetically), proving 
the specific interaction between the hormone and the anti-hCG antibodies. 
The sensitivity of the method was tested by adding different amounts of the 
hCG hormone to the nanoparticle buffer dispersion. The dark band observed in the 
nitrocellulose membrane shows an intensity that increases with the concentration of 
nanoparticles in the suspension and with the amount of hCG in the solution. Both 
the magnetic and colorimetric signals of the nanoparticles attached to the 
corresponding specific antibody directed against hCG (previously immobilised in 
the nitrocellulose strip) are proportional to the amount of antibody attached to the 
nanoparticles. It should be noticed that with the standard biochemical procedure 
followed in this work to attach the antibody to the external surface of the 
nanoparticles a random orientation of the antibody was obtained. In a recent work 
we achieved a more selective orientation, and therefore a more effective interaction 
by coupling the Fc zone of the antibody to the hybrid superparamagnetic 
nanoparticles [DeTeresa2008]. 
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Figure 4.6. XPS spectra of the monoclonal antibody-conjugated silica-coated magnetite 
nanoparticles, proving the presence of sulphur and the binding of the antibody to the 
surface of the nanoparticles. 
The presence of the anti-hCG monoclonal antibody IgG (anti-MH95) in the 
amine functionalised nanoparticles after the washing protocol was also 
demonstrated by means of XPS analysis. The main elements present in the surface 
were C, O, N, Na, Si, S, and Cl (Table 4.2). After covalent binding to the antibody, 
the functionalised nanoparticles were gently washed 3 times in the washing buffer, 
and then separated using a permanent magnet, dried and analysed. Sulphur was 
detected in the spectrum (Fig 4.6, Table 4.2). This sulphur can only come from the 
antibody because the anti-hCG monoclonal antibody anti-hCG contains inter- and 
intra-chain disulfides (Fig. 4.7). Detected sodium would also come from the 
antibody since it was not present previously in the amine-functionalised particles. 
Similar results of XPS analysis were obtained for the carboxyl-functionalised 
nanoparticles, confirming the presence of antibody attached to their surfaces.  
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Figure 4.7: Scheme of an antibody. The presence of intra- and inter- disulphide bridges is 
detected by XPS analysis. 
Table 4.2: XPS analysis of the amine-functionalised nanoparticles after antibody 
attachment 
Element 
Binding Energy. 
(FWHM) eV 
Atomic 
Concentration (%) 
C 1s 284.9 (2.6) 55 
O 1s 531.4 (2.0) 25 
N 1s 398.7 (1.8) 9 
Si 2p 102.3 (1.8) 7 
S 2p 167.2 (2.3) 3 
Na 1s 1070.6 (1.4) 1 
Cl 2p 196.7 (2.6) 1 
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4. 2 Coating with serum albumin and PEG  
Phagocytosis is a cellular phenomenon that describes the process in which 
phagocytes, which are specialised cells such as macrophages, destroy viruses and 
foreign particles in blood. Phagocytes then play a very important role in the 
immune system. Unfortunately, phagocytes are also a major limitation for the 
intravenous delivery of nanoparticles in any in-vivo application. Nanoparticles 
become recognizable to the cells of the mononuclear phagocyte system, and are 
subsequently cleared from circulation by phagocytosis, through a process called 
opsonisation. During this process particles circulating in blood are coated with 
molecules which make them more “appealing” to bind to receptors on phagocytes. 
Antibodies, especially immunoglobulins and complement proteins like C3b can 
opsonise and are therefore are referred to as opsonins. The IgG antibodies bind to 
the antigens by the Fab region leaving the Fc region sticking out. Phagocytes have 
Fc gamma receptors and therefore they can bind to the coated molecules and 
internalize them. The complement fragment, C3b, binds nonspecifically to foreign 
organisms. Phagocytes also have receptors for C3b on their surface. The antibodies 
and C3b tag the microorganisms or nanoparticles for destruction by phagocytes. 
If a particle is negatively charged, there is an electrostatic repulsion between 
the membrane of a phagocytising cell, also charged with negative groups, and the 
particle. That would avoid the mechanism of phagocytosis by the 
rethiculoendothelial system. However, during the process of opsonisation, particles 
are bound by opsonins, enhancing macrophage capture, since phagocytic cells 
express receptors that bind opsonin molecules. Moreover, opsonisation of a particle 
and subsequent binding to an activated phagocyte will cause increased expression 
of complement receptors on neighbouring phagocytes, accelerating the whole 
process. In fact, without opsonisation of the antigen phagocytic binding would 
practically disappear. 
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In order to improve the in-vivo survival rate of nanoparticles, the goal is to 
design a long circulating carrier with a functionalised surface in order to avoid 
opsonin adsorption and the subsequent clearance from the body by phagocytic 
cells. The physicochemical characteristics of a nanoparticle such as surface charge, 
size, functional groups, and hydrophilicity can affect its uptake by the cells of the 
phagocyte system. A neutral (or negatively charged) and hydrophilic surface can 
lead to a longer half-life in the blood circulation. 
Two strategies have been developed within this work to achieve this goal: the 
adsorption of serum proteins on the magnetic nanoparticles, and the coating with a 
hydrophilic polymer like poly(ethylene glycol) (PEG). The conjugation of Bovine 
Serum Albumin (BSA) to the surface of the particles has the objective of avoiding 
opsonisation by steric and electrostatic effects. The binding of serum proteins 
yields the particles electronegative at the physiological pH, impeding the specific 
recognition of receptors on the macrophages’ membrane.The incorporation of PEG 
on the surface of nanoparticles formulation has yielded a decreased uptake by cells 
of the RES and an increased circulation time to effectively target diseased cells. 
PEG molecules on the surface of a nanoparticle reduce the adsorption of opsonins 
and other serum proteins by a steric repulsion effect. PEG molecules on the surface 
of a nanoparticle will form a dynamic molecular cloud over the particle surface. 
This cloud of mobile and flexible PEG molecules produces a repulsive effect, 
which makes energetically unfavourable for proteins to be adsorbed onto PEG 
molecules. Pishko and coworkers determined a relationship between uptake by 
macrophages and physicochemical properties like surface charge and the 
hydrophilicity of core-shell nanoparticles, proving that a low negative to neutral 
and hydrophilic nanoshell can reduce uptake of coreshell nanoparticles in-vitro. 
They used a layer-by-layer (LbL) assembly process to produce core-shell 
polymeric nanoparticles where fluorescent nanobeads (to simulate a solid drug 
core) were encapsulated in macromolecular nanoshells. The nanoshell composed of 
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multilayered polyelectrolytes was modified with PEG of varying molecular 
weights (2000, 5000, or 20,000 Da) to form a hydrophilic and long-term circulating 
nanoparticle. [Zahr2006]. The choice of the utilised PEG is also vital. Zahr and co-
workers [Zahr2006] attached chemically PEG chains of varying molecular weights 
(2000, 5000 and 20000 Da) to polymeric particles to yield and electrically neutral 
and hydrophilic surface of core-shell nanoparticles. They studied the different in-
vitro uptake by macrophages and protein adsorption depending on the utilised 
PEG. 
The molecular weight of PEG and thus its chain length has an influence on 
phagocytosis. The hydration of coiled, flexible PEG chains from 1500 to 5000 Da 
can help to avoid the approach of proteins [Stolnik1995]. Napper and co-workers 
suggested that the stability of the polymer coverage could determine the 
distribution of a colloidal carrier in a biological environment [Hunter1983]. 
The covalent attachment of a neutral polymer, such as PEG, should produce a 
neutralisation in charge at the surface of the particle. The measurement of zeta 
potential before and after the introduction of PEG can then be a useful tool to 
determine the effectiveness of the attachment of the polymer to the particle. 
Besides, metyhlated PEG (mPEG) has been previously used to decrease 
immunogenicity and proteolysis of a number of various macromolecules, like 
albumin, interferon-γ, interleukin-1, colony stimulating factor, and superoxide 
dismutase, as well as to increase their circulation half-lives [Monfardini1998]. 
There are three common ways to attach PEG molecules to the surface of a 
particulate carrier: incorporation of PEG during the synthesis of the particles; 
covalent attachment of activated PEG molecules to the reactive surface of 
previously produced particles; and physical adsorption of appropriate PEG 
derivatives, such as poly-(lactyde-co-glycolide)-PEG to nanospheres. Particles with 
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poorly reactive surfaces and the rapid desorption of physically adsorbed PEG 
derivatives are severe limitations to these processes. Desorption of PEG leads to 
the formation of steric barriers when particles are in contact with blood, a process 
leading to quick capture of the particles by macrophages [Moghimi2001]. 
4.2.1 Bovine Serum Albumin Coating 
BSA was incubated with the particles at different concentrations to estimate 
the maximum capacity of adsorption. Sodium Phosphate buffer was used as the 
dispersion medium with a low ionic force (concentration of NaCl=0.01M) and a 
pH=8 to simulate mild conditions. Particles were first dispersed in the buffer and 
sonicated with an ultrasound probe to remove aggregates and achieve an optimum 
redispersion. BSA was added and the whole system was incubated with sonication 
for 1h. Particles conjugated with BSA were separated by centrifugation, and the 
remaining protein was detected by Vis-uv spectroscopy using the reagent BCA for 
protein quantification. The BCA Protein Assay is based on bicinchoninic acid 
(BCA) for the colorimetric detection and quantitation of total amounts of protein. 
The method combines the reduction of Cu2+ to Cu+ by proteins in an alkaline 
medium with the highly sensitive colorimetric detection of the cuprous cation. The 
product of the reaction is a purple-coloured solution formed by the chelation of two 
molecules of BCA with one cuprous ion. This water-soluble complex exhibits a 
strong absorbance at 562 nm, nearly linear with increasing protein concentrations 
over a broad working range (approximately from 20-2,000 μg/ml). Remnant BSA 
reduces Cu2+ to Cu+, and these ions are detected by conjugation with the BCA. The 
absorbance of the resulting liquid is measured at 562 nm, and the concentration of 
serum albumin bound to the surface of the particles can be calculated by difference. 
Increasing quantities of the protein were added to a fixed concentration of 
nanoparticles in an aqueous suspension at a pH=8 to study the loading capacity of 
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the particles. Maximum adsorption was achieved for a concentration of 2mg/ml. 
After saturation increasing concentrations of added protein do not mean an increase 
in adsorbed BSA (Fig. 4.8). 
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Figure 4.8 Loading capacity of the Fe@C particles with BSA. Maximum adsorption was 
achieved for a concentration of 2mg/ml. 
In order to avoid rejection reactions by the rabbits against a foreign protein, 
the serum BSA was substituted by commercial Rabbit Serum Albumin (RSA) for 
the in-vivo administration of particles. Ideally serum albumin should be extracted 
from the same animal in which it is going to be injected, but this was discarded 
because of the intrinsic difficulties in isolating the protein for each case. The 
adsorption of the protein was done following the same procedure as for the bovine 
serum albumin, using the maximum concentration of adsorbed protein. 
4.2.2 Poly(ethyleneglycol) coating 
The other strategy was the pegylation of the particles. An amphiphilic 
molecule, Poly (maleic anhydride-alt-1-octadecene) (PMAO), with a long 
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hydrophobic chain on one side adsorbed on the carbon hydrophobic surface, 
leaving its carboxyl, hydrophilic groups on the other side covalently bound to the 
amino groups of a methoxy-modified Polyethyleneglycol chain (PEG). Once the 
particles were functionalized with PEG, the presence of the polymer would prevent 
the adsorption of big proteins of the blood and hence delay the recognition of the 
particle from the immune system [Yu2006]. 
 
Figure 4.9: IR spectrum of the PMAO reagent. Inset: the decrease of the 1775 cm-1 peak 
and the increase of the 1715 cm-1 peak are characteristic of the decomposition of anhydride 
and the release of carboxyl groups, respectively. 
The formation of the copolymer after reaction of PMAO and PEG was 
followed by Infra-Red spectrometry. The decrease of the 1775 cm-1 peak and the 
increase of the 1715 cm-1 peak are characteristic of the decomposition of anhydride 
and the release of carboxyl groups, respectively [Atici2000, Kang2001]. The rest of 
the main peaks of both initial reactants are present at the final product (Fig. 4.9). 
128 Chapter 4. Functionalisation 
Table 4.3: XPS analysis of the Fe@C particles before and after pegylation 
Binding energy eV 
 
C 1s N 1s O 1s 
Bare Fe@C particles 284.9 eV   
Pegylated Fe@C 
particles 
a) 285eV C-C 
b) 289 eV C-O 
397eV NH2 534 eV 
XPS studies prove that the polymer effectively coats the particles. By XPS the 
presence of nitrogen on the surface of the particles was detected. This element can 
only appear due to the presence of the amino groups that result form the coating of 
the particles with the polymer. This can be checked comparing the spectrum of the 
PEG-PMAO functionalised particles with a blank spectrum of an Fe@C sample 
(Fig. 4.10) at the N 1s region, 397eV. Also, the C 1s and O 1s spectra reveal the 
functionalisation of the surface of the particles. The main carbon peak at 285 eV is 
the hydrocarbon or the C-C peak. Once the particle has been functionalised, there 
is a second peak, shifted at 289 eV, the C-O peak (Fig. 4.11), characteristic of PEG 
coupling [Popat2004]. The apparition of a secondary peak at 534 eV at the O 1s 
spectrum is another indication of the effective coupling reaction of PEG to the 
surface of the particles (Fig. 4.12). In all the cases, a 5 KV Ar ion etching was 
performed for different times to probe the chemical composition of each sample. 
No significant differences were observed as the outer surface was etched, except 
for the region of C 1s in the case of the PEG-PMAO functionalised particle: the 
peak at 289 eV slightly shifts, whereas a second peak at 292 eV appears, probably 
corresponding to the carbonous chain of the PMAO. 
4.2. Coating with serum albumin and PEG 129 
 
 
Figure 4.10: Regions of nitrogen 1s as a function of etching time a) bare Fe@C. b) PEG-
PMAO functionalised Fe@C. 
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Figure 4.11: Regions of carbon 1s as a function of etching time a) bare Fe@C b) PEG-
PMAO functionalised Fe@C. 
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Figure 4.12: Regions of oxygen 1s as a function of etching time a) bare Fe@C b) PEG-
PMAO functionalised Fe@C. 
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Further evidence of a proper coating of the particles has been obtained 
studying their ability to adsorb the protein BSA. Before the treatment naked 
carbon, highly hydrophobic, adsorbs rapidly BSA. The spontaneous desorption of 
the protein was studied by increasing the ionic force of the medium, and also by 
direct adsorption competition by adding detergents like tween® or triton®. The 
percentage of BSA that desorbs from the surface of the particles was minimum 
even at the strongest conditions of desorption. After the treatment with PMAO-
PEG the adsorption of BSA under the same conditions is practically null. 
 Chapter 5 
In-vitro experiments 
 
This chapter comprises the studies of biocompatibility of the synthesised 
particles and the uptake by living cells in culture. The interaction of Fe@C 
particles with blood cells and platelets and the main haematological and 
rheological parameters have been studied to check the biocompatibility of 
circulating particles in blood. 
The internalisation of Fe@C particles into dendritic cells (DCs) has been 
investigated to asses the final location of the particles and the viability of the 
resulting cell culture. Magnetic measurements of the magnetically loaded cells 
allow the detection of the nanoparticles into DCs, as well as their quantification. 
Fe@C particles were chosen because of their high saturation moment and high 
Curie temperature, in order to minimise the required clinical dose due to toxicity 
effects. Dendritic cells were able to incorporate magnetic nanoparticles in a range 
of size from few nanometers to about 200 nm, after 24 h of culture. The actual 
uptake of the magnetic particles by the DCs has been demonstrated directly from 
the transmission electron microscopy images. TEM images proved that the 
particles are located mainly in the lysosomes. Carbon encapsulated iron particles 
showed no toxic effects on the DCs and had no apparent effect in their viability.  
Finally, the physical adsorption and release of the chemotherapy agent 
doxorubicin on three types of particles: Fe@C produced by the discharge-arc 
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method, Fe3O4@SiO2 synthesised by the sol-gel method and Fe3O4@ZY obtained 
by mechanical milling, have been studied in-vitro. The drug spontaneously adsorbs 
on the surface of the particles and is released over time in a simulated experimental 
model of human plasma at 37ºC. Even though these are non-porous materials, the 
high sorption capacity of both carbon and silica allows them to load a significant 
amount of the cytotoxic medicine. The kinetics of adsorption and desorption of 
doxorubicin was followed by vis-uv spectrophotometry. 
5.1 Biocompatibility 
To test the biocompatibility of the particles in contact with circulating blood a 
series of “in vitro” and “in vivo” haematological and rheological studies were 
performed. The study of these hemorheological parameters is usually 
recommended for: biocompatibility [Nageswari1998], conventional radiological 
contrast media [Reinhart2005], and nanoparticle magnetic resonance imaging 
[Lind2002] testing. These protocols were followed and adapted to nanoparticles in 
the blood stream. Nanoparticles are similar in shape and length to large circulating 
plasma proteins, such as fibrinogen or immunoglobulins. As these proteins have a 
decisive influence on plasma and blood viscosity, it seems important to study the 
possible effect of nanoparticles on these two parameters. Moreover, another 
important parameter includes the possible increase of blood erythrocyte 
aggregation, which could have a dramatic effect on the micro-vessel circulation.  
To prepare the biocompatible suspensions, 100 mg of Fe@C nanoparticles 
produced by the arc-discharge method were suspended in 100 ml of Gelafundine®, 
a commercial succinylated gel commonly used as a substitute of blood plasma. The 
solution was then sonicated for fifteen minutes. Human blood from 5 healthy 
volunteer donors was tested in vitro, before and after being mixed with the particles 
suspension in different dilutions (1ml of blood and 0.06; 0.12; 0.24 and 0.5 ml of 
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particles).  The same procedure was followed for the tests in animals (ex-vivo 
tests): 10 non-injected New Zealand rabbits (as control) and other 10 animals (test 
rabbits) after intravenous injection of 1 ml of the particles suspension in 
Gelafundine®. Blood samples were taken 10´, 30´ and 24 hours after the injection 
of particles.  
A complete study of human blood coagulation and rheology in-vitro has been 
performed (see Fig. 5.1 and Table 5.1). All coagulation tests before and after 
mixing human blood with different concentrations of nanoparticles were in the 
normal range of our laboratory. D-Dimer levels over 200 micrograms/liter were not 
detected.  Higher levels would be expected in case of activation of the coagulation 
system. There are neither statistical, nor clinical significant differences between 
control blood and blood with different concentrations of particles. 
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Figure 5.1: Blood Viscosity at different shear rates. AE = Erythrocyte aggregation (M: 
stasis, M1 minutes under low shear rate). VS = Blood viscosity Shear rate (s-1). C= Particles 
concentration (mg/ml) 
Concerning the ex-vivo tests with rabbits’ blood samples, there are no 
significant differences between blood samples taken up at different times after the 
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injection of particles. 
PT (Prothrombin time) and APTT (Activated Partial Thromboplastin Time) 
are slightly longer in test rabbits than in controls but the difference has no 
statistical significance (see Table 5.2). From the clinical point of view, some test 
rabbits are in a very mild hypo-coagulation state that does not exceed the 
recommended value for prevention of thrombosis during surgery. PT and APTT 
experimental/control ratios are 1.35 and 1.15 respectively. The recommended ratios 
in humans for prophylaxis of thrombosis range from 2.0 to 3.0. The dispersant may 
contribute in part to this mild hypo-coagulation state in test rabbits, which is still 
within the tolerable limits. Fibrinogen is moderately elevated in test rabbits, as 
expected, because fibrinogen is an acute-phase reactant. Nevertheless the slight rise 
in fibrinogen is in the upper-normal range; it is within the tolerable limits and can 
be attributed to the stress produced for invasive procedures. Hemoglobin, 
erythrocytes, leukocytes (including differential count) and platelets are in the 
normal range both before and after the intravenous administration of particles. 
There are neither statistical, nor clinical significant differences. 
All previous data show good biological compatibility in this first approach. 
The laboratory tests applied in this experiment are the same as those used in human 
pathology in order to detect significant clinical disturbances in circulating cells, 
coagulation and rheology.  Mild adverse effects can be detected with more 
sophisticated coagulation tests that shall be done in a second step: aggregation of 
platelets, prothrombin fragment 1+2 and thrombin-antithrombin complex. Platelets 
aggregates have not been detected either by the cell-counter or by microscopic 
examination. However, we have not explored a possible inhibition of platelet 
aggregation. This can be done with different inductors: thrombin, epinephrine or 
collagen. Prothrombin fragment 1+2 and thrombin-antithrombin complexes detect 
minimal activation of coagulation, but there are not routine tests and they are 
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usually reserved for research purposes in human pathology [Iturbe1999]. The idea 
is to adapt these techniques to rabbit blood and explore them in a second step. 
Table 5.1: Mean values of blood viscosity (centipoises) in five Fe@C samples. BV 
= Blood Viscosity at different shear rates (s-1); EA = erythrocyte aggregation index; EA 
5/10M = integration time at 5 and 10 s of stasis, conventional units; EA 5/10 M1 = 
integration time at 5 and 19 s at very low shear rate. 
 Human 
Basal 
Human 
0.06 cm3 
Human 
0.12 cm3 
Human 
0.24 cm3 
Human 
0.5 cm3 
BV 230 s-1 4.44 4.36 4.45 4.33 4.1 
BV 23 s-1 6.7 5.0 7 5.4 6.2 
BV 5.7 s-1 7.2 7.6 8 6.8 6.4 
EA 5M 3.4 3.4 3 2.9 2.9 
EA 5M1 10 8.9 8.4 7 6.9 
EA 10M 8.3 7.6 7.6 7.1 8.8 
EA 10M1 22.5 20.6 18 18.6 20.1 
Table 5. 2: PT = prothrombin time (s); APTT = activated partial thromboplastin time (s); 
D-Dimer (μg/l). 
 Controls χ ±SD Experimental χ±SD P (Mann-Winley) 
PT 7.067 ± 0.071 9.6 ± 2.5 0.08 
APTT 57.025 ± 26.4 65.920 ± 30 0.253 
Fibrinogen 248 ± 149 381.8 ± 85.5 0.0388 
D-Dimer <200 <200  
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5.2 Cell uptake of nanoparticles 
Dendritic Cells (DCs) are the main antigen presenting cells (APCs) of the 
immune system. Their main features are the potential to capture antigens, to 
process several kinds of antigens and their ability to migrate from peripheral tissues 
to secondary lymphoid organs for presenting these antigens to T cells 
[Steinman1991, Hart1997, Banchereau1998]. The presence of dendritic cells has 
been identified in various types of tumours: like head and neck tumours, breast 
cancer, cervical or endometrial cancer [Coppola1998], gastric cancer [Kakeji1993] 
or renal cancer [Thurnher1996]. Clinical pathologists have also associated the 
presence of a great number of DCs with a better prognosis [Ambe1989, 
Furihata1992]. It is believed that DCs incorporate into the epithelial tissue of a 
growing tumour, therefore the inclusion of particles inside dendritic cells would 
play the part of a “Horse of Troy”, so as to stealthily reach the tumour site and 
there perform its function, whether it is the release of a chemotherapy agent, act as 
a contrast agent or selectively heat a specific area by applying an alternate 
magnetic field. With this purpose, the inclusion of Fe@C particles inside DCs has 
been studied by means of magnetic measurements to check the final location of the 
particles and the viability of the resulting cell culture. 
Dendritic cells are present in small quantities in tissues that are in contact with 
the external environment, mainly in the peripheral tissues. They can also be found 
at an immature state in the blood. Once activated, they migrate to the lymphoid 
tissues where they interact with T cells and B cells to initiate and shape the 
adaptive immune response. [Steinman1973]. DCs can be obtained from myeloid or 
plasmacytoid progenitors [Ito2005]. DCs obtained from myelomonocytic 
progenitors (MDCs) and maturated with tumour antigens have showed antitumoral 
activity in animal models [Mayordomo1995] and humans [Nestlé1998]. 
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Activation and maturation of DCs consists of a series of morphologic, 
phenotypic and functional changes, characteristic of their evolution from immature 
to mature state [Banchereau1998].  There are several mechanisms that induce the 
change from one state to the other. The recognition of pathogens patrons 
[Reis1996] or the alteration on the internal medium [Pulendran2004] are among 
them. Interaction between DCs and lymphocytes CD4+, CD8+ and Natural Killer 
cells (NKs) can also induce their activation and maturation [Wilson1997, 
Rissoan1999, Schuster2002, Fernández2003, Sousa2004]. 
Tissue DCs are normally in immature state. This state is characterised by high 
endocytosis capacity and low surface expression of human leukocyte antigen 
(HLA) and co-stimulation molecules, such as CD40, CD80 or CD86 
[Dodaphkar2001]. Therefore immature DCs have a poorly developed antigen 
presentation activity. Under the influence of certain stimuli, DCs are activated and 
evolve to a mature state. At this stage of development they grow branched 
projections, the dendrites, which give the cell its name. They progressively lose the 
endocytosis capacity, whereas the ability to process and present antigens on surface 
HLA molecules is significantly increased. Maturation of DCs involves changes that 
allow them to migrate to secondary lymphoid organs as well. Here they are able to 
interact with naive lymphocytes [Foti1999, Hopken2004]. The effectiveness of the 
interaction DC-T cell depends, amongst others, on the expression of the surface 
costimulatory molecules as CD80 and CD86 [Hart1993, Symington1993, 
McLellan1995]. 
First step of every specific immune response mediated by T lymphocytes 
consists on the reception of antigens by the APCs. Alive foreign cells or cells from 
the own organism, cells that have gone through necrosis or apoptosis, cells infected 
with viruses or parasites, bacteria, immunocomplexes and every kind of molecule 
that is in the medium surrounding the APC can be detected and considered as 
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antigens. Its structure and functional design allows the DC to endocyte the foreign 
molecule by different mechanisms: macropinocytosis, phagocytosis or receptor-
mediated endocytosis. In pinocytosis, molecules are transported inside the cell, 
forming small vesicles that subsequently fuse with lysosomes. Unlike phagocytosis 
or receptor-mediated endocytosis, pinocytosis is non-specific in the molecules 
internalised by the cell. Macropinocytosis is DCs’ main mechanism of 
internalisation, since it allows the cell to internalise the highest and more varied 
amount of antigens [Sallusto1995]. After the internalisation of the antigen, the 
dendritic cell increases its capacity to perform biochemical processes that mediate 
the intracellular processing of the internalised material and their charge over HLA 
molecules [Mellman2001], starting that way the immunologic response. 
Dendritic cells can also have an important role in angiogenesis mechanisms 
irrigating tumour cells. Angiogenesis is a physiological process involving the 
growth of new blood vessels from pre-existing vessels. It is a normal process in 
growth and development, as well as in wound healing. However, this is also a 
fundamental step in the transition of tumours from a dormant state to a malignant 
state [Prior2004]. Tumours with less than 2mm of diameter allow diffusion 
transport among their cells, however bigger tumours need a network of vessels to 
irrigate all the cells. On the other hand, VEGF (Vascular Endothelial Growth 
Factor) has been demonstrated to be a major contributor to angiogenesis, increasing 
the number of capillaries in a given network. Initial in vitro studies demonstrated 
that bovine capillary endothelial cells will proliferate and show signs of tube 
structures upon stimulation by VEGF. Recently the induction of endothelial cell 
features in MDCs cultivated with angiogenic factors like VEGF has been 
demonstrated [Conejo2005] and similar cells have been isolated from human 
tumour vessels [Conejo2005], opening the possibility of targeting MDCs with 
incorporated magnetic nanoparticles to tumours and use them to visualise tumours 
or in oncology therapy. 
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The mechanism by which a given cell type recognises and incorporates a 
passive nanoparticle is not well understood yet. Current improvements in this field 
rely on new functionalisation processes of the particles with specific ligands for 
targeting specific cell membrane receptors [Jaulin2000]. In any case, any 
particulate system to be used as targeting carrier should mimic biological units in 
order to pass through the reticuloendothelial system (RES) without being detected. 
Tumour targeting with nanoparticle-loaded DCs is a potentially interesting strategy 
because no RES activity is expected for the magnetic carrier, since DCs from the 
same patient would pass unnoticed as a part of the same immune system. 
Several previous studies have reported on the uptake of different complexes by 
the cell, or the inclusion of latex-type nanospheres [Wilhelm2003, Coester2006], 
proposing models for the mechanisms of phagocytosis as well [Christine2002]. 
However, only recently some works [Anderson2005, De Vries2005] have been 
devoted to the specific case of magnetic nanoparticles, composed of metallic and 
ceramic phases. The magnetic performance of the particles is usually enhanced if 
materials with large saturation magnetisation values are chosen, such as Fe, Ni or 
Fe3O4. One of the key issues that restricts the choice of the magnetic material is 
related to the toxicity effects that many of these elements (or their oxides) have on 
the cellular metabolism.  
Following informed consent, mononuclear cells obtained from 14 ml of blood 
of healthy volunteers were cultured during seven days with AIM-V media with 
Interleukin 4 (10U5/100ml) and Granulocyte-macrophage colony stimulation factor 
(10U5/100ml). On day five, 5μg/ml of media containing lypopolysacharides were 
added to induce maturation of DCs, which was confirmed by flow cytometry on an 
aliquot of cultured cells on day 6. On day 6, 15μl/ml of media of a 5% suspension 
of iron-carbon (Fe-C) nanoparticles were added to the culture. Finally, cells were 
collected on day 7, washed twice with PBS and resuspended in the same buffer and 
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centrifuged during 25 min at 400 G with Ficoll histopaque (1.077 g/ml). DCs were 
isolated from the PBS/Ficoll interfase and unincorporated NPs remained in the 
bottom of the tube. Incorporation of MNP was assessed by confocal microscopy 
(data not shown) and transmission electron microscopy. For the latter, pelleted 
cells were fixed in PBS containing 2% glutaraldehyde at room temperature for 30 
minutes and kept overnight at 4º C. The cells were then washed three times with 
PBS and treated with 1% OsO4 in PBS for 10 minutes. All of the samples were 
washed three times in H2O dehydrated in an ascending series of ethanol solutions. 
Propyleneoxide (PO) was used as a transitional solvent. The cells were incubated 
overnight in a solution containing a 1:1 mixture of PO and Epon-Araldite (EA) 
(Electron Microscopy Sciences). The next day, the mixture was replaced with 
100% EA, and the capsule was placed in a desicator for 8 hours. The sample was 
then placed in plastic capsules containing EA and polymerised at 60ºC for 48 
hours. Thin (0.1μm) sections were cut using a microtome and placed on 200 mesh 
Cu grids. The samples were stained with 1% aqueous uranyl acetate and Reynolds 
lead citrate. Sections were examined with a Hitachi 7100 transmission electron 
microscope (Hitachi High Technologies).  
Dendritic cells were cultured in a 12-well plate, and NPs incorporated as 
described above. Cells were collected from different plates on days 7, 8, 9, 10 and 
11 and viability of the DCs  was assessed by the exclusion of trypan blue. 
For magnetic measurements, all samples were conditioned in closed containers 
before quenching the DCs/MNPs mixture below its freezing point (~265 K) from 
room temperature. A commercial SQUID magnetometer was used to perform static 
measurements as a function field and temperature. Magnetisation data was 
collected in applied magnetic fields up to 1 T, between 5K and 250 K to avoid the 
melting of the solid matrix (solvent). 
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The incorporation of NPs onto CDs was assessed by electron microscopy. The 
nanoparticles are visible as aggregates in lysosomes (Fig 5.2).  
        
Fig. 5.2. Electron microphotographs of DCs without (A) and with (B) Fe@C particles. 
Intralysosomal particles aggregates are shown by a white arrow. 
Regarding viability after the co-incubation of dendritic cells with the magnetic 
particles suspension, the fraction of viable cells on days 7, 8, 9, 10 and 11 was not 
significantly affected by the incorporation of the nanoparticles (Fig. 5.3).  
0
20
40
60
80
100
0 1 2 3 4
Days after NPs incorporation
Vi
ab
ilit
y 
%
DCs alone C-Fe
 
Fig. 5.3: Fraction of viable cells after the incorporation of Fe@C nanoparticles compared 
with untreated DCs 
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After the centrifugation of loaded cells in a density gradient, all the magnetic 
particles not included into the DCs are located in the pellet, whereas the floating 
band is composed of DCs loaded with magnetic particles, with eventual small 
fractions of non-loaded cells. Magnetism was measured for both the material from 
the band (dendritic cells with magnetic particles), and from the pellet (magnetic 
particles only). 
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Figure 5.4: a) Magnetic response of the dendritic cells culture. The linear response with a 
negative slope is significant of a diamagnetic behaviour. b) Hysteresis loop of the Fe@C 
particles. 
Figure 5.4 compares the magnetic response from the initial DCs, before 
loading the particles, with the original curve for the isolated magnetic particles. For 
DCs alone, the negative response to positive applied fields indicates that the overall 
signal is diamagnetic. For the loaded cells a hysteresis loop is obtained (Fig. 5.5), 
due to the contribution of the internalised particles (Fig 5.4 b). This ferromagnetic 
component is superimposed to the (small) diamagnetic signal from the DCs. This 
can be deduced from the negative slope of the M (H) curves at high fields. After 
normalising both measurements to the total culture volume, the diamagnetic signal 
of the cells can be subtracted from the total system signal to obtain a net magnetic 
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signal, which shows the expected nearly saturation behaviour for a ferromagnetic 
system, as in the case of the Fe@C particles (Fig. 5.5). 
Identical magnetic parameters of both the initial Fe@C particles and 
magnetically loaded DCs were obtained, indicating that the particle size 
distribution remains unaltered after the incorporation into DCs. The endocytosis 
process is then not size-selective within the size range of Fe@C particles: between 
10-200 nm. Also, the amount of magnetic material incorporated by the DCs yielded 
a magnetic signal (10-3 emu) that is larger than the diamagnetic signal from 
biological tissues (10-4-10-5 emu for DCs at low fields), and quite above the 
detection limit of SQUID measurements (10-7 emu). This situation makes the 
separation process potentially powerful for the detection of small amounts of all 
types of targeted cells as, for example, the case of metastatic cells within the blood 
stream or lymph nodes. 
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Fig. 5.5 Magnetic Response from Culture DCs incubated with Fe@C particles. The 
diamagnetic signal of the cells can be subtracted from the total system signal to obtain a net 
magnetic signal, which shows the expected nearly saturation behaviour for a ferromagnetic 
system.
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5.3 Drug adsorption and release studies 
The capability of the particles to spontaneously adsorb and release a drug has 
been tested for the Fe@C, Fe3O4@ZY and Fe3O4@SiO2 samples. Kinetics of 
adsorption was measured following the procedure described by Kuznetsov 
[Kuznetsov1999]: A 100 µg/ml solution of doxorubicin hydrochloride was mixed 
with 1 mg/ml of the particles in distilled water. The suspension was incubated on a 
shaker at room temperature, and samples were taken after fixed intervals of time. 
The adsorbent magnetic phase was sedimented with a 3 KOe permanent magnet, 
and the optical density of the supernatant measured with a UV spectrophotometer 
at 498 nm (Fig. 5.6). A calibration curve is previously done for known 
concentrations of the drug, then the concentration of the adsorbed drug can be 
directly calculated making an extrapolation from the curve. Experimental details 
are described in section 2.4.3 (page 69). 
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Figure 5.6. 3D representation of the molecule of doxorubicin. This compound absorbs 
visible light at 498 and 296 nm. 
Desorption kinetics was studied trying to simulate in-vivo conditions. 5 mg of 
the particles, previously incubated in a solution of doxorubicin, were suspended in 
5 ml of real human plasma, and warmed at 36ºC while gently stirring. The 
magnetic phase was sedimented with a magnet, and the optical density of the 
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supernatant measured with a UV spectrophotometer at 296 nm every 2h intervals 
during the first day and every 8 h thereafter. The particles slowly release the drug, 
and saturation is reached after 3 days. Figure 5.7 shows the scheme for the 
incubation of particles with doxorubicin, for the adsorption of the drug and its 
release in human plasma. Figure 5.8 is an example of the kinetics of adsorption and 
release of the drug from the surface of the particles, in this case from the 
Fe3O4@ZY samples. Doxorubicin is released from the surface of the particles at a 
slow enough rate to reach the affected organ with the permanent magnet and 
efficiently treat the tumour. 
a)  
b)  
Figure 5.7: a) Diagram of the incubation of drug and nanoparticles. Particles are suspended 
in a doxorubicin solution. At fixed intervals of time particles are separated with a magnet 
and the absorbance of the supernatant is measured, then the magnet is removed and 
suspension stirred again. After reaching the maximum adsorption, the liquid is decanted. b) 
The particles, loaded with the drug, are again suspended in a human plasma solution and 
incubated at 37ºC. Again, at fixed intervals of time particles are separated and the 
absorbance of the supernatant measured to obtain the kinetics of adsorption and release. 
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Figure 5.8: Absorbance spectra of the adsorption and desorption of doxorubicin on the 
Fe3O4@ZY particles.  
There are several kinetics models to describe drug dissolution or release 
profiles [Costa2001]. These theoretical models account for the amount of drug 
dissolved from the pharmaceutical dosage system as a function of time. The 
quantitative interpretation of the values obtained in the dissolution assay is 
facilitated by the use of a generic equation that mathematically translates the 
dissolution curve in function of some parameters related with the pharmaceutical 
dosage forms. In some cases, the fit equation can be deduced by a theoretical 
analysis of the process, as in the case of the zero order models. In most cases, 
however, theoretical fundament is very complex and more adequate empirical 
formalisms are required. Also, the intrinsic nature of the drug crystallinity, particle 
size or solubility can affect the kinetics of release [El-Arini1995] 
The release models with major acceptance and best describing drug release 
phenomena are the zero order models, the Higuchi model and the Korsmeyer-
Peppas model [Costa2001]. The zero order models describe the case in which the 
drug release kinetics follows a linear response: 
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ktf t =  
Where ft is a function of time related to the amount of drug released from the 
particles. This equation becomes ideal to describe coated dosage forms or 
membrane controlled dosage forms. 
The Higuchi model has a large application in polymeric matrix systems. 
Higuchi developed several theoretical models to study the release of water soluble 
and low soluble drugs incorporated in semi-solid and solid matrixes [Higuchi1961, 
Higuchi1963]. Mathematical expressions were obtained for drug particles 
dispersed in a uniform matrix which behaves as the diffusion media. One of these 
models describes the drug release from spherical homogeneous matrix systems and 
planar or spherical systems with a granular or heterogeneous matrix. 
Higuchi power law equation 2/1tkf Ht =  
Where kH is the Higuchi dissolution constant, treated in a different manner by 
different authors and theories. Higuchi describes drug release as a process based in 
Fick’s law, square root time dependent. This relation can be used to describe the 
drug dissolution form several types of modified release pharamaceutical dosage 
forms, as in the case of some transdermal systems [Costa1996] and matrix tablets 
with water soluble drugs [Desai1966, Scwhartz1968]. 
The Higuchi and the zero order model represent two limit cases of drug 
transport and release, whereas the Korsmeyer-Peppas can be useful to describe an 
intermediate situation between both models. This is a semiempirical model that 
relates the drug released to the elapsed time exponentially: 
Korsmeyer-Peppas model: nt atf =  
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Where a is a constant that incorporates structural and geometrical 
characteristics of the drug dosage form, n is the release exponent, indicative of the 
drug release mechanism, and the function of t is Mt/M∞, fractional release of drug. 
A water soluble drug incorporated into, or adsorbed onto a matrix, is mainly 
released by diffusion. This is the case of doxorubicin from the surface of the 
magnetic nanoparticles. Temperature is increased from room temperature for 
adsorption to 37ºC of the release experiment; two possible effects govern then the 
diffusion of doxorubicin out of particles: increasing hydrophobicity of the matrix, 
which should slow down the release, and increasing mobility of the molecule, with 
the opposite effect [Missirlis2006]. 
Table 5.3: Comparison of the adsorption and release capability for different 
materials 
Particle 
C doxo 
adsorption 
Time of 
adsorption 
(saturation) 
C doxo 
desorption 
Time of 
desorption 
FeC 71ppm 3h 60ppm 72h 
Fe3O4-ZY 168ppm 8h 100ppm 75h 
Fe3O4-SiO2 107ppm 24h 70ppm 80h 
Table 5.3 is a comparison of the loading capacities and kinetics of adsorption 
and release of the three studied materials. Maximum adsorption was achieved for 
the magnetite–zeolite composites, up to 168ppm after 8h of incubation, increasing 
to 186ppm after 23h of incubation. The adsorption for the magnetite-silica 
nanoparticles is also high, 107 ppm, whereas the lowest adsorption is found the 
carbonous particles. This can be explained in terms of porosity of the materials, 
since silica is more porous than graphite, so its capacity of loading a drug is higher. 
Moreover, the BET adsorption and desorption surface areas of the iron-carbon 
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particles are also much smaller than silica and zeolite coated particles, as low as 35 
m2/g and 14 m2/g respectively. Nevertheless, lower values of the specific surface 
area have proved to be effective for a faster desorption [Cerri2004]. Therefore 
these particles still seem suitable for being used as drug delivery vehicles. The use 
of activated carbon from the first step of the synthesis could increase the specific 
surface area, improving that way the capability of the system to adsorb 
chemotherapy agents. 
Doxorubicin adsorption and desorption profiles for the Fe3O4-ZY composites 
are shown in figures 5.8 and 5.9. Doxorubicin molecular dimensions are 1.27 x 
1.16 nm (calculated using molecular modeling; Spartan 5.0, Fig. 5.6) which are 
larger than the mean pore size of the obtained coated magnetic nanoparticles (0.87 
nm). Therefore most of the adsorption would be limited to the external surface of 
the nanocomposite. The BET surface area of the composite material is 442.9 m2/g. 
It is important to point out that the BET values are given per unit of total mass 
(m2/g) that is, considering the total weight of both zeolite and magnetite in the 
composite material. 77 % of the initial concentration of doxorubicin was adsorbed 
in 3.1 h. Before washing to remove all the non-adsorbed doxorubicin the drug 
storage capacity reached was as high as 92 % of the initial doxorubicin (Fig. 5.9). 
After washing to remove all the non-adsorbed doxorubicin and dispersing the dried 
drug loaded nanoparticles in human plasma at 37 ºC it was observed that the drug 
loading capacity of the magnetic nanocomposites was the 50 % of the initial 
doxorubicin concentration. 77 % of the doxorubicin loaded on the nanoparticles 
was released in 13h, reaching saturation after 75h. On the other hand, final release 
was 84% of the initial adsorbed amount for the Fe@C, and 65% for the 
Fe3O4@SiO2, reaching saturation after 3 days. This release, associated with a 
diffusion controlled mechanism, is an agreement with an adsorption limited to the 
external surface of the nanoparticles (Fig. 5.10). Higuchi model seem a good 
description of both adsorption and desorption profiles. 
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Figure 5.9: Kinetics of adsorption of doxorubicin by the Fe3O4@ZY particles. 
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 Figure 5.10: Desorption kinetics of the adsorption of doxorubicin from the Fe3O4@ZY 
particles. 
Regarding the iron at carbon particles, 39 % of the initial concentration of 
doxorubicin was adsorbed in 3 h, reaching saturation. This low adsorption may be 
due to the small surface area of the carbonous particles in comparison to the silica 
surfaces (Fig. 5.11). A modified Korsmeyer-Peppas model seems to be the best fit 
for this profile. On the other hand, release was quite fast, reaching 84% after 72h, 
in agreement with diffusion from the non-porous surface of the particles. Release 
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profile fits quite well with a Higuchi model (Fig. 5.12).  
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Figure 5.11: Adsorption kinetics of the adsorption of doxorubicin from the Fe@C particles. 
Saturation seems to be reached after three hours of incubation. 
Magnetite encapsulated in silica particles had a slow adsorption profile, 
reaching 59% after 24h (Fig. 5.13). Release was fast in the first hours of 
desorption, following a linear behaviour, reaching 37% in 60h. After 80h 65% of 
the adsorbed doxorubicin had been released to the medium. After a fast initial 
release and a slower desorption at the end, the overall release profile could not be 
fitted to a Higuchi or Korsmeyer-Peppas model (Fig. 5.14). 
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Figure 5.12: Desorption kinetics of doxorubicin from the Fe@C particles. Release is 
completed after three days. 
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Figure 5.13: Adsorption kinetics of doxorubicin by the Fe3O4@SiO2 particles. 
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Figure 5.14: Desorption kinetics of the adsorption of doxorubicin from the Fe3O4@SiO2 
particles. Earlier set of data can be adjusted to a linear fit. 
In conclusion, the three studied materials show an appreciable loading capacity 
of adsorption and release of the chemotherapy agent doxorubicin. Adsorption is 
fast and achieved within a few hours, whereas complete release takes place after 
several days. This controlled release would be slow enough to allow the carriers to 
reach the target and desorb the load only at the specific site. Fe3O4@ZY has the 
maximum loading capacity but a faster release, related to a superficial adsorption 
of the drug on the surface of the particles. 
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 Chapter 6 
In-vivo results 
 
The distribution, behaviour and tolerance of nanoparticles in a living body 
after the implantation of a permanent magnet inside a deep solid organ has been 
thoroughly studied. Our hypothesis of work is that magnetic drug carriers injected 
systemically inside a living body will be attracted and retained by an internal 
magnetic implant. In the target area they will deliver their drug load over a 
prolonged time. Based on this hypothesis, a surgical experimental model of 
minimally invasive surgery has been developed, and it has proved to be highly 
efficient.  
Kidney has been chosen as the target organ by several reasons: It is a double, 
symmetrical organ, which allows a comparative necropsy study. It has a very 
vascularised parenchyma, which assures a constant flow of circulating particles 
through it. It is situated deeply in the abdomen, but at the same time it allows easy 
exploration by radiology or ultrasound scan. In rabbit, whose size and 
characteristics are ideal for our purpose, kidneys, besides being retroperitoneal 
organs, can be easily visualised and approached by transperitoneal laparoscopy. 
This facilitates in great extent the insertion of the magnetic implant. 
Moreover, the surgical team that has developed this surgical model and 
performs this surgery experiments is directed by an urologist with wide experience 
in minimally invasive surgery and urology laparoscopy. Finally, it is also important 
to point out that renal parenchyma tumours are, in most cases, malign and highly 
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resistive to chemotherapy treatment. Nowadays, the only efficient method against 
them is surgical exeresis. This practice finds great difficulties when it multiple 
tumours or metastasis, bilateral-sited tumours, or tumours affecting organisms with 
only one functional kidney. 
The intrarenal localisation of these tumours has to be seriously borne in mind, 
especially in the cases where partial nefrectomy or tumorectomy is performed. 
Sometimes, if tumours are placed on the hiliar or deep mesorenal zones, the total 
sacrifice of the organ is demanded. The general state of the patient is another 
circumstance to be borne in mind, as it can advice against the use of exeresis 
surgery. 
As it is mentioned above, the efficiency of chemotherapy drugs for the 
treatment of renal tumours is rather low. Not all chemotherapy agents are efficient 
against neoplasic cells, present in tumour tissue. Most commonly used drugs, like 
vimblastin® or floxuridin® have yielded positive results only in the 7% and 16% 
of the cases, respectively. In a phase II study carried out with 3500 patients an 
objective response rate of 5.6% was obtained after using 72 anti-tumoral drugs 
[Yagoda1989]. And not much success has been achieved in this field during the 
last years [Yagoda1995]. 
These medicines are very toxic when administered at high doses, even if 
injected through a continuous infusion system adjusted to the circadian beat 
[Hrusesky1990, Dexeus1999].  Besides, a factor to be taken into account is the 
defensive mechanism of the renal cells carcinoma, which is based on the presence 
of glycoprotein P. This is a product of the gene MDR-1, and it is implied in the 
intracellular pumping mechanisms of toxic products to the outside of the cells, 
which to a certain extent could explain the resistance of the carcinoma renal cells to 
conventional chemotherapy [Mickish1994]. 
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If a very high concentration of such chemotherapy agents could be 
concentrated inside a renal tumour, avoiding their systemic effects, eventually the 
defensive pumping mechanisms of the tumour cells could be overpassed, leading to 
tumour cell death. This is the starting hypothesis of the model, how to concentrate 
inside a tumour massive doses of a drug transported by a particulate system, 
leaving healthy tissue unaffected. We chose doxorubicin as the chemotherapy 
agent because it has been previously evaluated in combination with magnetic 
carriers [Wu2003, Jain2005]. The systemic administration of doxorubicin, like any 
other anti-tumour drug, has the serious inconvenience of its high toxicity. In its 
case it is manifested specially in the cardiac muscle. 
Currently, medical treatment of renal tumours is mainly focused on the 
stimulation of the natural defences of the organism by the use of cytokines 
(interleukin and interferon) or the use of vaccines, with not too positive results. 
New drugs are also under development, mainly designed to block the growth 
factors of tumours. These drugs have achieved to slow down transitorily tumour 
growth, although in no case a real tumour regression has been observed 
[Tamaskar2008]. Therefore, it seems highly necessary to achieve a high 
impregnation of the tumour with the chemotherapy agents, avoiding as much as 
possible their systemic action. 
Several strategies have been described to achieve an effective targeted 
accumulation of drug carriers into tumours, and only a very little number of them 
have been devoted to the theoretical or experimental development of magnetic 
implants. The classical approach has been to use a single source of magnetism to 
magnetize the carriers and attract them to a specific site inside the organism 
[Lübbe2001, Rudge2001, Flores2002]. This, however, presents many 
disadvantages, specially the impossibility to generate strong magnetic fields that 
permit a high capture efficiency of the carriers at the targeted site. 
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To overcome this, Yellen et al. suggested with a theoretical approach the use 
of two independent magnetic sources. A small size magnetic mesh, consisting of a 
3x3 array of magnetic wires, in combination with long range externally applied 
fields were used to magnetize and localize the carriers in an in-vitro experiment 
[Yellen2005]. They proved that fields in the range of 0.1Tesla should be used in 
order to reach magnetic saturation of both the particles and the implant. Fields over 
0.1T would have little additional effect on the particles capture. Therefore, their 
results would demonstrate that superparamagnetic nanoparticles at high 
concentrations can be captured at flow conditions consistent with the dimensions 
and flow velocity occurring in the coronary artery in the human blood. 
Ritter and coworkers studied the feasibility of using a ferromagnetic wire 
implanted under the skin and next to the carotid artery for the collection of 
magnetic carriers using external magnets. A complete 2D mathematical analysis of 
the hydrodynamic and magnetic forces involved in the process was performed 
[Avilés2005]. Based on these calculations, they designed a coiled ferromagnetic 
wire stent in order to simulate an intravascular stent in-vitro. They used magnetite 
nanoparticles embedded in poly(styrene/divinylbenzene) matrixes as carriers, and 
an external permanent magnet to magnetize the wire stent. Changes at the capture 
efficiency by varying the applied magnetic field, the particle concentration and the 
fluid velocity were studied [Avilés2007]. They concluded that an increase in the 
fluid velocity and the concentration of particles had a positive effect on the 
efficiency of the capture of the magnetic carriers. This is due to the increase in the 
hydrodynamic force of the fluid and the formation of small aggregates. On the 
other hand, an increase in the applied magnetic field strength yielded a very slight 
improvement in the capture efficiency, since not very high fields were required for 
the saturation of particles and implants. 
The implantation of small permanent magnets by minimally invasive surgery 
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is a new alternative for magnetic targeting. Despite the preliminary achievements 
in in-vitro models, very little research has been performed in experimental animal 
models. This work reports some of the first in-vivo experiments of localisation of 
magnetic nanoparticles with implanted permanent magnets performed in animals 
[F.Pacheco2005, F.Pacheco2007]. 
As it was overseen in section 1.3.4, the effective delivery of magnetic carriers 
to the target has been usually approached by means of an external source of 
magnetism applied on the desired area to localise and concentrate magnetic 
particles. This method produces very low values for the intensity and the magnetic 
field gradient at the target region. The aim of the research carried out and described 
in this chapter is to validate a new approach, in which a permanent magnet 
allocated at the target organ is the source of magnetic field. The model is based on 
the implantation of small permanent magnets by minimally invasive surgery, which  
produces the localisation of magnetic particles at the desired zone. 
Figure 6.1 shows the simulation of the magnetic field created by a Nd-Fe-B 
cylindrical permanent magnet. The dimensions of the magnet are 2 mm high and 4 
mm diameter. The lines in the figure are the magnetic field lines, for the magnet 
magnetised along the vertical axis. The maximum number of field lines is found at 
the vicinity of the edge of the magnet, which means that maximum variation of 
field is achieved in this region (Fig. 6.2). Since magnetic field gradient, and not 
magnetic field intensity, is what really drives magnetic particles to move towards 
the magnet, maximum attraction of the particles shall be found near the edges of 
the magnet. These small, gold-coated permanent magnets generate a 3KOe field at 
the surface, being the magnetic field gradient approximately 30T/m. 
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Figure 6.1 Simulation of the magnetic field created by a cylindrical permanent magnet. The 
figure represents half a magnet with cylindrical symmetry 
Along with the use of a powerful and efficient source of magnetism that will 
retain the magnetic carriers at the tumour site, the second point is the choice of the 
adequate particles for drug delivery: Iron and iron oxide nanoparticles are generally 
well tolerated by the organism and can degrade with time [Ocón1994]. The ideal 
size for biomedical applications is below one micron, and preferred nanoparticles, 
or aggregates of particles size is below 200 nm. Smaller particles have high surface 
areas and small cohesion forces, preventing that way aggregation before a magnetic 
field is applied. On the contrary, they have small magnetic susceptibility and 
saturation magnetisation, hence their magnetic response is much worse. A balance 
to meet both requirements is then necessary to achieve an efficient delivery of their 
drug load.  
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Figure 6.2 Variation of magnetic field with distance at the edge of the magnet. 
This preclinical model is oriented to the local treatment of tumours with a 
difficult surgical approach, like meso-renal or hepatic multiple metastasis. Certain 
tumours, because of the difficulty of accessibility, cannot be directly extracted. The 
percutaneous implantation of a permanent magnet inside these tumours and the 
intravenous administration of drug magnetic carriers can increase the local 
chemotherapy effect, since the doses reached in-situ are very high. We also 
propose an alternative method to systemic delivery. It consists of an ecographic 
guided insertion of the magnetic carriers, which are retained near the zone of 
insertion of a permanent magnet to deliver their chemotherapy load over prolonged 
time. The clinical feasibility of the latter procedure has been checked 
experimentally, since the puncture with a 22 or 24 gauge needle produces less 
physical disturbances than the application of an insulin dose. 
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6.1 Results: overview 
All experiments were done at the Minimally Invasive Surgery Unit of the 
Veterinary Hospital of the University of Zaragoza (UTMI). The assistance of a 
very experienced team of co-workers was crucial to obtain the desired results. This 
unit is experienced in laparoscopy surgery and has been even performed 
percutaneous nefroscopy. Their experience has allowed achieving insertion of the 
magnet in one step by means of puncture and dilatation. 
Experimental details are described in chapter 2. The use of a rabbit as the 
animal model presents many advantages, because of its size, easy handling and 
reproducibility. On the other hand, we observed that the overweight of the animals 
was an additional difficulty: in several cases fat covered completely the kidneys, 
impeding an easier approach to the target. Besides, the mobility of the organ also 
increases the experimental complications, since it has to be held in place by manual 
compression from the external part of the abdomen. 
The magnet was successfully inserted in 52 rabbits (Fig. 6.3), in 4 of them the 
magnet was displaced out of the kidney, found outside the renal parenchyma or 
directly excreted via the urinary system, probably because the implantation had 
been done directly in the urinary tract. In 48 cases insertion was performed in the 
left kidney and in four of them it was done in the right one, as specified in the 
chirurgic protocol. In all the cases same chirurgic trauma was performed: a 12 
french puncture in the opposite kidney so that both organs suffered an 
intraparenchyma hemorrhage, therefore serving as a control organ. In 54 cases 
laparoscopic technique was used. In other two animals medium supra- and infra-
umbilical laparatomy was carried out. In 41 animals the particles suspension was 
administered intravenously through the marginal ear vein. In seven cases the fluid 
was administered in a more central vessel, by means of a cutaneous mini-incision, 
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three in primitive carotid artery and four in abdominal aorta artery. In 36 animals 2 
ml of the 1% suspension in gelafundine were injected. In other three higher doses 
of commercially available nanoparticles were injected, and in another one 10 ml of 
a 2% Fe@C particles suspension. 
 
Figure 6.3 Longitudinal section of a rabbit’s left kidney with a magnet inserted in the 
middle. Several haemorrhagic trajectories due to the insertion of the magnetic implant can 
be observed. 
A transitory gas hyperpressure on the abdomen is enough to fulfil 
haemosthasia, that is, the stabilisation of the point of insertion without bleeding, 
avoiding the necessity of sutures. The approach was, in all cases, trans-peritoneal. 
Laparoscopy avoids the perforation of the intestines in an animal model, however 
in a human the approach could be retroperitoneal and guided by ultrasound scan, 
both trocarisation and insertion of the magnet.  
In three cases intra-surgery death occurred after the insertion of the magnet. In 
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two cases death was caused by anaesthesia failure, one because of kinking of the 
tracheal tube and another one due to accidental deflation of the balloon. In the 
other case death occurred after the injection of an overdose of particles. If 10 ml of 
a 2% suspension was administered to a 4 Kg rabbit, then the dose of 200mg is 
lethal. In other two cases death of the animals happened immediately after 
operation. In one of them immediate autopsy revealed the presence of haemorrhage 
coming from the kidney in which an implant had been set.  
Thirty-five surviving animals were sacrificed after general terminal 
anaesthesia. 20 rabbits were sacrificed after 24 h form the insertion of the magnet. 
25 animals were sacrificed after one week form the intervention. Two rabbits, 
operated by laparatomy, had to be sacrificed after 3 and 5 days because signs of an 
incipient evisceration were detected. Another animal died 24h after surgery 
because of mucous enteritis, not caused by the administration of the magnetic fluid. 
Histopathological study was carried out in all of the cases. 
Initial results of the surgical experimental model are satisfactory, although the 
trauma produced during the insertion of the magnetic implants should be reduced. 
A 9 french spear is an alternative that allows the introduction of two cylindrical 
magnets of a smaller size: 3 mm diameter and 1.5 mm high. The introduction of 
these two magnets would create a similar magnetic field gradient to the one created 
by the single magnet previously used. A percutaneous procedure, exclusively 
directed by radioscopy, is under development. There is another possibility under 
study: the insertion of magnets tied to polypropylene wires, the extreme of which 
would be abandoned under the skin, in the cellular subcutaneous tissue. Once the 
treatment would be concluded, the magnet could be extracted by simple local 
anaesthesia. 
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A good tolerance to the administration of particles was observed, since no 
cardiac stops or secondary effects, like partial or total limp of any of the animals 
was detected. Regarding the general state of survivor no significant changes in the 
vital parameters were objectivised. 
In the moment of sacrifice, in the cases where minimally invasive surgery had 
been performed, a positive tolerance was detected, whereas eviscerations were 
found in some of the cases when laparotomy had been performed. During 
intervention no pus was detected. A slight peri-renal inflammation was detected in 
several cases, probably because surgery was not always performed in a completely 
aseptic environment. Non-magnetic material had to be used for the proper 
extraction of all of the organs to avoid undesired removal of the implant. Magnetic 
particles were found in many cases adhered to the surface of the magnet, proving 
its capacity to attract and retain magnetic material. 
Histopathology examination proves, as expected, that the targeting of carbon 
coated iron nanoparticles injected intravenously inside the organism is hampered 
by the action of the immune system. Before reaching their target particles are 
filtered by the liver and spleen (Fig. 6.4). The size of big aggregates and the 
tendency of hydrophobic carbon to adsorb proteins in blood lead to their immediate 
recognition by kupffer cells, which remove them from circulation, impeding 
particles to reach their target in a considerable amount. Despite these problems the 
efficacy of the internal magnet can be checked in 25 out of 27 cases, when a 
significantly higher quantity of particles was found in the test organ compared to 
the control organ. Moreover, the presence of particles in the test organ was mainly 
due to the haemorrhage associated with the insertion of the magnet. 
In the region of the kidney where particles were detected no macrophages 
were observed, only normal tissue, therefore the tolerance seems positive. This is 
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in agreement with the results detected in-vitro, where no particles were detected 
inside macrophages in circulating blood. The capture of particles by the immune 
system is therefore restricted to the action of the filter organs. 
 
Figure 6.4 a) Liver capture of particles inside Kupffer cells. b) 5 Hyperaemic spleen with 
macrophages that contain nanoparticles and infiltration of neutrophiles. H.-E. X 400. 
No studies of the local or general tolerance to doxorubicin have been 
performed, since the induction of tumours in living healthy tissue is a further step 
in this research. Once a higher concentration of particles at the desired target has 
been attained, even more adequate chemotherapy agents could be tested. 
Histopathology results are summarised in Table 6.1: Different groups of animals 
were sacrificed by terminal anesthesia after half an hour, 2, 7, 14, 21 and 28 days, 
and the main organs (lungs, liver, spleen, kidneys and bone marrow) were 
extracted for histological study. Table 6.2 is a summary of control animals. In order 
to assess the fate of the particles inside a living organism without the influence of a 
magnetic field, 8 rabbits were used as control animals. 2ml of a 1% Fe@C particles 
in GFM were injected via the ear vein, and animals were sacrificed after 1, 7, 12 
and 21 days after operation. Almost no particles were found inside the kidneys, 
whereas most of the particulate material was detected inside the lungs, liver and 
spleen. 
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Table 6.1: Summary of Histopathology results. Legend: 1) Time of sacrifice 2) left kidney 
3) right kidney 4) lungs 5) liver 6) spleen 7) Bone Marrow 8) Thymus 9) Type of 
administration 10) Incidences 11) Type of particle. *Insertion of magnet 
# 1 2 3 4 5 6 7 8 9 10 11 
1 30 min ++ * + ++++  + +   IV  FeC 
2 8 h.      + + + - IV  FeC 
3 30 min + * +  ++ *    IV  FeC 
4 30 min +++ * + ++ ++++  +++   IV  FeC 
5 1 h. +++ * + ++ ++++ * ++++   IV  FeC 
6 10 min ++ * + +++ ++++ ++++   IV  FeC 
7 30 min. ++ * + ++ ++++ ++++   IV  FeC 
8 30 min. ++ * + + +++ +++   IV  FeC 
9 30 min. ++ * + + +++ +++   IV  FeC 
10 36 h + * - - +++ ++++   IV  FeC 
11 
 
36 h 
 
++++ * 
 
- + ++++ +++++   IV  FeC 
12 36 h + * - + ++++ ++++   IV  FeC 
13 36 h ++ ++++ * + ++++ ++++   IV  FeC 
14 30 min +++ * +++ +++ +++++ +   IV  FeC 
15 36 h + * + + ++ +++   IV  FeC 
16 
 
36 h + ++ * +++ + ++   IV 2 doses FeC 
17 
 
36 h + * ++ +++ ++ ++   IV 2 doses FeC 
18 36 h + * -  ++++ ++++ ++++   IV  FeC 
19 36 h +++ * + +++++ ++++ +++++   IV  FeC 
20 36 h + ++++* +++++ ++++ ++   IV  FeC 
21 36 h +++ * ++ +++ + +++   IV  FeC 
22 36 h ++ * - +++++ ++ +   IV  FeC 
23 36 h ++ * - ++++ ++ ++   IV  FeC 
         IV   
24 7d +  + + +   IV  Fe-
albumin 
25 7d        IV No particles 
were found 
Fe3O4-
PEG 
26 7d ++ *    +   IV  350nm 
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27 7d ++ *  + + +   IV  80nm 
28 15’ +++ * + +  +   Aorta 
Artery 
 FeC 
29 36h ++ * ++      Aorta 
Artery 
 FeC 
30 36h +++ * ++  + ++   Aorta 
Artery 
 FeC 
31 15’ ++ *  +     Aorta 
Artery 
 FeC 
32 
 
15d ++++ 
* renal 
capsule 
      Ultrasound  
Scan guide 
Clodronates FeC 
33 7d + * + +++ +++ + +
+
 Ultrasound  
Scan guide 
Detachment 
of gold 
FeC 
34 7d + * + +++ +++ + +
+
 Ultrasound  
Scan guide 
Detachment 
of gold 
FeC 
35 7d *   + +   Ultrasound  
Scan guide 
Magnet 
placed in 
renal 
capsule 
FeC 
36 7d *   + +   Ultrasound  
Scan guide 
Detachment 
of gold 
coating 
FeC 
37 7d + * + ++ + + +  Ultrasound  
Scan guide 
 FeC 
38 7d + * + + + +   Ultrasound  
Scan guide 
Detachment 
of gold 
coating 
FeC 
39 30’ +++ * + ++ ++  +  Carotid 
Artery 
 Fe3O4-
SiO2 
40 30’ +++ * ++ ++ ++ ++ +
+
 Carotid 
Artery 
 FeC 
41 9d + * +++  ++ ++ +
+
 Carotid 
Artery 
 Fe3O4-
SiO2 
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42 7d +++ *       Ultrasound  
Scan guide 
 FeC 
43 7d + *       Ultrasound  
Scan guide 
Excretion of 
magnet 
FeC 
44 7d ++ *   + ++   IV  FeC-
PEG 
45 7d ++ *  ++ ++ +   IV Detachment 
of gold 
coating 
FeC-
PEG 
46 7d *  + +++ ++   IV  FeC-
PEG 
47 7d + *  + + +   IV Corrosion 
of the 
magnet 
FeC-
PEG  
48 7d *   +++ ++   IV Lungs edema 
Displacement 
of the magnet 
FeC-
RSA 
49 7d *   + +++   IV Corrosion 
of the 
magnet 
FeC-
RSA 
50 7d *  + + +   IV Displaceme
nt of the 
magnet 
FeC-
RSA 
51 7d *   ++ +   IV Displaceme
nt of the 
magnet 
FeC-
RSA 
52 7d +++ *   + +   IV  FeC-
RSA 
53 7d ++ *    +   IV Detachment 
of gold 
coating 
FeC-
PEG 
54 7d ++ *  + + +   IV  FeC-
PEG 
55 Death 
24h 
++ * ++ + +++ ++   IV  FeC-
RSA 
56 7d + *   + +   IV  FeC-
RSA 
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Table 6.2: Summary of histopathology in control animals. Legend: 1) Sacrifice 2) Left 
Kidney 3) Right kidney 4) Lungs 5) Liver 6) Spleen 7) Bone Marrow 
# 1 2 3 4 5 6 7 
57 24 h - + ++ ++ +++  
58 24 h + + - - -  
59 7 d - + + ++ +++  
60 7 d - - + +++ +++  
61 21 d - - ++ +++ +++  
62 21 d - - + ++ +  
63 21 d + - - ++++ ++++  
64 12 d - - ++ ++++ +++  
 
6. 2 Intra-arterial administration 
For a better assessment of the efficacy of the selective magnetic interaction, 
and in order to avoid passing through the filters of the organism a larger amount of 
particles was injected through the carotid and abdominal aorta and renal arteries. 
That way particles could directly reach the target organs. In 6 of these cases there is 
an evident preference of distribution around the test control. A big quantity of 
particles was found localised in the zone of implantation, oriented towards the 
direction of the magnetic field gradient (figure 6.5). The injection of particles in 
artery is not an alternative to an ambulatory treatment that implies intravenous 
administration, since it requires minimum surgery and the access is much more 
difficult than in the case of veins. However, it is good proof of the efficacy of the 
method and the necessity to avoid the action of the immune system so as to 
effectively reach the target.  
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Figure 6.5 Particles accumulate in the vessel of a kidney in which a magnetic implant has 
been inserted. They remain there and tend to align in the direction of the magnetic field 
gradient. 
 
Figure 6.6 a) Cross-section of a left kidney, test organ. The presence of particles is evident 
inside the organ in which a magnet has been inserted. H.-E. X 200. b)Rigth kidney, control 
organ. Absence of nanoparticles on the non-implanted organ. H-E. X 200. 
a) 
b)
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6.3 Ultrasound scan-assisted injection of the particles 
 
Figure 6.7: The ultrasound scan displays the image of a gold coated magnet inserted inside 
a kidney. After the injection magnetic nanoparticles remain attracted to the magnet, the 
amount of metallic then increases and the echo of the ultrasound is broadened 
As an alternative to the intra-venous injection of the particles, a group of 9 
animals underwent injection of the particles directly into the target organ with the 
aid of ultrasound scan equipment. This method allows visualising the position of 
the magnet and the direction of injection of the particles onto the desired zone. 
Seven days after the injection, 1ml of 1% Fe@C particles in GFM were directly 
injected into the kidney carrying the magnetic implant. After the injection magnetic 
nanoparticles remain attracted to the magnet, the amount of metallic material 
increases. This is manifested by the broadening of the echo of the ultrasound. As 
expected, a very big quantity of particles was located inside the renal parenchyma 
6.3. Ultra-sound scan assisted administration 175 
(Fig. 6.8), even though a significant amount of magnetic material was still found 
inside the macrophages of liver and spleen. 
 
Figure 6.8 Macroscopic Image of the localistaion of the magnetic implant in the kidney. 
Nanoparticles, injected under ultrasound scan control, aggregate around the magnet. 
The trajectory of injection of the particles is vital to reach the exact implant 
site. The use of a guide to direct the needle helps a better localisation of the 
particles around the zone influenced by the magnetic field. The perforation of the 
capsule of the kidney presents difficulties because of its fibrosity, whereas the renal 
parenchyma is softer. Besides, a kidney is a very mobile organ, and it slightly 
displaces during insertion, increasing the difficulty of operation. Once inserted, the 
exact identification of the magnet with the ultrasound scan is very easy. This 
facilitates enormously the direction of the needle for particle injection. 
6.4 Functionalised nanoparticles 
To avoid the action of the immune system and increase the average life time of 
particles in circulation, different encapsulations were tested. Commercial albumin-
coated particles and magnetite coated with PEG were injected, however the 
difficulty to detect these materials with the haematoxylin-eosin dye made it very 
complicated to evaluate their final destination inside the organism. Silica particles, 
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injected in a great concentration via the carotid artery, were positively detected in 
one case, proving the selectivity of the particles towards the implanted organ. 
 
Figure 6.9 Left kidney, test organ. a) Nanoparticles in the traumatic haemorrhage zone 
caused by the implantation of the magnet. H.-E. X 200. b) Group of nanoparticles next to 
renal tubules and on the margins of the haemorrhage. 
Particles functionalised with Rabbit serum albumin (RSA) and PEG were also 
injected intravenously, in 7 and 6 cases respectively. In 6 of them technical 
difficulties did not allow a correct study of the localisation of the particles, because 
of the corrosion of the core or displacement of the magnet. The presence of iron 
rust, positive to Blue Pearls dye, is a symptom of the corrosion of the coating 
which encapsulates the sintered Nd-Fe-B magnet. In one animal the magnetic 
implant had migrated to the ureter, identified by X-Rays. Regarding the RSA 
coating, results are not reproducible or especially conclusive. Only in one case the 
amount of particles found on the test organ was significant compared to the control 
organ, and in any case the apparition of particles inside the macrophages in a large 
extent means that the serum albumin coating has not produced the desired stealth 
effect. In two animals strong lungs infection were detected after the administration 
a) b) 
6.4. Functionalised nanoparticles 177 
of the Fe@C – RSA fluid. Even though there could be reactions of refusal of the 
organism to a foreign protein, like commercial RSA, these infections seem to be 
due only to diseases of the animals before treatment. 
 
Figure 6.10 Detail of a hyperaemic glomerulus and the presence of plinuclear neutrophiles. 
H.-E. X 400. 
In four cases in which Fe@C – PEG particles were injected, a significant 
concentration of particles was found in the test organ, localised in the zone of 
implantation or generalised inside the renal parenchyma (Fig 6.9). And, more 
importantly, the coating of the particles really seemed to have diminished the 
amount of particles captured by the macrophages of spleen, and especially kupffer 
cells inside the liver. The hydrophilic PEG coating, and the improvement in the 
stabilisation of the particles in aqueous suspension after the incorporation of the 
polymeric coating increases the permanence of particles in circulation in blood, 
thus increasing the probability to reach the target organ without being removed by 
the immune system. These are anyhow preliminary results, and the process of 
coating the particles with more adequate PEGs is still to be optimised. 
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6.5 Summary of results 
The experimental model proves that the laparoscopic insertion of a small 
magnetic implant inside the renal parenchyma is an unprecedented, effective and 
easily reproducible method to deliver magnetic carriers to a target organ. The 
tolerance of well-coated, biocompatible magnets is excellent, and its position can 
be easily tracked after operation by means of abdominal ultrasound scan or X-Ray. 
During the development of the surgical model the anaesthesia procedure was 
improved, being the endotracheal intubation eventually unnecessary because of the 
reduction in surgery time. The elimination of the endotracheal intubation led to a 
reduction in morbility associated to surgery. 
Regarding surgical equipment, the dimensions of the used trocar are too big 
for the size of a rabbit’s kidney. Same chirurgic procedure in humans is expected to 
cause lesser trauma. The approach for the insertion of the magnets is 1cm, a 
tolerable length in a human organism. In human urological surgery (percutaneous 
nephrostomy or percutaneous nephroscopy) it is possible to reach in the kidney 
parenchyma tract a diameter of 1 cm without haemorrhagic difficulties, but in 
rabbit the diameter of the used trocar is, in proportion, much bigger. 
An alternative to these experiments could be the insertion of magnets of a 
smaller diameter through narrower trocars, in order to avoid possible traumas 
caused by the surgery procedure. Other possibilities envisage the utilisation of 
magnets inside a capsule of titanium, or with a sharpened edge. A prospect in the 
future is the use of polypropylene wires attached to the magnet, coiled up and fixed 
subcutaneously for an easier removal of the magnet and the magnetic material after 
treatment has been completed. 
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 Figure 6.11 Residual cavity left after the extraction of the magnet (right down corner). H.-
E. X 40. b) In detail, necrotic material on the margin of the cavity left by the removal of the 
magnet. 
Histopathology studies show the distribution inside the organism and the 
short-term and medium-term tolerance of nanoparticles inside the main organs of 
the body. Particles are attracted under the influence of the internally created 
magnetic field gradient, and are retained near the magnet. In the case of drug-
loaded particles this will permit a slow and controlled diffusion of the 
chemotherapy agent in the desired zone.  
All the results obtained in histological analysis performed in samples obtained 
from different organs, showed the lack of Perls stain reaction, as was also observed 
in haematological test. These results confirmed the good encapsulation of the 
magnetic particles core, as confirmed by the morphological characterisation of the 
particles. From histological studies, we observed a larger particles concentration in 
the implanted kidney in comparison to the non-implanted one. Although it is 
difficult to quantify the results, a significant quantity of the particles concentrates 
on the kidney in which a magnet has been inserted. This is an indication of the 
capability of the magnet to attract particles specifically to the target organ. This is 
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the key issue to the method, and the main advantage of using internal magnets over 
the use of external magnetic fields. A relatively important amount of the particles 
are found to concentrate on the main filters of the body: liver and spleen, whereas a 
quite lower quantity of particles have been found in the bone marrow (Fig. 6.12) 
and lungs of some animals (Fig. 6.13).  
Despite the inert surface of our material, the size of the particles is big enough 
to be recognised by the macrophages of these organs, which capture them and 
retain them, eventually excreting them after several days. This fact could be a 
drawback for the purpose of delivering chemicals to specific targets in the body 
but, on the other hand, it could also be helpful for other applications, such as 
treatment of liver or spleen tumours, or for the treatment of leishmania. 
[Chellat2005]. The obtained results have opened a new research direction that is 
being developed to confirm these assertions. 
 
Figure 6.12. Bone marrow. A very low amount of particles was found, pointed with an 
arrow on the image. H.-E. X 600. 
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Figure 6.13. A very low concentration of particles was found in lungs. H.-E. X 600. 
The injection of particles directly inside the abdominal aorta artery is a way to 
avoid the withdrawing of the particles by the Reticuloendothelial System. That way 
we have confirmed the ability of the magnet to actually concentrate the particles in 
the target organ. More work needs to be done in order to avoid the action of 
macrophages of the liver and spleen. These organs retain some of the particles, 
preventing them from reaching the desired goal. The functionalisation of the 
nanoparticles’ surface with chemical groups that specifically avoid opsonisation 
and repel the macrophages is a profitable solution. This led to the necessity of a 
hydrophilic coating with poly (ethyleneglycol). Given the fact that the internal 
magnet actually concentrates a big amount the magnetic material, the use of 
smaller particles, under the limit of detection of the body (100 nm) is another 
interesting possibility. 
  
 Summary and conclusions 
The work carried out throughout this doctoral thesis concerns the synthesis, 
characterisation and functionalisation of magnetic nanoparticles for biomedical 
applications. With this aim, four novel types of particles have been synthesised: 
iron encapsulated in carbon (Fe@C) and iron encapsulated in silica (Fe@SiO2), by 
the arc-discharge method; megnetite embedded in zeolite Y (Fe3O4@ZY) by 
mechanical milling; and magnetite crystallites encapsulated in amorphous silica 
(Fe3O4@SiO2) by a combination of the co-precipitation method and the sol-gel 
technique. All four types of particles have been characterised morphologically, by 
electron microscopy tecniques, magnetically at the SQUID magnetometer and 
chemically, by IR and VIS-UV spectroscopy, and by N2 adsorption following the 
BET method. 
The discharge-arc method is a non expensive, simple way to obtain perfectly 
encapsulated, highly magnetic particles. Fe@C and Fe@SiO2 are ferromagnetic 
and present aggregates of particles of several hundreds of nanometers in 
suspension. Fe@SiO2 presented the highest saturation magnetisation referenced in 
bibliography. Fe3O4@ZY preserves the high surface area and the crystallinity of 
the starting zeolite after the mechanical activation with magnetite. Fe3O4@SiO2 are 
superparamagnetic crystallites with a high surface area. TEM proved the perfect 
encapsulation of all magnetic cores. Stable aqueous suspensions of all particles 
have been obtained in order to use them in in-vitro and in-vivo applications in 
Biomedicine. 
Biocompatibility of the obtained nanoparticles has been analised in-vitro. 
Studies of Coagulation, platelet aggregation, variations in blood and plasma 
viscosity and a complete rheological study, both in human and in rabbit circulating 
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blood have been performed. In all cases the results obtained were within tolerable 
limits. The capability of particles to be uptaken by living cells has also been 
studied. Dendritic cells are able to internalise Fe@C particles, as proved by 
electron microscopy and magnetic measurements.  
Fe@C and Fe@SiO2 particles have been functionalised with carboxyl and 
amine groups on their surface to bind to the specific monoclonal antibody directed 
against the human chorionic gonadotropin hormone (hCG). The presence of the 
antibody was detected by XPS measurements and by detection with a lateral-flow 
immunoassay. This way, functionalised particles could be used for a more effective 
delivery to a target zone: the grafting of a specific antibody to the surface of a 
magnetic particle allows magnetic targeting and molecular recognition at the same 
time. 
In order to delay the action of the immune system inside the organism, and 
therefore allow a circulation of the particles for a longer time in blood, Fe@C 
particles have been coated with the copolymer PEG and the serum albumin protein. 
The effectiveness of the coating was assessed by XPS and VIS-UV spectroscopy, 
respectively. 
The adsorption and release of the chemotherapy agent doxorubicin was studied 
for Fe@C, Fe3O4@ZY and Fe3O4@SiO2 particles. Al three materials show an 
appreciable loading capacity of adsorption and release of the chemotherapy agent 
doxorubicin. Adsorption is fast and achieved within a few hours, whereas complete 
release takes place after several days. This controlled release would be slow 
enough to allow the carriers to reach the target and desorb the load only at the 
specific site. Fe3O4@ZY has the maximum loading capacity but a faster release, 
related to a superficial adsorption of the drug on the surface of the particles. 
The laparoscopic insertion of a small magnetic implant inside a solid organ is 
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an alternative to conventional chemotherapy and externally-driven magnetic drug 
delivery. A preclinical experimental model is described. Kidneys were chosen 
because of their symmetry and good vascularisation, and the method proved to be 
effective for the concentration of magnetic nanoparticles at the zone of 
implantation.  The direct injection of particles inside the target organ via a long 
needle is another possibility. It can be easily tracked by means of abdominal 
ultrasound scan.  
Histopathology studies showed a bigger concentration of particles in the 
implanted kidney in comparison to the non-implanted one. Although it is difficult 
to quantify the results, a significant quantity of the particles concentrates on the 
kidney in which a magnet has been inserted. This is an indication of the capability 
of the magnet to attract particles specifically to the target organ.  
The injection of particles directly inside the abdominal aorta artery also 
confirmed the ability of the magnet to actually concentrate the particles in the 
target organ. Some of the particles are retained in the main filters of the body: 
lungs, liver and spleen. Pegylation of particles avoids opsonisation, allowing a 
longer time of circulation in bloodm leading to a bigger concentration of particles 
in the target organ, and a lesser amount of magnetic material in liver and spleen. 
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